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ABSTRACT
The process of epithelial to mesenchymal transition (EMT), in which
epithelial cells assume a mesenchymal cell phenotype with enhanced migratory
capacity plays an integral role in development and wound healing but also
contributes pathologically to fibrosis and cancer progression. This switch in cell
differentiation and behavior is mediated by key transcription factors like SNAI1
(SNAIL) and SNAI2 (SLUG) in response to several signaling pathways like TGF-β
and EGF. There are three key events that occur during TGF-β induced EMT,
namely extracellular cues that must be transmitted to the nucleus to elicit activation
of SNAI1 transcription, recruitment of transcription factors (TFs) to the SNAIL gene
and subsequent transcription, and finally propagation of the signaling response
over multiple generations to maintain the EMT response.
In study I we show that blocking store-operated calcium entry (SOCE) with
2-aminoethoxydiphenylborane (2APB) reduces cell migration but increases the
level of TGF-β mediated Snai1 expression. We also demonstrate that the calcium
channel proteins ORAI3 and STIM1 are involved in this increased transcription of
Snai1 via the NF-κB -AKT pathway.
In study II we show that the transcription factor CTCF associates with the
SNAI1 promoter in steady state cancer cell lines and in TGF-β mediated induction
of EMT in non-cancerous cell lines. We observed this association of CTCF with

xviii

the SNAI1 is stimulus dependent and CTCF might regulate TGF-β mediated Snai1
activation either directly or indirectly.
In study III we established a model to study how cells “remember” previous
exposures to environmental stimuli and pass on this memory to future generations,
thus enabling them to mount a more robust response when they next encounter
the same stimuli. We demonstrated that this “memory” is transmitted across cell
divisions and is largely attributed to the acquisition of chromatin marks like
H3K4me1, H3K27Ac and loss of repressive mark H3K27me3.

xix

CHAPTER 1
INTRODUCTION
Epithelial to Mesenchymal Transition
The Epithelial to Mesenchymal Transition (EMT) refers to the trans
differentiation of epithelial cells into mesenchymal cells. EMT contributes to the
processes of embryonic development, wound healing, and stem cell behavior, as
well as to pathological conditions including fibrosis and cancer progression [1], [2]
During induction of EMT (Fig. 1.1), epithelial cells that are attached to a
basement membrane undergo multiple changes to form mesenchymal cells with
increased migratory capacity [1–3]. It is important to note that EMT is not a binary
process, rather it involves a series of intermediate steps, and can be partial or
incomplete depending on the tissue and signaling context [4–7]. Partial EMT is
characterized by epithelial cells that have lost some of the epithelial characteristics
and retained others, and by simultaneous acquisition of some mesenchymal traits
[5], [6]. The presence of this hybrid E/M phenotype is potentially a reason that
classical pathology methods were previously unable to find clear evidence for EMT
in clinical samples.
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Figure 1.1. The Epithelial to Mesenchymal Transition (EMT). EMT involves
the transition of polarized epithelial cells into motile mesenchymal cells.
Epithelial cells are attached to a basement membrane, lack migratory capacity
and express epithelial markers like E-cadherin (CDH1). In the intermediate state
of EMT, epithelial cells gradually lose their adhesive properties and become
more migratory in nature due to environmental signals and epigenetic selection.
During this intermediate state, the cells also show increased expression of Snail
and/or Slug transcription factors, which are considered as the “master
regulators” of EMT. Upon completion of EMT, the mesenchymal phenotype
lacks cellular junctions and are not attached to a basement membrane. These
mesenchymal cells are migratory and express markers such as Fibronectin
(FN1).

EMT can be transient in nature, and cells that have undergone EMT can
revert to an epithelial-like state through a mesenchymal-to-epithelial transition
(MET) [8], [9]. Thus, “plasticity” allows epithelial cells to undergo multiple cell state
transitions, which in turn is responsible for a wide range of cell phenotypes [7]. The
process of EMT involves several distinct molecular events starting from initiation
to completion of EMT. These events include activation of EMT transcription factors
like Snail (SNAI1), Slug (SNAI2), Zinc finger E-box binding homeobox 1 (ZEB1),
Zinc finger E-box binding homeobox 2 (ZEB2), expression of specific cell-surface
proteins, reorganization and expression of cytoskeletal proteins, production of
extra cellular matrix (ECM)-degrading enzymes, and changes in the expression of
specific microRNAs [1], [8], [10–12]. The work described in this thesis focuses on
2

understanding the molecular mechanisms involved in the Epithelial to
Mesenchymal (EMT) with emphasis on (a) understanding how changes in the
cellular environment influence EMT, (b) determining how the EMT transcription
factor SNAI1 is upregulated in response to EMT induction, and (c) understanding
how cells “remember” and “record” prior exposures to environmental stimuli
through epigenetic mechanisms during the process of EMT. Based on the
biological context, EMT can be classified into 3 types [13]. Type I EMT is involved
in early development and is highly conserved across several species; Type II EMT
is specific to wound healing and some pathological states like fibrosis, while Type
III EMT is involved in cancer metastasis and drug resistance. Most of the work in
this thesis focuses on Type III EMT. Below, I will briefly summarize the three types
of EMT.
Type I EMT: Development
EMT plays an integral role in normal development at the embryonic stage,
as it is essential for germ layer formation, cell migration, embryo implantation, and
neural crest formation during early vertebrate development [13], [14]. The concept
of EMT was first described by Elizabeth Hay in a model of chick primitive streak
formation, where she showed that epithelial cells undergo phenotypic changes to
transform into mesenchymal cells. Type 1 EMT generates mesenchymal cells and
gives rise to secondary epithelia via the reverse process of Mesenchymal to
Epithelial Transition (MET) that form new tissues with diverse functions during
development [13]. This process of EMT in development is orchestrated by a group
of transcription factors like SNAI1, TWIST and ZEB families, and these factors are
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highly conserved across vertebrate species [15]. Expression of these factors drive
changes in gene expression patterns that ultimately result in the phenotypic
changes associated with EMT, the chief among these being downregulation of Ecadherin by SNAIL and other family members [15].
Type II EMT: Wound Healing and Fibrosis
Type 2 EMT is associated with tissue repair, regeneration, wound healing
and organ fibrosis following an inflammatory injury or trauma. During Type 2 EMT,
epithelial cells trans-differentiate into myofibroblasts to heal injured tissues. When
the injury is acute, the repair process is termed as reparative fibrosis; whereas
when the injury is due to chronic inflammation, abnormal formation of
myofibroblasts causes progressive fibrosis leading to organ destruction through
excessive extracellular matrix (ECM) deposition [16]. It has been reported that
during wound healing, keratinocytes at the border of the wound undergo EMT and
undergo re-epithelialization or MET when the wound is closed [9]. SNAI2
expression at the migratory front influences this state, as its overexpression
accelerates wound healing [5].
Type III EMT: Cancer Metastasis
Besides being critical during development, the process of EMT has also
been implicated in cancer metastasis, the process by which cancer cells spread
from a primary site to secondary organs. Cancer cells undergo multiple steps like
invasion through the ECM, intravasation into blood vessels, extravasation from the
blood vessels to the distant site, and colonization at the new site to develop
secondary metastases in organs distant from the primary site [17]. The earliest
4

events in cancer metastasis involves loss of cellular adhesion and polarity in
epithelial cells, followed by an increase in cell motility and invasiveness to break
through the underlying basement membrane [3], [14]. Epithelial cancer cells have
well defined cellular adhesion junctions, and express cell adhesion molecules like
E-cadherin. During the process of EMT, cells lose expression of epithelial markers
like E-cadherin, and gain expression of mesenchymal markers like N-cadherin and
Vimentin, thereby facilitating cell dissemination and generation of circulating tumor
cells (CTCs) [18]. Not all tumor cells undergo a full EMT, but can instead retain
properties of both phenotypes, by acquiring some mesenchymal characteristics
and retaining some epithelial markers. Recent studies have suggested that partial
EMT can drive distinct migratory properties and enhance and/or contribute to the
epithelial-mesenchymal plasticity of cancer cells [19], [20].
Following dissemination, cancer cells need to undergo the reverse process
of MET in order to establish distant metastases. Several studies have reported the
importance of EMT and its reverse MET in forming metastases [19–22]. In addition
to cellular motility EMT is also associated with enhanced stem cell properties and
acquisition of drug resistance in cancer cells thus leading to tumor recurrence and
resistance to therapy in the context of cancer [23], [24]. As above, several
transcription factors help drive Type III EMT. These factors and their roles will be
discussed in the next section.

5

EMT Markers and Transcriptional Regulators
The process of EMT is marked by the downregulation of epithelial proteins
including cell junction proteins like E-cadherin, and upregulation of mesenchymal
proteins like N-cadherin and Vimentin. These changes in cellular protein makeup
are positively correlated with increased tumor invasion and metastasis [3], [13],
[25–27], and the “Cadherin switch” from E-cadherin to N-cadherin is commonly
used as a marker of EMT progression during embryonic development and cancer
metastasis. Further, the switch from expressing epithelial to mesenchymal proteins
is due to an intricate and diverse network of transcription factors that contribute to
the repression of the epithelial phenotype and activation of the mesenchymal
phenotype. These transcription factors include the master regulators of EMT like
Snail (SNAI1), Slug (SNAI2), Zinc finger E-box binding homeobox 1 (ZEB1), and
Zinc finger E-box binding homeobox 2 (ZEB2), which directly bind to promoters of
epithelial specific genes including E-cadherin (CDH1) and repress transcription.
Other EMT transcription factors like Twist (TWIST1) and fork-head box protein C2
(FOXC2) can repress CDH1 expression indirectly [10], [26], [28–31]. Studies
suggest that there is a temporal order to the expression of these transcription
factors during EMT [32], which suggests a tight regulatory network of genes is in
place to regulate and/or fine-tune EMT.
SNAIL, EMT and cancer.
The zinc finger transcription factor SNAIL is one of the most important
repressors of CDH1. SNAIL homologs have been found in many species from
invertebrates to vertebrates, such as nematodes, mollusks, and humans. SNAIL
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was first discovered in Drosophila melanogaster [33], where it acts as a suppressor
of the shotgun gene (an E-Cadherin homolog) to control embryogenesis. In
vertebrates, the SNAIL family of proteins has three members: Snai1 (SNAIL),
Snai2 (SLUG), and Snai3 (SMUC). All three proteins encode transcription factors
and have highly conserved N- and C-terminal domains. The N-terminus of all
vertebrate SNAIL members contains the evolutionarily conserved SNAG
(Snail/Gfi) domain from aa 1-9, which includes the consensus sequence PRSFLV.
Interestingly, the SNAG domain resembles the N-terminal tail of histone H3 [34]
and it competes for the binding of several transcriptional regulator complexes like
lysine-specific demethylase 1 (LSD1) a key component of several co-repressor
complexes including CoREST, C-terminal binding protein (CtBP) and histone
deacetylase 1/2 (HDAC1/2) [35], [36], Sin3A and HDAC1/2 complex, Polycomb
repressive

complex

2

(PRC2)

, protein

arginine

methyltransferase

5 (PRMT5)/Ajuba complex and Suv39H1 (suppressor of variegation 3-9 homolog
1) [37]–[42]. The C-terminal DNA binding domain contains between four to six
C2H2 type zinc fingers, which bind to the E-box motif (5′-CANNTG-3′) in target
gene promoters.
In early embryonic development, SNAIL is integral to the process of
gastrulation, as Snai1 knockout mice are not viable past early gastrulation [43].
Interestingly, Snai2 knockout mice can survive into adulthood, although with
developmental defects such as cleft palate [44], [45], suggesting potentially
different roles for these proteins, despite their similarity. This was corroborated by
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work demonstrating specific downstream mRNA changes in SNAIL vs SLUG
expressing MCF7 cells [46].
In cancer, SNAIL is associated with metastasis, tumor recurrence and
acquisition of drug resistance [47]. Recent studies have shown that SNAIL is
required for lymph node metastasis of human breast carcinoma MDA-MB-231 cells
[48]. SNAIL also regulates a set of “lung metastasis genes” such as ID1 (Inhibitor
of DNA Binding 1, HLH protein) , SPARC (Secreted Protein Acidic And Cysteine
Rich) or MMP2 (matrix metallopeptidase 2) either directly or indirectly [49].
Elevated levels of SNAIL expression have also been observed in metastatic
ovarian cancer[50]. SNAIL is associated with the downregulation of epithelial
markers like Claudins, Occludins and MUC1 (Mucin 1) [13], and upregulation of
FN1 (fibronectin) and MMP9 (matrix metallopeptidase 9), which are associated
with mesenchymal and invasive properties [30], [51]–[54]. Studies have also
demonstrated that knockdown of SNAIL significantly inhibits tumor growth and
metastasis by increasing tumor-infiltrating lymphocytes and systemic immune
responses [55].
In breast cancer MCF-7 cells, SNAIL was shown to be repressed by the
Metastasis Associated 1 Family Member 3 (MTA3) containing Mi-2/NuRD
(Nucleosome Remodeling Decaetylase) complex [56]. MTA3 in turn is positively
regulated by estrogen receptor alpha (ER-α) [57] , an important molecule in breast
cancer that is the target of several chemotherapy drugs. SNAIL expression in
MCF7 using adenoviral vectors resulted in acquisition of adhesive and invasive
properties associated with EMT [58]. Further, SNAIL expression resulted in
8

feedback inhibition of ER-α, suggesting a potential mechanism for ER-α loss in
breast cancer [58]. Aberrant SNAIL expression was shown to promote resistance
to apoptosis in MCF7 cells, further underscoring its importance in breast cancer
malignancies [59]. Increased SNAIL expression has also been reported to promote
mammary tumor recurrence in vivo, and to predict decreased relapse-free survival
in women with breast cancer [60].
Clinical data from superficial bladder tumors have shown that high
expression of SNAIL is a significant predictor of tumor recurrence[61], potentially
due to the reported ability of SNAIL to mediate cell survival and acquisition of
cancer stem cell (CSC)-like traits [62] as seen in ovarian cancers. Indeed, SNAIL
indirectly contributes to the activation of a stem-cell-like self-renewal program by
up-regulating transcription factors like NANOG, TCF4 (Transcription factor 4),
KLF4 (Kruppel like factor 4) and GPC3 (Glypcian 3) , which further induce
expression of other pluripotency genes like OCT4 (Octamer-binding transcription
factor 4) , BMI1 and Nestin [47]. Studies have shown that SNAIL also increases
the population of cells expressing CD44+CD117+, which are ovarian CSC markers
[62], and correspondingly, the CD44(high)/CD24(low) population in breast cancer
cells, suggesting a shift to a more stem-cell like phenotype [63]. On the other hand,
work from two laboratories suggested that SNAIL-induced EMT is not
indispensable for invasion and metastasis in cancer, but was required for
chemoresistance [64], [65] [66]. However, while their finding challenged the
prevailing idea that EMT is a key player in metastasis, the question of redundancy
should be considered. While they did delete SNAIL, they failed to knock out or
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suppress other EMT- TFs (transcription factors) including TWIST, which can
function redundantly with and perform similar functions to SNAIL.
Nonetheless, these publications also pointed out that SNAIL was still
required for acquisition of drug resistance, thus highlighting the importance of
SNAIL and EMT in cancer progression, regardless of the role in metastasis.
Suppression of SNAIL-induced EMT was shown to increase cell proliferation and
sensitivity to the chemotherapeutic drug gemcitabine, thereby increasing overall
survival of mice in cervical cancer [66]. Overall, therefore, ample evidence exists
that underscores the importance of SNAIL in tumor progression, and links it to
acquisition of both drug resistance and cancer stem cell like traits. Further, if we
consider redundancy, SNAIL likely is also important for, but can be dispensed with,
for metastasis.
Regulation of SNAIL in EMT.
The process of EMT is regulated by a diverse group of extracellular
signaling molecules like epidermal growth factor (EGF), transforming growth
factor-β (TGF-β), Notch, Wingless-related integration site (Wnt), tumor necrosis
factor-α (TNF-α), and other cytokines [67], [68]. SNAIL expression is induced by
several signaling molecules from tumor microenvironment in different cellular
contexts (Fig. 1.2). For example, the growth factors EGF and Fibroblast growth
factor (FGF) induce SNAIL via activation of receptor tyrosine kinase (RTK)
signaling [69], [70]. The RTKs are activated by Hepatocyte Growth Factor (HGF),
FGF, or EGF and signal via the RAS GTPase and Mitogen Activated Protein
Kinase(MAPK) or the Phosphoinositide-3 kinase(PI3K) and Protein Kinase B also
10

Fig 1.2. Regulation of Snail by different signaling pathways. Exposure of
cells to growth factors like Fibroblast Growth Factor (FGF) and Epidermal
Growth Factor (EGF) activates the Receptor Tyrosine Kinases (RTKs). This
leads to the activation of multiple pathways: (1) The Ras pathway activates the
mitogen-activated protein kinase (MAPK), which gets translocated to the
nucleus to activate SNAI1. (2) The second pathway activates PI3K and AKT,
AKT phosphorylates Glycogen Synthase Kinase 3 Beta (GSK3β) resulting in
its inactivation. Since GSK3β negatively regulates SNAIL, decreased GSK3β
activity results in SNAIL activation. The canonical WNT pathway gets activated
by binding of WNT ligands to the Frizzled family of membrane receptors. This
leads to the release of β -Catenin from the GSK3β-Axin-APC complex which
then translocate to the nucleus to activate SNAIL. (3) The TGF- β signaling
pathway induces the phosphorylation of Smad2/3 proteins to form the RSmad/Smad4 complex, which modulates the expression of Snail. (4) TNF-α
leads to the activation of Snail via NF-κB. (5) Activation of Notch and HIF1-α
also induces the expression of SNAIL, thereby promoting EMT.

11

known as AKT pathway [69–71]. SNAIL is also upregulated by the TGF-β
signaling pathway [66]. The switch from the tumor suppressive effects of TGF-β to
tumor progression is mediated in part by the upregulation of SNAIL [66], [72], which
confers resistance to TGF-β mediated programmed cell death, leading to tumor
progression [73].
TGF-β induces EMT by upregulating SNAIL in a Smad-dependent manner
[74]. It has been reported that Smad-dependent activation of SNAIL involves
upregulation of high mobility group A2 (HMGA2) protein, which regulates
expression of many important repressors of E-cadherin [75]. Both Smads and
HMGA2 bind to the SNAI1 promoter and induce SNAI1 expression and CDH1
repression, thereby contributing to the overall EMT phenotype [75], [76]. There is
crosstalk between TGF-β- Smad pathway and Ras, Notch and Wnt signaling in
inducing SNAIL expression during development as well as in tumor metastasis [8],
[24], [77], [78]. Notch regulates SNAIL expression by either acting as a direct
transcriptional activator of SNAI1, or indirectly via lysyl oxidase (LOX). Notch
upregulates LOX by recruiting hypoxia-inducible factor 1α (HIF-1α) to the LOX
promoter, which in turn stabilizes SNAIL protein and leads to increased migration
and invasion in cancer cells [79].
SNAIL expression is also regulated by the NF-κB pathway which can be
activated in response to TNF-α which is an inflammatory cytokine [80]. TNF-α is
one of the major inflammatory cytokines that regulates SNAIL expression and
induction of EMT. In Drosophila, it has been shown that SNAIL can be directly
activated by the NF-κB homologue Dorsal [81]. NF-κB can bind to the human
12

SNAI1 promoter and regulate its transcription. Additionally, it has been
demonstrated that AKT can activate NF-κB through direct phosphorylation of IKKα
( Inhibitor of nuclear factor kappa-B kinase subunit alpha) and result in the
upregulation of SNAIL [82], [83].
Recent studies have shown that NF-κB activity is inhibited by the metastatic
suppressor Raf kinase inhibitor protein (RKIP), and conversely, SNAIL can repress
the expression of RKIP [84].
EMT can be transient in nature, and cells that have undergone EMT can
revert to an epithelial-like state through a mesenchymal-to-epithelial transition
(MET) [8], [9]. Thus, “plasticity” allows epithelial cells to undergo multiple cell state
transitions, which in turn is responsible for a wide range of cell phenotypes [7]. The
process of EMT involves several distinct molecular events starting from initiation
to completion of EMT. These events include activation of EMT transcription factors
like Snail (SNAI1), Slug (SNAI2), Zinc finger E-box binding homeobox 1 (ZEB1),
Zinc finger E-box binding homeobox 2 (ZEB2), expression of specific cell-surface
proteins, reorganization and expression of cytoskeletal proteins, production of
extra cellular matrix (ECM)-degrading enzymes, and changes in the expression of
specific microRNAs [1], [8], [10–12]. The work described in this thesis focuses on
understanding the molecular mechanisms involved in the Epithelial to
Mesenchymal (EMT) with emphasis on (a) understanding how changes in the
cellular environment influence EMT, (b) determining how the EMT transcription
factor SNAI1 is upregulated in response to EMT induction, and (c) understanding
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how cells “remember” and “record” prior exposures to environmental stimuli
through epigenetic mechanisms during the process of EMT.
Molecular Mechanisms Involved in TGF-β-induced EMT
Of all the signaling mechanisms that regulate EMT, the TGF-β family is the
most well-studied inducer of EMT. The TGF-β family members are a group of
secreted peptide growth factors that under normal conditions inhibit epithelial
growth, but paradoxically can promote tumor growth to advance cancer
progression [85]. Other than TGF-β, the TGF-β superfamily includes peptides like
activins, nodals, Bone Morphogenetic Proteins (BMPs), growth differentiation
factors (GDFs) and anti-Müllerian hormone. These secreted factors have from
66% to 80% sequence homology and are ubiquitously expressed at development
and continues into the adulthood of the organism [14] . The TGF-β ligands exist
in three isoforms (-β1, -β2, -β3) with >76% sequence homology, with TGF-β1 being
the predominant isoform in adults[86]. Active TGF-β is a 25 kDa dimeric protein
that is linked by disulfide bonds and is capable of binding to TGF-β receptors, and
is released by the action of specific proteases on latent TGF-β [87]. TGF-β
receptors are widely expressed in many human cell types, and are involved in
biological processes like development, tissue homeostasis, organogenesis, and
tissue repair under normal circumstances [88], [89].
In cancer, the TGF-β cytokine regulates cell proliferation, differentiation and
apoptosis [86], and functions as a tumor suppressor in the early stages of tumor
development, but contributes to tumor progression in the later stages when cells
become resistant to TGF-β [51]. During tumor progression, TGF-β signaling can
14

induce EMT through both a Smad-dependent as well as a Smad-independent
mechanism at the same time (Fig. 1.3) [90]. Activation of the Smad family of
transcription factors induces expression of EMT regulator genes such as SNAI1,
SNAI2 and TWIST1[91]. This Smad-dependent TGF-β signaling, also known as
the canonical TGF-β signaling pathway, involves binding of active TGF-β to a TGFβ type II receptor, leading to the activation of type I TGF-β receptor (TβRI). TβRI,
a serine/threonine kinase, subsequently phosphorylates SMAD2 and SMAD3,
which then form a complex with SMAD4 and translocates to the nucleus to regulate
transcription of target genes [66]. The importance of this mechanism can be
highlighted by the demonstration that knockdown of SMAD4 in MDA-MB-231
cancer cells prevents bone metastasis in nude mice, and significantly prolonged
survival of the treated animals [92].
Interestingly, SMAD proteins and their downstream target SNAIL can also
interact with each other. During TGF-β mediated EMT in breast epithelial cells,
SMAD3 and SMAD4 form a complex with SNAIL to target the tight-junction
proteins Coxsackievirus-adenovirus receptor (CAR) and E-cadherin, and silencing
of both SNAI1 and SMAD4 by siRNA resulted in the de-repression of CAR and
Occludin (OCLN) [93]. It has also been observed that SMAD3/SMAD4-mediated
SNAI1 transcription contributes to EMT during skin carcinogenesis [94], [95]. On
the other hand, SMAD7 can negatively regulate TGF-β signaling, as upregulation
of SMAD7 was observed to prevent TGF-β-induced EMT and cancer cell invasion
[96].
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TGF-β can also induce EMT in a non-SMAD dependent fashion, or noncanonical pathway, either directly or indirectly [51]. For example, non-Smad
signaling can be directly initiated through the activation of MAP kinase (MAPK)
pathway, Rho-like GTPase signaling pathways, the phosphatidylinositol-3-kinase
(PI3K)/AKT pathway and the TNF Receptor Associated Factor 6-Transforming
growth factor beta-activated kinase 1- Jun N-terminal kinase/P38 (TRAF6-TAK1JNK/P38) pathway [97]. In another example of a noncanonical pathway, TGF‐β
induces NF‐κB activity [98], which in turn induces transcription of cyclooxygenase‐
2 (COX‐2) and MMPs, proteins essential for tumor progression. The NF‐κB
proteins include five related proteins p50, p52, p65, RelB and c-Rel, of which NF‐
κB subunit p65 is required for activation of COX‐2 in cancer cells [99–101]. NonSmad signaling can be indirectly initiated through TGF-β/SMAD-stimulated
expression of growth factors, such as platelet-derived growth factor (PDGF) and
epidermal growth factor (EGF). This mechanism leads to the activation of ERK,
which is required for cytoskeletal remodeling. The activated extracellular receptor
kinase (ERK) protein forms a complex with SHC adaptor protein or Growth Factor
Receptor Bound Protein2 (GRB2) , which is one of the key components of the noncanonical TGF-β-induced tumor invasion and metastasis [59], [102]. Activation of
the non-Smad signaling pathways occurs in a context-dependent manner, and
these pathways often crosstalk with the canonical Smad pathway.
In addition to these SMAD/non-SMAD pathways, TGF-β signaling also
cooperates with other EMT-triggering signaling pathways like NOTCH, WNT, and
Integrins by activating several complexes [93], [103], [104]. For example, SMAD3,
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one of the downstream effector molecules of the TGF-β pathway, increases Notch
activity through upregulation of both Jagged1 (JAG1) and the Hes Related Family
BHLH Transcription Factor with YRPW Motif 1 (HEY1) genes. Upregulation of
JAG1 and Notch promote expression of SNAI2 and repression of E-cadherin,
thereby leading to an EMT phenotype [105]. Extensive research has shown that in
vivo, SMAD4 can form a complex with β-catenin and lymphoid enhancer factor1
(LEF1/TCF), which are downstream effector molecules of the WNT signaling
cascade. Thus, components of the SMAD signaling pathway induces the formation
of β-catenin/LEF1 and SNAIL-LEF1 complexes, which promote EMT by repressing
E-cadherin[106]. It has been demonstrated that TGF-β also promotes EMT
through the WNT-11 receptor FZD8 (Frizzled class receptor 8) in prostate cancer
[106]. Thus, TGF-β plays a dual role in cancer progression where it acts both as a
tumor-suppressor in normal and premalignant cells and as well as a tumor
promoter during the more advanced stages of many cancers. For example, it
functions as a tumor-suppressor in pancreatic cancer where studies have reported
that genes encoding components of the TGF-β signaling pathway like SMAD4
have been either deleted or mutated in 50% pancreatic cancer patients [107].
However, in breast cancer, since such specific mutations in TGF-β signaling
components are relatively rare [108–110] , it can be speculated that the fate of
TGF-β signaling in breast cancer development is controlled by epigenetic
mechanisms.
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The Epigenetic Regulation of EMT
Epigenetics can be defined as stable or dynamic heritable changes in gene
expression without any alterations in DNA sequence. These epigenetic changes
include chromatin structure and histone modifications, DNA methylation, and gene
silencing by non-coding RNA, and due to their reversibility, these changes can
dynamically regulate gene expression. It comes as no surprise therefore that EMT,
being a reversible and plastic process, is regulated by epigenetic changes that
modulate interaction of EMT transcription factor (EMT-TFs) with epigenetic
modifier complexes, thus contributing to cellular plasticity in cancer [111]. Below is
a brief summary of these different alterations within the context of EMT.
Histone modifications and higher order chromatin structure in EMT.
Epigenetic gene regulation is dependent on chromatin architecture, and
induction of EMT can result in dramatic alterations in histone modifications and
chromatin structure [112], which in turn impacts changes in gene expression.
Several studies have recorded changes in histone modifications during EMT. The
nucleosome is the fundamental repeating unit of chromatin, containing 147 bp of
DNA wrapped around an octamer containing two copies of each of four core
histones (H2A, H2B, H3 and H4) [113–116]. The histone proteins are positively
charged, and they interact with the negatively charged DNA to form a compact
structure [113–116]. The N-terminal tail residues of histone proteins are subjected
to post-translational modifications (PTMs) such as acetylation, methylation,
phosphorylation, ubiquitination and sumoylation by enzymes called ‘writers’ [117–
120]. Similarly, ‘reader’ proteins recognize and bind to the PTMs, while ‘eraser’
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proteins can remove the PTMs, thus demonstrating the dynamic nature of
epigenetic modifications [118].

PTMs can directly condense or de-condense

chromatin structure, and therefore regulate gene transcription [121]. Genes
located in regions of highly condensed heterochromatin are less accessible to
transcription factors and RNA polymerase complexes, and thus are typically
repressed transcriptionally [122]. On the other hand, genes located in regions of
decondensed euchromatin, which is loosely packed, are more easily accessible to
transcription factors and are sites of active gene transcription [122].
For example, acetylation of the lysine residues on histone N-terminal tails
by histone acetyltransferases (HATs) neutralizes the positive charge on the
lysines, leading to a more ‘open’ chromatin conformation [123]. Conversely,
histone deacetylases (HDACs) eraser proteins deacetylate lysine residues and
lead to transcriptional repression [123]. Methylation or demethylation of lysine
residues does not contribute to a change in the overall charge on the nucleosome,
but they turn the genes in DNA "off" and "on,” respectively, either by loosening
their tails, or by encompassing their tails around the DNA, thereby restricting
access to the DNA. Histone methylation is in general associated with
transcriptional

repression.

However,

methylation

of

some

lysine

and arginine residues of histones results in gene activation [124]. Histone lysine
methyltransferases (KMTs) lead to mono-, di-, or trimethylation of lysines [125–
130]. These methyl groups are removed (demethylation) by histone lysine
demethylases (KDMs) [125–130]. Active promoters are marked by trimethylation
of histone H3 on lysine 4 (H3K4me3) [131], while inactive promoters or
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heterochromatin regions are marked by trimethylation of lysine 9 or 27 (H3K9me3
or H3K27me3) [125], [132], [133].Though these two marks are recognized as
repressive signals, these marks are found in different chromosomal regions [133].
H3K27me3 is usually present at gene-rich regions and promoter regions of certain
developmental genes that are associated with animal development, and not in
embryonic pluripotent stem cells; whereas H3K9me3 is usually found at gene-poor
regions and is associated with permanent repression or silencing [133], [134]. Both
KMTs and KDMs target specific lysine residues. For example, G9a (KMT1C) is
responsible for mono- or demethylation of H3 lysine 9 (H3K9me1/me2) from an
unmethylated state [128], [135]. SUV39H1 (KMT1A) is responsible for
trimethylating H3K9 (H3K9me3) [126], [127] and LSD1 (KDM1A) plays a role in
demethylating H3K4me1/me2 [136]. The repressive histone marks H3K9me3 and
H3K27me3 are target sites for binding of heterochromatin protein 1 (HP1) and
Polycomb repressive complexes (PRC), respectively, which are linked to DNA
methylation and repression of gene activity [137], [138].
During EMT progression, a global reduction in the heterochromatin mark
H3K9Me2 and increase in both the euchromatin mark H3K4Me3, as well as the
transcriptional elongation mark H3K36Me3 have been observed upon addition of
TGF-β [139]. A genome-wide redistribution of the repressive mark H3K27me3 has
been observed in mouse mammary epithelial cells undergoing EMT [140]. This
redistribution of the repressive mark is mediated by histone methyltransferase
EZH2 ( enhancer of zeste homolog 2) [140]. Knockdown of EZH2 is known to
affect EMT and leads to reduction of metastasis in mouse models [141].
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Recruitment of histone modification enzymes occurs via transcription
factors, and it has been reported that the N-terminal SNAG domain of SNAIL can
act as a molecular ‘hook’ to recruit chromatin modifying enzymes [34] such as
LSD1. The very first chromatin remodeler shown to be recruited by SNAIL to Ecadherin was the Histone Deacetylase (HDAC) enzyme [142]. Since then, other
complexes including the Lysine specific Demethylase, LSD1 [35], Ajuba [39],
PRC2 [38], G9a and SUV39H1 [143] were also shown to be required for Snailmediated repression of E-cadherin [143]. SNAIL has also been reported to recruit
histone modifying enzymes like HDAC complexes to repress the E-cadherin gene
[144]. Thus far, an order of recruitment of these complexes has not yet been shown
and might be important in different cellular and pathological contexts.
Beyond the nucleosome structure, higher order chromatin structure and the
formation and function of chromatin interactions are crucial for many biological
processes such as transcription in the cellular environment. Epigenetic changes
during the process of EMT are accompanied by alterations of 3D chromatin
architecture, such as the switching of active and inactive compartments,
topologically associated domain (TAD) boundaries, and short- and long-range
chromatin looping [145]. Although a number of distinct molecular mechanisms
involved with the process of EMT in cancer have been identified but the role of
higher‐order chromatin architecture in EMT regulation and acquisition of
mesenchymal traits is still unknown [146].
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DNA methylation in EMT.
DNA methylation is a stable, heritable epigenetic mark that regulates
transcription and is important for biological processes, such as X-chromosome
inactivation, genomic imprinting and maintenance of genomic stability [147], [148].
In mammals, cytosines in DNA can be covalently methylated by DNA
methyltransferases (DNMTs) using S-adenosylmethionine as a methyl donor,
generating 5-methyl cytosine. Methylated cytosines are usually found at sites
where a cytosine is bridged to a guanine by a phosphodiester bond, also referred
to as CpG sites [149]. Barring CpG sites found in regions known as CpG islands
(CGIs), which are short stretches of DNA(~1000 bp) in which CpG is frequent (~1
per 10bp) and free from methylation, most CpG sites in the genome are methylated
[150], [151]. These CpG islands are usually found near gene promoters, and
methylation of the CpG islands near the gene promoter often, but not always, leads
to stably silenced genes [152], [153]. DNMT1 is responsible for preserving the
methylation pattern of genes after every replication [154]. It recognizes hemi
methylated DNA and adds a methyl group to the newly synthesized strand [154].
De novo DNMTs, DNMT3A and DNMT3B, can recognize and add methyl groups
to both unmethylated and hemi methylated DNA [155]. Another family member
DNMT3L, while possessing no methylation ability of its own, can interact with
DNMT3A and DNMT3B to enhance their DNA methylating activities [156]. De novo
DNA methylation of several gene promoters, including that of E-cadherin, have
been observed in human mammary epithelial cells undergoing EMT. It has also
been demonstrated in breast cancer cell lines that E-cadherin repression during
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EMT is usually associated with promoter hypermethylation, rather than mutations
[142], [157], [158].
Studies have also observed that DNA hypomethylation or demethylation
plays a role in EMT and cancer. This process is facilitated by ten-eleven
translocation

methylcytosine

dioxygenase

1

(TET1),

which

oxidizes

5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) [159], [160], which
seems to promote gene expression during active demethylation. It is hypothesized
that conversion of 5mC to 5hmC by TETs blocks the binding of the repressive
Methyl-CpG- binding domain (MBD) and DNMT proteins that would typically be
recruited to 5mC [161]. TET1 has been observed to promote properties of
stemness, and drives inhibition of EMT in cervical cancer lesions through 5hmCdependent mechanisms [162]. TET1 also serves as a co-activator of HIF-1α
transcriptional regulation to modulate HIF-1α downstream target genes and
promote epithelial-mesenchymal transition [163].
TGFβ-Induced epigenetic reprogramming in EMT.
During TGFβ-induced EMT, the activation of SMAD, PI3K/AKT or MAPK
signaling are associated with changes in the phosphorylation of histones or
epigenetic enzymes and histone deacetylases (HDAC1, 4, and 6) and EZH1/2 that
regulate chromatin architecture and remodeling [164]. In mouse hepatocytes it has
been reported that TGFβ-induced EMT is associated with genome-wide changes
in histone modifications [165]. A reduction in the repressive mark H3K9me2 and
increase in the activation mark H3K4me3 and H3K36Me3 was observed within the
large, organized heterochromatin regions after TGFβ treatment. Elevated levels of
24

LSD1(KDM1), a H3K4 and H3K9 demethylase, that is responsible for changes in
histone marks were also observed after TGFβ treatment. The decreased levels of
H3K9me2 were mainly observed in the heterochromatin-rich, large organized
chromatin K9-modifications (LOCKs) domains and the increase in levels of
H3K36me3 were found in gene-rich regions between LOCKs (at LOCKs
boundaries) that contain motility genes and genes with EMT-related functions
[112]. Thus, the changes in histone modifications in response to TGF-β are highly
context-dependent in terms of the residue and the region within the genome in
which it occurs. Loss of histone acetylation and gain of repressive marks like
H3K27me3 can be associated with the repression of epithelial genes. Coexistence of bivalent marks represent a poised transcription state [166], [167]. It
has been observed that co-existence of H3K4me3 and H3K27me3 can lead to reexpression of genes after withdrawal of EMT-inducing signals or under specific
physiologic conditions [168]. Continuous EMT-inducing signals lead to subsequent
loss of H3K4me3 and enrichment of more stable repressive histone marks
including H3K9me2 and H3K9me3 [139].
Besides histone modification changes, it has been noted that the
TGFβ/Smad signaling pathway plays an integral role in the maintenance of DNA
methylation patterns of epithelial genes. It has been observed that knockdown of
Smad2 is associated with reversal of the methylation pattern thereby blocking EMT
[169]. SNAIL is known to form a complex between G9a and DNMT1 to modulate
DNA methylation of E-cadherin promoter [144]. In a nutshell, various histone
modifications and DNA methylation events regulate the highly dynamic
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transcriptional events of the EMT program, ranging from fully epithelial to fully
mesenchymal state. Even DNA methylation in the promoter of epithelial genes can
create a highly stable mesenchymal state that can persist over many cell
generations. Studies have reported on emergence of epigenetic silencing of Ecadherin after a single round of EMT [170]. Studies have also observed that
histone acetylation or demethylation can also suppress the induction and
maintenance of SNAI1-mediated EMT [171]. However, there is a gap in knowledge
as to whether epigenetics can give rise to ‘cellular memory’ in the context of EMT,
and how this might be maintained over generations.
Dissertation Objective
This dissertation is sectioned into three projects that describe three key
events that occur during TGF-β induced EMT, namely extracellular cues that must
be transmitted to the nucleus to elicit activation of SNAIL transcription, recruitment
of transcription factors (TFs) to the SNAIL gene and subsequent transcription, and
finally propagation of the signaling response over multiple generations to maintain
the EMT response. The first project aims to determine the role of the calcium
channel protein ORAI3 in activation of SNAIL during TGF-β mediated EMT. The
second study contrasts SNAIL activation through two signaling mechanisms,
namely EGF vs TGF-β signaling focusing on the promoter activation of SNAIL. The
third project aims to determine how some (but not all) genes, including SNAIL,
respond to EMT-inducing signals and establish a ‘memory’ of gene transcription
that is faithfully propagated across several cellular generations, enabling cells to
show an elevated response to subsequent rounds of EMT.
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First, we demonstrate that blocking store-operated calcium entry (SOCE)
with

2-aminoethoxydiphenylborane

(2APB)

reduces

cell

migration

but,

paradoxically, increases the level of TGF-β -dependent Snai1 gene activation. We
determined that this increased Snai1 transcription involves signaling through the
AKT pathway and subsequent binding of NF-κB (p65) at the Snai1 promoter in
response to TGF-β. We also demonstrated that the calcium channel protein ORAI3
and the stromal interaction molecule 1 (STIM1) are required for TGF-β
dependent Snai1 transcription. These results suggest that calcium channels
differentially regulate cell migration and Snai1 transcription, indicating that each of
these steps could be targeted to ensure complete blockade of cancer progression
[172].
Next, we sought to identify the upstream transcriptional regulators of the
SNAI1/Snai1 gene in EMT. We used a bioinformatics approach to determine which
protein binding sites were present at the SNAI1/Snai1 gene and determined that
the CCCTC-binding factor (CTCF) potentially associated with the SNAI1/Snai1
gene. We used two different stimuli, TGF-β and EGF, to induce EMT using a
classic model of EMT, the non-cancerous NAMRU Murine Mammary Gland Cells
(NMuMGs). We observed the enrichment of CTCF protein at the SNAI1 gene in
both steady state cancer cells, as well as in TGFβ- induced EMT in non-cancerous
cells. However, there was no significant change in CTCF enrichment at the SNAI1
gene in non-cancerous cells induced with EGF. We also observed that knocking
down CTCF leads to a decrease in TGFβ- induced Snai1 expression, but not in
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EGF-induced EMT, thereby indicating that CTCF might play a role in transcriptional
upregulation of Snai1 gene in TGFβ induced EMT.
For the third project, I used an in vitro cell culture model of short and longterm transcriptional memory using mouse mammary gland cells to study the
response to TGF-β. I show that TGF-β stimulation establishes transcriptional
memory in mouse mammary gland epithelial cells leading to elevated
transcriptional response upon restimulation. In our model of long-term memory,
the memory response was inherited through 27 cell divisions, and led to increased
migratory capacity upon restimulation with TGF-β.

Of the ~1800 TGF-β -

responsive genes, about 490 genes show an increased “memory” response
relative to naïve cells, which we classified as memory genes. The rest are defined
as non-memory (no differential expression compared to naïve cells) or refractory
(decreased expression relative to naïve cells) genes. Mechanistic analysis showed
that TGF-β memory was not due to enhanced TGF-β signaling or retention of
transcription factors on the memory genes (Smad3 ChIP-qPCR) but higher
recruitment of SMAD3 and Pol II at the promoter of the memory genes upon
restimulation with TGF-β might contribute to the memory formation. We observed
that all TGF-β responsive genes in the long-term memory model were marked by
histone H3K4 monomethylation and H3K27 acetylation, which persists several
generations after removal of the initial response, unlike H3K4Me3 and other
histone marks that we tested, which do not remain once the initial burst of
transcription is lost upon removal of TGF-β, nor are they retained over the next
several generations. We show that this increased response is potentially due to
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more repressed chromatin at a subset of TGF-β responsive genes which coincides
with the acquisition of H3K4Me1 and H3K27Ac marks, loss of H3K27Me3 mark at
those genes and higher recruitment of transcription factors and Pol II at the
memory genes after restimulation in the 1xT cells.
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CHAPTER 2
PROJECT 1: THE CALCIUM CHANNEL PROTEINS ORAI3 AND STIM1
MEDIATE TGF-ß INDUCED SNAI1 EXPRESSION.

“The calcium channel proteins ORAI3 and STIM1 mediate
TGF-β induced Snai1 expression.”
Oncotarget.2018 Jun.

Contents of this chapter are derived from the publication
Atrayee Bhattacharya, Janani Kumar, Kole Hermanson, Yuyang Sun, Humaira
Qureshi, Danielle Perley, Adam Schiedegger, Brij B. Singh and Archana
Dhasarathy.
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Abstract
Calcium influx into cells via plasma membrane protein channels is tightly
regulated to maintain cellular homeostasis. Calcium channel proteins in the plasma
membrane and endoplasmic reticulum have been linked to cancer, specifically
during the epithelial-mesenchymal transition (EMT), a cell state transition process
implicated in both cancer cell migration and drug resistance. The transcription
factor SNAI1 (SNAIL) is upregulated during EMT and is responsible for gene
expression changes associated with EMT, but the calcium channels required for
Snai1 expression remain unknown. In this study, we show that blocking storeoperated calcium entry (SOCE) with 2-aminoethoxydiphenylborane (2APB)
reduces cell migration but, paradoxically, increases the level of TGF-β dependent
Snai1 gene activation.
We determined that this increased Snai1 transcription involves signaling
through the AKT pathway and subsequent binding of NF-κB (p65) at the Snai1
promoter in response to TGF-β. We also demonstrated that the calcium channel
protein ORAI3 and the stromal interaction molecule 1 (STIM1) are required for
TGF-β dependent Snai1 transcription. These results suggest that calcium
channels differentially regulate cell migration and Snai1 transcription, indicating
that each of these steps could be targeted to ensure complete blockade of cancer
progression.
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Introduction
Most cancer-associated deaths (about 90%) result from metastatic disease
rather than the primary tumor. The spread of cancer cells from their primary
regions of origin to distant metastatic sites is a multi-step process beginning with
invasion of the cancer cells into surrounding tissue, intravasation of cells into the
blood stream, extravasation to the secondary site, and finally, regrowth of the
tumor cells as secondary metastases. A reversible process termed the ‘epithelial
to mesenchymal transition’ (EMT) is an important developmental program that
enables epithelial cells to lose apico-basal polarity, detach from their neighbors
and from the extracellular matrix, and become more migratory and mesenchymal
reviewed in [1-3]. This process is essential during the early developmental stages
of gastrulation and neural crest migration [4, 5]. This developmental EMT program
is hijacked by cancer cells to facilitate the process of metastasis, and can be
induced by stimuli released in the tumor microenvironment such as the cytokine
TGF-β [6]. TGF-β binds to the TGF-β receptor II (TGFBR2) in the plasma
membrane and, through a well-studied signaling cascade [7-9], causes
upregulation of Snai1 gene expression [10].
The SNAI1 transcriptional repressor protein has been well studied in the
context of EMT and is essential for gastrulation, as deletion of the gene results in
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lethality due to inhibition of embryonic development past the gastrula stage [4, 5].
SNAI1 is also positively correlated with metastatic tumors, and high levels of
SNAI1 are predictive of decreased relapse-free survival in women with breast
cancer [11]. Following binding to its cognate DNA sites, SNAI1 functions as a
transcription factor, repressing expression of genes such as E-cadherin (CDH1)
by recruiting chromatin remodeling complexes, leading to loss of cell-cell adhesion
[12]. SNAI1 is also known to be upregulated in response to genotoxic stresses in
the environment, thus preventing apoptosis [13]. A recent study suggested that
while SNAI1-induced EMT is not absolutely needed for the physical migration of
cells during metastasis, it does contribute to increased tumor survival and drug
resistance [14].
TGF-β induced EMT in MCF7 breast cancer cells has also been shown to
be associated with increased calcium influx into the cell [15]. Calcium levels in the
cell can also influence cell migration during EMT [16-18]. Protein channels in the
plasma membrane including the transient receptor potential (TRP) and ORAI
channels function as store-operated calcium (SOC) channels that regulate the
influx of calcium into the cell to modulate various biological processes. Importantly,
TRPC1 and the Stromal Interaction Molecule 1 (STIM1) have been shown to
facilitate cell migration during EMT [19]. Further, treatment with TGF-β caused an
increase in calcium-induced calpain activity, which reduced E-cadherin protein
levels, thereby increasing cell migration [19].
Blockade of SOCE was also shown to inhibit cell migration. For instance,
pharmacological inhibition of SOCE with SKF [19] or silencing of ORAI1 and
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STIM1 was shown to inhibit cell migration in MDA-MB-231 breast cancer cells [20].
Further, chelation of intracellular calcium with BAPTA-AM reduced EGF-induction
of cell migration in the MDA-MB-468 breast cancer cell line [16]. On the contrary,
BAPTA-AM had opposite effects on two EMT transcription factors- it increased
levels of TWIST1, but decreased the EGF- induced expression of SNAI1, a factor
associated with decreased relapse-free survival in women with breast cancer [11].
This seemingly paradoxical finding can be potentially explained by a recent study
suggesting that SNAI1 is not absolutely needed for the physical migration of cells,
but contributes to increased tumor survival and drug resistance [14]. Although
these studies point to a link between calcium and migratory events leading to EMT,
the identity of calcium channels needed for regulation of transcription factors that
could modulate EMT was not explored.
Similar to our previous study [19], we noted that addition of the SOCE
inhibitor 2-Aminoethoxydiphenylborane (2APB) prevented migration induced
during EMT by TGF-β. However, 2APB amplified the TGF-β dependent expression
of the Snai1 gene, while induction of EMT genes Zeb1, Zeb2, Twist1 and Twist2
remained unaffected (Fig. 2.1) at the time points tested. Expression of Slug (Snai2)
was amplified relative to TGF-β alone in response to TGF-β+2APB at the 2h point,
but the effect was lost at later points. On the other hand, use of SKF96365
hydrochloride (SKF), another SOCE inhibitor that blocks SOC and voltage gated
calcium channels, decreased the extent of TGF-β -induced Snai1 induction
(Fig.2.2). To better understand how 2APB specifically increased TGF-β dependent
Snai1 expression, and to determine how calcium-signaling proteins alter cellular
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Figure 2.1. 2APB amplifies the TGF-β dependent upregulation of Snai1
transcription NMuMG cells were serum-starved for 4h, and then treated with DMSO
or 2APB for 24h, and TGF-β for 2 (A), 8 (B) and 24 (C) hours. RNA was isolated from
NMuMG cells and cDNA prepared using reverse transcription. Expression of EMT
genes was examined by real-time PCR of the cDNA using primers against each of the
genes and normalized to 18S rRNA. Data were derived from at least three
independent biological replicates and are represented as mean ± SEM values. The *
indicates p-value of ≤ 0.05, and *** indicates p-value ≤ 0.001 as measured by a paired
t-test. (D) Protein analysis of NMuMG lysates treated with DMSO, or 2APB for 24h,
and with TGF-β for 8h (added after 16h of treatment with 2APB) as above was
performed using western blotting with antibodies against SNAI1 and ACTIN. The blot
is representative of at least 3 independent biological replicates. Quantitation was
performed as described in methods, normalizing the signal to ACTB loading control.
(E) Expression of E-cadherin, a downstream target of all the above EMT was
measured from the same time points as in (A, B and C). (F) To test whether the
increase seen in Snai1 expression is due to increase in transcription, cells were
treated with DMSO or 2APB for 24h, followed by TGF-β, and Actinomycin D was
added 2h after addition of TGF-β for 1h. RNA isolation was followed in a time course
of up to 2h after Actinomycin D treatment. RNA was converted to cDNA and Snai1
expression measured as in (A, B, C and E). Statistical analyses were performed with
Graphpad Prism software. *= p-value ≤ 0.05.
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Figure 2.2. The SOCE inhibitor SKF96365 decreases TGF-β induction of
Snai1 gene expression, but not other EMT TFs. NMuMG cells were serumstarved for 4h, and then treated with DMSO or SKF for 24h, and TGF-β for 2
hours. RNA was isolated from NMuMG cells and cDNA prepared using reverse
transcription. (A) Expression of Snai1 and (B) other EMT genes was examined by
real-time PCR of the cDNA using primers against each of the genes and
normalized to 18S rRNA. Data were derived from at least three independent
biological replicates and are represented as mean ± SEM values. The * indicates
p-value of ≤ 0.05, and *** indicates p-value ≤ 0.001 as measured by a paired t-test.

responses to TGF-β, we used RNA-sequencing to examine gene expression
changes in the presence of 2APB. We observed that expression of a subset of
genes in response to TGF-β was reversed with the addition of 2APB, which might
reflect the reversion of the EMT phenotype. On the other hand, some Snai1 target
genes were either relatively unaffected, or affected to an increased level,
suggesting

that

sustained

Snai1

expression

could

have

downstream

consequences. Next, we show here that the 2APB dependent amplification of the
TGF-β induced Snai1 activation occurs in part via the AKT and NF-κB signaling
pathways. Finally, we show that 2APB appears to activate the ORAI3 [21-24]
calcium channel, as knockdown of ORAI3 (or its interacting partner protein STIM1)
results in loss of Snai1 activation even in the presence of TGF-β. Taken together,
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these studies highlight the fact that cancer therapies should not only target physical
migration of cells (EMT), but also prevent cancer cell survival and drug resistance
through targeting genes like SNAI1, which are associated with increased
chemoresistance.
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Materials and Methods
Cell Culture
NMuMG (ATCC #CRL-1636) and MDA-MB-231 (ATCC #HTB-26) cells
were obtained directly from American Type Culture Collection and were cultured
at 37°C under 5% CO2 in DMEM/F-12 media (Thermo Fisher) containing 10% fetal
bovine serum (FBS, Atlanta Biologicals). Cells were serum-starved for 4h prior to
treatment with TGF-β (Sigma # H8541).
Treatments
Cells were treated with TGF-β (5ng/ml final; Sigma-Aldrich) for 8h prior to
protein isolation, and for 2h, 8h or 24h prior to RNA isolation, unless noted
otherwise. Cells were treated with 2APB (50uM final; Sigma-Aldrich) for a period
of 24h prior to TGF-β treatment. Actinomycin D (1ug/ml final; Sigma-Aldrich)
treatments were for 1h after stimulation with TGF-β. Cells were treated with 10uM
final SKF96365 hydrochloride (Sigma, #567310-M) for a period of 24 h prior to
TGF-β treatment for 2h. For treatment with p65 inhibitor ACHP, NMuMG cells were
serum starved for 4hours. After serum starvation, the cells were treated with 2APB
for 24 hours. At 18 hours, the cells were treated with 50uM of the NFKB inhibitor
ACHP for a 4-hour pretreatment as previously published. Before addition of TGFB at 22 hours. For the AKT1/2 inhibitor, NMuMG cells were treated with 10uM of
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the inhibitor at 20 hours for a 2-hour pretreatment as described previously [38]
before the TGF-B treatment at 22 hours for 2 hours.
Transfection
Transfections of cells with siRNAs (mouse for NMuMG and human for MDAMB231, Ambion) were performed using Lipofectamine 3000 for two rounds of
transfection (50pmol reverse for 48h, 50pmol forward for 48h) using a final
concentration of 100 pico moles of siRNA. The cells were treated with 2APB or
TGF-β after 96h of transfection for appropriate time points prior to RNA and Protein
isolation.
RNA Isolation
RNA was isolated from cells using the RNeasy kit (Qiagen) according to the
manufacturer’s instructions. Genomic DNA was removed by on-column DNA
digestion with RNase-Free DNase Set (Qiagen). RNA quality and concentration
were assessed using a spectrophotometer (NanoDrop), and by electrophoresis on
a 2% agarose gel.
qRT-PCR
Total RNA was extracted from cells using RNeasy kit (Qiagen) and checked
for integrity using agarose gel electrophoresis. One microgram of RNA was used
to synthesize cDNA using random hexamer priming and SSRT-III reverse
transcriptase (Life Technologies), followed by qPCR using Quantitect (Qiagen)
primer assays or primers designed and ordered from IDT as listed in Table 2.1.
Data were normalized against Rrn18S gene transcripts (Quantitect, Qiagen). Data
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Table 2.1. List of primers used for gRT PCR
IDT RT PRIMERS
Mm_Twist2_RT_F
cgctacagcaagaaatcgagc
Mm_Twist2_RT_R
gctgagcttgtcagagggg
Mm_Zeb1_RT_F
ccatacgaatgcccgaactg
Mm_Zeb1_RT_R
aacactgagatgtcttgagtcct
Mm_Zeb2_RT_F
agagcttgaccaccgactcaa
Mm_Zeb2_RT_R
ttgcaggactgccttgatctc
Mm_Orai1_RT_F
atgagcctcaacgagcact
Mm_Orai1_RT_R
gtgggtagtcatggtctg
Mm_Orai3_RT_F
gtaccgggagttcgtgca
Mm_Orai3_RT_R
ggtattcatgatcgttctc
Mm_Stim1_RT_F
accgaagcagagttttgccga
Mm_Stim1_RT_F
tcttcccttaggaactcatcact
Mm_Stim2_RT_F
actggagcaggtccgcatg
Mm_Stim2_RT_F
tctgcctcgtccttagcgat
Hs_ORAI1_RT_F
tactccgaggtgatgagcct
Hs_ORAI1_RT_R
acctccaccattgccaccat
Hs_ORAI3_RT_F
ctgccttgctctcgggctt
Hs_ORAI3_RT_R
gacacgtggagaccatgagt
Hs_STIM1_RT_F
gagttggagcaggttcggg
Hs_STIM1_RT_R
ttgcacctccacctcatgtgt
Hs_STIM2_RT_F
ttggacctctaacacgccca
Hs_STIM2_RT_R
tttcaagcctctcctgtaagtc
Qiagen Quantitect Primer Assays
Hs_SNAI1_1_SG
QT00010010
Hs_SNAI2_1_SG
QT00044128
Hs_ZEB1_2_SG
QT01888446
Hs_ZEB2_1_SG
QT00008554
Hs_TWIST1_1_SG
QT00011956
Hs_CDH1_1_SG
QT00080143
Hs_GAPDH_1_SG
QT00079247
Hs_RRN18S_1_SG
QT00199367
Mm_Snai1_1_SG
QT00240940
Mm_Snai2_1_SG
QT00098273
Mm_Twist1_1_SG
QT00097223
Mm_Cdh1_1_SG
QT00121163
Mm_Rn18s_3_SG
QT02448075
Mm_Gapdh_3_SG
QT01658692
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were derived from at least three independent biological replicates and are
represented as mean ± SEM values. Data were analyzed using the delta-delta Ct
method as described previously [43, 56]. Statistical analyses were performed using
the GraphPad Prism software, version 7.0.
Library Construction and RNA-Sequencing
The total RNA isolated as described above was used for 50 bp single-end
RNA-Sequencing at the University of Minnesota Genomics Center (UMGC) on the
Illumina HiSeq 2000. RNA quality was assessed with the Agilent Bioanalyzer, and
samples with high RNA integrity number (RIN >8) were used for library
construction following the manufacturer’s (Illumina) instructions. In summary, 1
microgram of total RNA was oligo-dT purified using oligo-dT coated magnetic
beads, chemically fragmented and then reverse transcribed into cDNA. The cDNA
was fragmented, blunt-ended, and ligated to indexed (barcoded) adaptors and
amplified using 15 cycles of PCR. Final library size distribution was validated using
capillary electrophoresis and quantified using fluorimetry (PicoGreen) and via QPCR.

Indexed libraries were normalized, pooled and then size selected to

320bp +/- 5% using Caliper’s XT instrument. TruSeq libraries were hybridized to a
single end flow cell and individual fragments clonally amplified by bridge
amplification on the Illumina cBot. Once clustering was complete, the flow cell was
loaded on the HiSeq 2000 and sequenced using Illumina’s SBS chemistry. Two
biological replicates for each treatment were sequenced, resulting in an average
of 50 million reads per sample. Base call (.bcl) files for each cycle of sequencing
were generated by Illumina Real Time Analysis (RTA) software. The base call files
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and run folders were then exported to servers maintained at the Minnesota
Supercomputing Institute. Primary analysis and de-multiplexing were performed
using Illumina’s CASAVA software 1.8.2. The end result of the CASAVA workflow
is de-multiplexed FASTQ files that were subject to subsequent analyses as
described below.
RNA-seq Data Analyses
Preliminary quality control analysis of fastq files was performed with FastQC
v0.11.2 [57]. Reads were aligned to human genome (hg19), using TopHat v2.0.13
[58]. Read counts were summarized at the gene level using the featureCounts [59]
function in the Rsubread v1.16.1 package [60]. Differential expression analysis
was performed using the R/ Bioconductor package DESeq2 v1.6.3 [61]. Genes
were considered differentially expressed if they had a FDR of 0.05 or less and a
mean count of 20 or more. Hierarchical clustering of Pearson correlation values
was performed using the aheatmap function in the R package NMF v0.20.6 [62].
Venn diagrams were drawn with the R package VennDiagram v1.6.17 [63].
Network mapping and functional analyses were generated through the use of IPA
(QIAGEN

Inc.,

https://www.qiagenbioinformatics.com/products/ingenuity-

pathway-analysis) [64]. RNA fastq files are accessible via the NCBI Gene
Expression Omnibus (GEO) database [65] with experiment series accession
number GSE98596. To investigate the expression changes causing the reversion
of the mesenchymal phenotype seen in the 2APB treated cells, we looked for
genes whose expression changes when treated with TGF-β were reversed by the
addition of 2APB. First, we calculated the ratio of the expression log2 fold change

68

values (as calculated by DESeq2) of the TGF-β to DMSO treated cells and the
TGF-β to TGF-β + 2APB treated cells. We reasoned that values of this ratio around
1, with a sign change, would indicate expression values that had changed in one
direction upon treatment with TGF-β, and then changed a similar magnitude in the
opposite direction when adding the 2APB treatment. We filtered out genes with a
mean expression value less than 10 normalized counts to remove noise in the data
set. A range of ratio values of -1.5 to -0.5 was chosen for further analysis to catch
the bulk of the distribution around -1.0 relating most accurately to the effect we
were trying to capture. As above, hierarchical clustering of Pearson correlation
values was performed using the aheatmap function in the R package NMF v0.20.6
[62] and network mapping and functional analyses were generated through IPA.
Protein Isolation and Immunoblotting
Proteins were extracted by lysing cell pellets in urea lysis buffer (8M urea,
1%SDS in Tris-HCl pH 6.5) containing CompleteTm protease inhibitors (Roche) and
phosphatase inhibitors (Sigma- Aldrich), and subsequent heating to 95°C for 5 min.
Protein concentration was estimated using the Qubit (Thermo Scientific) protein
assay kit, following the manufacturer’s instructions. Western blotting was
performed as previously described [43, 56], using the following antibodies: antiSNAI1 (Cell signaling, mouse mAb #3895), anti-phosho-AKT (Ser 473) (Cell
signaling, rabbit pAb #9271), anti-total-AKT(Cell signaling, rabbit pAb #9272), antiPhospho-NF-κB p65 (Ser536) (Cell signaling, rabbit mAb #3033), anti-total-NF-ΚB
p65 (Cell Signaling, rabbit mAb #8242), anti- STIM1 (Cell Signaling, rabbit mAb #
5668), anti-STIM2 ( Proteintech, rabbit pAb #211921-1-AP), anti-ORAI1
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(Proteintech, rabbit pAb #13130-1-AP), anti-ORAI3 (Genetex, rabbit pAb
#GTX85677: this antibody worked best with mouse samples) anti-ORAI3 (
BosterBio, rabbit pAb A09399; this antibody worked best for human samples) with
a dilution of 1:1000 in 5% non-fat dried milk (5% BSA for the antibodies specific to
phosphorylated proteins) in 0.1% TBS-T. Anti-GAPDH (Millipore, rabbit pAb #
ABS16) was used with a dilution of 1:5,000 in 5% non-fat dried milk in 0.1% TBST. Secondary antibodies anti-rabbit IgG, peroxidase-linked species-specific whole
antibody (from donkey)-45-001-276(GE Healthcare) and anti-mouse IgG,
peroxidase-linked-species-specific whole antibody (from sheep; 45-001-275; GE
Healthcare) were diluted 1:10,000 in 5% non-fat dried milk in 0.1% TBST and blots
were developed using the Li-COR Odyssey instrument (Li-COR Biosciences)
using Luminata Forte Western HRP substrate (WBLUF0500). Western blots
presented are representative of at least 3-4 biological replicates, and were
quantified using Licor software, and signal normalized to GAPDH, ACTB or total
p65/ total AKT as denoted for each figure. Statistical analyses were performed with
GraphPad Prism software.
Chromatin Immunoprecipitation (ChIP)
ChIP was performed as previously described [44, 56] with the following
exceptions. In brief, cells were crosslinked with 1% formaldehyde for 5 minutes at
37°C, Quenced with 2M glycine and washed with PBS, and then sonicated in the
Covaris

S220

sonicater

(fill

level=8,

peak

power=120,

duty

factor=3,

cycles/burst=200) to generate 300–600bp DNA fragments. Immunoprecipitation
was preformed using the antibodies indicated, and IgG was used as a control.
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Precipitated DNAs were detected by PCR using specific primers as shone in Table
2.2. Quantitation was performed on immunoprecipitated DNA using the CFX384
real-time PCR machine (Bio-Rad) with SYBR-green, and the percent input for each
sample was calculated based on a standard curve 10%, 1%, 0.1% and 0.01% of
input DNA.
TABLE 2.2. List of primers used for ChIP-qPCR
ChIP PRIMERS
Snai1_ChIP_U1_F
aggatgcccgtaccttagtg
Snai1_ChIP_U1_R
tggccatgcagctcagagat
Snai1_ChIP_U2_F
ggaagaactctggcctttca
Snai1_ChIP_U2_R
agcatccctgagatcaatcc
Snai1_ChIP_P1_F
tgtttattctgtctgtctctctct
Snai1_ChIP_P1_R
agccagaaagtgcgatgatatg
Snai1_ChIP_prom_F
tacctaggtcgctctggccaacat
Snai1_ChIP_prom_R
cgtcctgcagctcgctatagt
Snai1_ChIP_P2_F
ttcaccttccagcagccct
Snai1_ChIP_P2_R
gacagcgaggtcagctcta
Snai1_ChIP_P3_F
gacctgtggaaaggccttct
Snai1_ChIP_P3_R
aatggagaacaaccaacatctact

Calcium Measurements
Cells were incubated with 2 μM fura-2 (Molecular Probes) for 45 min,
washed twice with calcium free SES (Standard External Solution, include: 10 mM
HEPES, 120 mM NaCl, 5.4 mM KCl, 1 mM MgCl2, 10 mM glucose, pH 7.4) buffer.
For fluorescence measurements, the fluorescence intensity of Fura-2-loaded
control cells was monitored with a CCD camera-based imaging system (Compix)
mounted on an Olympus XL70 inverted microscope equipped with an Olympus
40× (1.3 NA) objective. A monochrometer dual wavelength enabled alternative
excitation at 340 and 380 nm, whereas the emission fluorescence was monitored
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at 510 nm with an Orca Imaging camera (Hamamatsu, Japan). The images of
multiple cells collected at each excitation wavelength were processed using the C
imaging, PCI software (Compix Inc., Cranbery, PA), to provide ratios of Fura-2
fluorescence from excitation at 340 nm to that from excitation at 380 nm
(F340/F380). Dispersed cells were placed on glass-bottom poly-D lysine plates
and used for the study. Fluorescence traces shown represent [Ca2+]i values that
are averages from at least 30-40 cells and are a representative of results obtained
in at least 3-4 individual experiments.
Migration Assays
Confluent cells in a 6-well plate were serum starved for 4h prior to treatment,
and TGF-β (for 8h) and/or 2APB (for 24h) were added to the wells prior to
wounding using a sterile 200ul tip. Three representative fields were marked and
imaged immediately at time of (0h) and a time period after (8h) wounding as
described [66, 67]. Cell migration across the wound was analyzed using ImageJ
with MRI Wound healing plugin [68]. The tool measures the area of the wound, i.e.
the area that does not contain cells, in each image. A ratio of the area of the wound
at the start of wounding and at the end of wound closure is estimated as the
percent of cell migration. Data are the average of at least 4 independent
experiments, and statistical analyses were performed using GraphPad Prism 7
software.
Statistical Analysis
All statistical analyses for RT-PCR, ChIP and migration assays were
performed using GraphPad Prism 7 (GraphPad Software). Data were expressed
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as mean ± standard error of the mean (S.E.M). The statistical correlation of data
between groups was analyzed by a two-tailed Student’s t-test, where P<0.05 was
considered significant.
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Results
2APB Amplifies the TGF-β Dependent Upregulation of SNAI1 Transcription
We previously demonstrated that blocking calcium influx hindered EMT as
seen by loss of cell migration [19]. Further, previous work has demonstrated that
inhibition of SOCE could differentially affect transcription of EMT proteins [16].
However, the calcium channel essential for observed Snai1 upregulation in
response to blocking calcium entry has not yet been identified. To evaluate how
SOCE influenced EMT transcription factor expression in response to TGF-β, we
induced EMT in the murine mammary gland cell line, NMuMG. As expected, we
found that addition of TGF-β upregulated Snai1 expression ~9-fold relative to
DMSO treated cells within 2hr of TGF- β treatment shown in Fig. 2.1.A. Upon
treatment with both TGF-β and 50nM of the SOCE modulator 2APB
(2- aminoethoxydiphenyl borate), there was a further increase in Snai1
transcription (~20-fold total increases relative to DMSO) (Fig. 2.1.A). The increase
in Snai1 mRNA expression gradually decreased over time (within 24 hr). SNAI1
protein levels remained elevated with both TGF-β and TGF-β+ 2APB treatments
relative to DMSO or 2APB controls as assessed by western blot (Fig. 2.1.D).
Further, the expression of Slug (Snai2) was not significantly increased with TGFβ treatment at 2h but increased ~6 fold when cells are treated with 2APB and TGFβ in combination (Fig. 2.1.A). Transcription of the other EMT factors appear
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unaffected even after longer treatments with TGF-β at the time points tested (Figs.
2.1.A, B, and C). Together these results suggest that only Snai1 gene expression
is increased following TGF-β induction and maintained above background in the
presence of 2APB (Figs. 1.1.A–C) at the time points tested.
As blockade of SOCE has been previously shown to prevent cellular
migration associated with EMT [16, 19], we next asked if the SNAI1 protein was
still functional. To this end, we assayed expression of E-cadherin mRNA, a wellknown downstream target of SNAI1 (Fig. 2.1.E). Consistent with SNAI1 remaining
fully functional, E-cadherin mRNA levels are downregulated with TGF-β treatment
and remain low even with addition of 2APB (Fig. 2.1.E). Next, to determine whether
the increase in Snai1 expression is due to elevation of transcription or,
alternatively, reflects increased mRNA stability, we used Actinomycin D, a
commonly used inhibitor of transcription. We induced Snai1 gene expression for
2h with TGF-β or TGF-β + 2APB, followed by Actinomycin D treatment (Fig. 2.1.F).
Snai1 mRNA expression is highest at 2h following TGF-β addition and then
gradually decreases over time, as previously observed. When cells are treated
with Actinomycin D, there is a more rapid loss of Snai1 mRNA expression relative
to cells treated with TGF-β alone, suggesting that TGF-β addition affects Snai1
gene transcription. With the addition of 2APB, we see a similar result to the
TGF-β treatment, although the initial levels of Snai1 mRNA are higher, there is still
a gradual loss of transcription over time, as seen with the TGF-β treatment alone.
Addition of Actinomycin D prior to the treatment with TGF-β and 2APB results in
rapid loss of Snai1 transcription, like the TGF-β with Actinomycin D treatment,
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suggesting that addition of 2APB does indeed affect transcription of Snai1.
Together, these findings show that 2APB causes a specific increase in TGF-βdependent transcription of Snai1, but not other EMT genes at the time points
tested.
Next, we tested the effect of another SOCE inhibitor SKF96365
hydrochloride (SKF), that blocks STIM1, TRPC, ORAI and voltage gated calcium
channels. Unlike 2APB, treatment of cells with SKF96365 hydrochloride (SKF), the
TGF-β induced increase in Snai1 mRNA expression was decreased, but not
completely blocked by SKF as shown in Fig. 2.2.A. Use of SKF did not significantly
influence expression of other tested EMT transcription factors as shown in Fig.
2.2.B.
We also tested the effect of 2APB on SNAI1 expression in the metastatic
MDA-MB-231 breast cancer cell line as shown in Fig.2.3. We noted sustained
increase in SNAI1 expression at all time points tested above the levels seen with
TGF-β alone. While SNAI2 expression increases with TGF-β, there is no additional
effect on its expression with 2APB treatment (Fig.2.3), and other EMT factors are
unaffected by 2APB treatment as well at the time-points and concentrations tested.
Addition of 2APB Reverses TGF-β-Specific Gene Expression to Inhibit
Migration
To obtain a genome-wide view of the gene expression changes induced by
TGF-β then affected by 2APB, we performed RNA-sequencing on NMuMG cells
that were treated with Dimethylsulfoxide (DMSO, vehicle control), TGF-β, or TGFβ+ 2APB for 24h as shown in Fig 2.4. Differential expression analysis revealed
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Figure2.3. Blocking SOCE with 2-APB causes increase in Snail transcription
following TGF-β treatment in MDA-MB-231 cells. MDA-MB-231 cells were
serum-starved for 4h, and then treated with DMSO or 2APB for 24h, and TGF-β for
2 (A), 8 (B) and 24 (C) hours. RNA was isolated from NMuMG cells and cDNA
prepared using reverse transcription. Expression of EMT genes was examined by
real-time PCR of the cDNA using primers against each of the genes and normalized
to 18S rRNA. Data were derived from at least three independent biological
replicates and are represented as mean ± SEM values. The * indicates p-value of
≤ 0.05, and *** indicates p-value ≤ 0.001 as measured by a paired t-test.

that there were 5,992 genes significantly altered in TGF-β treatment relative to
DMSO, and this number increased to 7,326 when 2APB was added to TGF-β
(Fig. 2.4.B). Of these 7,326 genes, 5,185 were also differentially expressed in
response to TGF-β alone (Fig. 2.4.B, C). Therefore, 2,141 genes were uniquely
altered in expression due to 2APB+TGF-β alone. Of the genes that were
upregulated in both comparisons (3,105 with TGF-β only and 3,671 with
2APB+TGF-β), there was a substantial overlap between the two (2,516 genes
were common to both datasets). This left 1,155 genes that were unique to the
2APB+TGF-β dataset. Similarly, of the differentially downregulated genes (2,887
with TGF-β and 3,655 with 2APB+TGF-β), 2,606 genes overlapped in both
datasets. We generated network maps and functional analyses of differentially
expressed genes in all three comparisons (TGF-β vs DMSO, TGF-β +2APB vs
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Figure 2.4. Differential gene expression changes following TGF-β and
TGF-β+2-APB treatment. (A) RNA isolated from NMuMG cells treated with
DMSO, TGF-β or TGF-β+2APB was sequenced, and gene expression changes
calculated. Using this gene list, a hierarchical clustering of their Pearson
correlation values was performed using the aheatmap function in the R package
NMF v0.20.6. (B) List of number of differentially expressed genes with three
different treatments. (C) Venn diagram depicting the number of unique and
overlapping genes with the three different treatments. (D) The differentially
expressed genes with the three different treatment conditions were analyzed
using IPA. The top five scoring hits in these categories using IPA are shown,
together with significance scores (p-values) and the number of genes included
in each class.
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DMSO, and TGF-β vs TGF-β +2APB) using QIAGEN’s Ingenuity Pathway Analysis
(IPA) software.
All three comparisons generated the same top 5 significantly altered gene
ontologies that are important for EMT, namely cell movement, cellular
development, cell-to-cell signaling and interaction, cell growth and proliferation,
and cell death and survival, although with different numbers of molecules in each
category (Fig. 2.4.D). Overall, 2APB and TGF-β treatment appears to result in a
set of gene expression changes like the changes due to TGF-β alone.
We and others previously showed that blocking SOCE leads to loss of the
EMT phenotype [16, 19]. To understand the effects of 2APB in altering the TGF-β
response, we investigated which genes had an increased expression with TGF-β
but were then decreased in response to 2APB (an “Up-Down” pattern). Similarly,
we also looked for genes that had reduced expression in response to TGF-β but
then increased with 2APB (“Down-Up” pattern). We reasoned that these reciprocal
gene expression changes might be reflective of the reversion of the mesenchymal
phenotype seen after TGF-β induction. We found 739 genes that showed the “UpDown” pattern, and 853 genes in the “Down-Up” group (Fig. 2.5.A, B). Gene
ontology (GO) analysis of both the Up-Down and Down-Up genes resulted in top
5 significantly altered gene categories very similar to that of the overall analysis,
namely, DNA replication, recombination and repair, cell cycle, cellular
development, cell morphology, and cellular assembly and organization (Fig. 2.5.B,
top panel). Genes that were downregulated with TGF-β but then upregulated with
2APB addition, and vice versa, included many of the same categories as above
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Figure 2.5. Reversal of gene expression comparing TGF-β to TGF-β+2APB
treatments. (A) RNA isolated from NMuMG cells treated with DMSO, TGF-β or
TGF-β+2APB was sequenced, and gene expression changes calculated. Using
this gene list, we extracted genes with expression changes when treated with
TGF-β that were reversed by the addition of 2APB. We selected genes that had a
range of ratio values of -1.5 to -0.5 and hierarchical clustering of their Pearson
correlation values was performed using the aheatmap function in the R package
NMF v0.20.6. (B) Genes that were upregulated with TGF-β addition, and then
downregulated with 2APB addition were analyzed using IPA. The top five scoring
hits in these categories using IPA are shown, together with significance scores (pvalues) and the number of genes included in each class. A similar analysis was
conducted with genes that were downregulated with TGF-β, but then reversed
(upregulated) with 2APB, and analyzed with IPA as above.

.
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(Fig. 2.5.B, lower panel). Of note in this category is Klf4, which acts as a
transcriptional activator of epithelial genes and as a repressor of mesenchymal
genes [25]. Klf4 is downregulated around 2-fold by TGF-β addition and is
upregulated with 2APB and TGF-β (~4 fold). Several integrins and other
cytoskeletal genes are downregulated with TGF-β but seem to be increased in
expression with 2APB and TGF-β. These categories are seen in the GO analysis
of the changes caused by TGF-β alone, (Fig. 2.4), but change in an opposite
fashion.
Interestingly, we noted upregulation of EMT-promoting genes with 2APB
and TGF-β addition, including Osm [26, 27], Msi1 [28] and 2610018G03Rik (Mst4)
[29]. On the other hand, one of the top ten genes that is upregulated with 2APB
during TGF-β induced EMT was Reln, which was previously shown to prevent
TGF-β induced migration [30]. This suggested a potential mechanism for 2APBdependent reversal of TGF-β induced migration, and further supports a role for
calcium signaling in EMT. Consistent with the increase in Snai1 transcription and
no loss of SNAI1 protein (Fig 1), TGF-β–dependent expression of Snai1 target
genes were maintained even with 2APB treatment. For example, Snai1 target
genes Cdh1 [12] and Krt19 [31] displayed a fold change of -1.7 and -3.55
respectively with TGF-β treatment, and decreased to -2.34 and -12.34 with TGFβ+ 2APB treatment (Fig. 2.5.C). This is consistent with our data that SNAI1 protein
levels are unaffected with 2APB addition (Fig. 2.1.D).
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2APB Activates AKT Signaling in Response to TGF-β, Resulting in
Increased NF-κB at the Snai1 Promoter
Comparison of differentially regulated gene networks between TGF-β and
TGF-β+2APB treatments using IPA revealed significant changes in the AKT
signaling pathway as shown in Fig 2.6. AKT signaling has been previously shown
to be involved in both EMT [32, 33] and in regulation of Snai1 expression through
affecting the transactivation potential of NF-κB, including binding to the Snai1
involved in the increase in Snai1 transcription seen with 2APB and TGF-β addition,
we treated NMuMG cells with Akti-1/2, a potent and selective dual Akt1 and Akt2
inhibitor [38]. There was little to no change in Snai1 transcription both with Akti1/2 with DMSO, or in combination with 2APB (Fig. 2.7.A). However, when used in
combination with TGF-β treatment, or with 2APB+TGF-β, there was a significant
decrease in Snai1 expression (Fig. 2.7.A), suggesting that the AKT pathway is
required for TGF-β dependent Snai1 transcription. Similar results were observed
when the cells were treated with the inhibitor ACHP [39], which interferes with the
DNA binding ability of NF-κB (Fig. 2.7.B)
As the phosphorylated form of AKT is indicative of activity in these
pathways, we examined levels of total and phosphorylated AKT using
immunoblotting (Fig. 2.7.C). Specifically, we investigated a form of AKT
phosphorylated at serine 473 (AKTSer473) [40], and found increased levels upon
TGF-β treatment, which were not diminished with the addition of 2APB (Fig. 2.7.C).
Examination of our RNA-sequencing data did not reveal significant mRNA changes
in Rictor or mTOR genes, which are known to phosphorylate AKTSer473, nor was
there a change in levels of total AKT, although it is quite possible that protein
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Figure 2.6. AKT network is differentially regulated when
comparing TGF-β to 2APB+TGF-β. IPA analysis of RNA-seq
datasets revealed the AKT network as being differentially regulated in
2APB and TGFβ treated cells.

.
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Figure 2.7. 2APB increases TGF-β dependent activation of the AKT
pathway and recruitment of NF-κB and Pol II to the Snai1 promoter.
(A) NMuMG cells were serum starved for 4hours and then treated with 2APB for
24 hours. At 18 hours, the cells were treated with 50uM of the NFKB inhibitor
ACHP for a 4-hour pretreatment before addition of TGF-β at 22 hours. (B)
NMuMG cells were serum starved for 4h and then treated with 10uM of the
inhibitor at 20 hours for a 2-hour pretreatment before the TGF- β treatment at 22
hours for 2 hours. (C) NMuMG cells were serum-starved for 4h, and then treated
with DMSO, 2APB, TGF-β or TGF-β+ 2APB for 24h. Protein isolation from these
cells followed by immunoblotting using antibodies to phospho- AKTSer473, total
AKT, and GAPDH. Data are representative of 3-4 independent biological
replicates. Bar graphs next to the image represent the quantitation of blots using
LiCOR image software, and statistical analyses performed using GraphPad
Prism. *= p-value ≤ 0.05. (D) The samples from (C) were immunoblotted for
phospho-p65Ser536, total p65 (RelA subunit of NF-κΒ) and normalized to GAPDH
as above. (E) Schematic representation of the primer sets used in chromatin IP
covering ~3.8 Kb of the Snai1 promoter region. The putative NF-κΒ binding sites
are depicted as vertical lines. Locations of primer sets are indicated below the
gene, as are the distances between the primer pairs in bp. (F) Chromatin
immunoprecipitation (ChIP) was performed using antibodies against Pol II and
p65. real-time PCR amplification of ChIP DNA across the Snai1 locus reveals a
peak of Pol II over the promoter region in cells treated with TGF-β (white bars).
This peak increases with 2APB treatment (grey bars). (G) While no p65 is
apparent in DMSO treated cells, there is increased association of p65 at the
Snai1 promoter DNA with addition of TGF-β and with TGF-β+2APB. All data are
representative of three independent biological replicates.
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levels might be increased. Regardless, it seemed likely that the AKTSer473 isoform
is able to sustain and increase SNAI1 transcription through downstream signaling,
possibly through NF-κB transactivation as previously reported [35, 36, 40]. Further,
IPA analysis listed RICTOR as one of the top 5 sets of upstream regulatory
pathways in the genes that were upregulated specifically with 2APB+TGF-β alone.
Phosphorylation of the RelA (p65) subunit of NF-κB leads to the recruitment of
transcriptional coactivators such as CBP/p300 and enhances NF-κB dependent
transcription [41, 42]. To test whether 2APB addition changed protein levels of p65,
we used antibodies specific to total and phosphorylated p65. While TGF-β induced
a significant increase in phospho-p65 relative to total p65, we observed no
significant loss or gain in p65 phosphorylation when comparing TGF-β to 2APB
and TGF-β treatments (Fig. 2.7.D).
As the AKT pathway is actively involved in NF-kB regulation, specifically
stimulating its transactivation potential in the nucleus [35, 36], we sought to
determine whether increased expression of Snai1 might be due to direct and
increased binding of p65 at its promoter. Therefore, we performed chromatin
immunoprecipitation (ChIP) of p65 and the RNA polymerase II (Pol II) enzyme
[43, 44] using primers designed across the Snai1 promoter, gene body, and in a
region ~11kb upstream from the Snai1 transcription start site (Fig. 2.7.E). We
found that relative to DMSO-treated cells, there is increased association of Pol II
at the promoter region of Snai1 at 2h after addition of TGF-β (Fig. 2.3.F). The
amount of Pol II at the Snai1 promoter is further increased with the addition of
2APB relative to TGF-β alone, consistent with increased transcription from the
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Snai1 promoter (Fig. 2.1.A). Next, the binding of p65 at the promoter is increased
in cells treated with TGF-β, and even more so with addition of 2APB (Fig. 2.7.G),
suggesting that p65 activation in response to 2APB is responsible for the increased
Snai1 transcription. Thus, the AKT and NF-κB pathway activation appears to be
responsible for the increased activation of Snai1 induced by TGF-β in the presence
of 2APB.
ORAI3 and STIM1 Mediate TGF-β-Induced Snai1 Expression
While our data suggested that AKT and NF-kB were involved in the
amplified TGF-β dependent Snai1 transcription in response to 2APB, how this
signal is transmitted to the nucleus to regulate gene transcription was still unclear.
While 2APB is a widely used SOCE inhibitor known to block calcium signaling
through ORAI1 and ORAI2 channels, some studies have suggested that 2APB
increases calcium entry through the closely related ORAI3 channel that is activated
by its interaction with the stromal interaction molecule 1 (STIM1) [45, 46]. STIM1
and STIM2 are important components of SOCE and integral type I membrane
proteins of the endoplasmic reticulum (ER). Further, we noted that SKF decreases
the expression of TGF-β induced Snai1 (Fig. 2.2), suggesting involvement of
SOCE channels and STIM1.
To test whether calcium influx through ORAI and STIM proteins is required
for Snai1 expression, we knocked down Orai1, Orai3, Stim1 and Stim2 using
siRNA in NMuMG (Fig. 2.8.A-D) and MDA-MB-231 cells (Fig. 2.8.E-H). We
induced Snai1 expression as before, through addition of TGF-β for 2h. We then
measured RNA and protein expression to validate knockdown (Fig. 2.8). All four
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Figure 2.8. Orai3 and Stim1 silencing blocks TGF-β induced SNAI1
transcription. NMuMG (A-D) or MDA-MB-231 (E-H) cells were transfected with
indicated siRNAs for 96h using a final concentration of 100 picomoles of siRNA.
The cells were treated with TGF-β for 2h prior to RNA and protein isolation. RNA
was converted to cDNA and RT-PCR performed to analyze both the gene
knockdown efficiency for each gene, and Snai1 transcript levels. Western blots
were performed against each protein to test efficiency of knockdown and
normalized using GAPDH. All data are representative of at least 3 biological
replicates. Statistical analyses were performed with Graphpad Prism software. *=
p-value ≤ 0.05, **= p-value ≤ 0.01; ***= p-value ≤ 0.001.

targets were significantly knocked down as seen by measurement of RNA
(Fig. 2.8.A-H, black bars) and protein.
We next measured if TGF-β induction of Snai1 transcription was affected
by the knockdowns relative to the siControl treatments. Of the four knockdowns
tested, only loss of ORAI3 and STIM1 impact expression of Snai1 in response to
TGF-β treatment (Fig. 2.8, gray bars), which is consistent with the results seen
with 2APB and SKF treatments. TGF-β dependent Snai1 transcription was
maintained even with a partial knockdown of Orai1 (Fig. 2.8.A) unlike with Stim1
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and Orai3. Quantification of blots in Fig 2.8 are shown in Fig. 2.9. Further, we found
no significant changes in any of the other EMT factors in response to knockdown
of these channel proteins (Fig. 2.10), suggesting their specific influence on Snai1
transcriptions.

Figure 2.9. Western blot quantification of calcium channel knockdowns.
NMuMG (A-D) or MDA-MB-231 (E-H) cells were transfected with indicated siRNAs
for 96h using a final concentration of 100 picomoles of siRNA. The cells were
treated with TGF-β for 2h prior to protein isolation. Western blots were performed
against each protein to test efficiency of knockdown and normalized using
GAPDH. All data are representative of at least 3 biological replicates. Statistical
analyses were performed with Graphpad Prism software. *= p-value ≤ 0.05, **= pvalue ≤ 0.01; ***= p-value ≤ 0.001.
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Figure 2.10. EMT transcription factor expression is unaffected by calcium
channel knockdowns. The cDNA from the experiment in Figure 4 (NMuMG cells
were transfected with siRNAs for 96 h) was used to examine transcript levels of
EMT genes using RT-PCR. Data were derived from at least three independent
biological replicates and are represented as mean ± SEM values. No Ct values
were obtained with Twist1 primers.

2APB-Dependent SOCE Occurs Through ORAI3
We next tested whether store depleted calcium influx that is altered with
2APB is further limited through knockdown of Orai3. We measured calcium levels
using Fura-2 in siControl (Fig. 2.11.A) and siOrai3 treated (Fig. 2.11.B) NMuMG
cells. In the absence of external calcium (0 mM Ca2+), the addition of Thapsigargin
(Tg, a sarcoendoplasmic reticulum calcium transport ATPase pump blocker, which
thereby releases calcium from the internal ER stores), did not produce a significant
difference between the control and siOrai3 treated samples (Fig. 2.11.A and B).
Initiation of calcium entry by the addition of 1mM calcium was not significantly
different between the two sets of cells. However, addition of 2APB showed a
statistically significant difference between the siControl and siOrai3 treated cells
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Figure 2.11. Orai3 silencing blocks 2APB dependent increase in SOCE
Calcium imaging was performed in control (A) and Orai3 knockdown (B)
NMuMG cells. Analog plots of the fluorescence ratio (340/380) from an average
of 40-60 cells are shown. (C) Quantification (mean ± SD) of fluorescence ratio
(340/380). All data are representative of at least 3 biological replicates.
Statistical analyses were performed with Graphpad Prism software.
*= p-value ≤ 0.05.

(Fig. 2.11.A-C), whereby there was a drop-in calcium entry in cells that were
treated with both 2APB and siOrai3. This loss of calcium influx with 2APB is about
half of the level seen with the siControl treated cells (Fig. 2.11.C). This is consistent
with the fact that knockdown of Orai3 is not absolute (Fig. 2.4.B), and there is still
some mRNA message in the cell. Taken together, these results support the idea
that the influx of calcium through ORAI3 upon 2APB addition [45, 47] might be
responsible for Snai1 activation.
Effect of Orai3 Silencing on Migration and Snai1 Transcription in Response
to TGF-β
We next focused on delineating the specific role of ORAI3 in migration
versus Snai1 transcription in response to TGF-β. Consistent with the idea that
ORAI3 channel protein is required for Snai1 expression, a significant decrease
(around 8 fold) in Snai1 expression was observed when siOrai3 treated cells were
induced with TGF-β and 2APB, relative to TGF-β and 2APB (Fig. 2.12.A).
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Figure 2.12. Orai3 silencing inhibits both cell migration and Snai1
transcription in response to TGF-β. (A) NMuMG cells were treated as
indicated with TGF-β, TGF-β+2APB or DMSO, in the presence or absence of
siOrai3 and RNA isolated. RNA was converted to cDNA and analyzed by realtime PCR using primers specific to mouse Snai1, Snai2 or Twist1, and
normalized to Gapdh. Data represent the average of 3 individual biological
replicates. (B) Proteins isolated from the same cells as in (A) were evaluated for
SNAI1 expression by immunoblotting. Antibody to ACTIN was used a loading
control, and the blots are representative of at least 3 independent biological
replicates. Blots were quantitated using the LiCOR imaging software and are
represented as SNAI1/ ACTB signal, after normalizing to DMSO control. Error
bars represent SEM and statistical analyses were performed Graphpad PRISM.
*= p-value ≤ 0.05, **= p-value ≤ 0.01 relative to control. (C) Confluent NMuMG
cells in a 6-well plate were serum starved for 4h prior to treatment, and TGF-β
(for 8h) and/or 2APB (for 24h) were added to the wells prior to wounding using a
sterile 200ul tip. Three representative fields were marked and imaged
immediately at time of (0h) and a time period after (8h) wounding as described
in materials and methods. The images were captured using an Olympus IX71
microscope camera. All data are representative of at least 3 biological
replicates. Statistical analyses were performed with Graphpad Prism software.
*= p-value ≤ 0.05, **= p-value ≤ 0.01; ***= p-value ≤ 0.001; ****= p-value
≤0.0001. (D) Model for ORAI3-mediated Snai1 upregulation. AKT (green oval)
pathway can be activated by both calcium (black circles) and by TGF-β
signaling. 2APB prevents SOCE via ORAI1 and ORAI2, while increasing
calcium influx through ORAI3. Activation of AKT triggers increased binding of
p65 at the Snai1 promoter, leading to increased recruitment of Pol II and hence
transcription of Snai1.
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Interestingly, knockdown of Orai3 also caused a significant loss of TGF-β induced
Snai1 transcription relative to TGF-β alone, even without addition of 2APB
(Figs. 2.8.B, 8F and 12A). This result suggested that ORAI3 channel is needed for
robust activation of Snai1 expression. Knockdown of Orai3 also repressed the
TGF-β dependent induction of Snai2, similar to 2APB (Fig. 2.12.A). We also noted
that the loss of Snai1 expression seen as a result of siOrai3 treatment was
reflected as a loss of SNAI1 protein expression (Fig. 2.12.B). While we do not
observe a complete loss of SNAI1 protein expression, this is to be expected, as
we still observed a small amount of protein by western blot when we knocked down
Orai3 (Fig. 2.8.B).
Having established that ORAI3 allows calcium entry and is primarily needed
for increased Snai1 expression, we asked if ORAI3 was also needed for cell
migration that occurs as a result of TGF-β induced EMT. Therefore, we tested
wound healing by a scratch assay in cells following induction with TGF-β
(Fig. 2.12.C). As expected, cells treated with TGF-β resulted in more rapid
migration and wound healing than DMSO-treated controls, or cells treated with
2APB alone (Fig. 2.12.C). We have previously demonstrated that inhibition of
SOCE with SKF reduces cell migration caused by TGF-β [19], and we see the
same with addition of 2APB. Moreover, we did not see a significant difference
(Fig. 2.12.C) in wound closure relative to vehicle treated cells when we compared
TGF-β induced cells that were also treated with 2APB or siOrai3, or both, indicating
that 2APB and siOrai3 both had similar effects in hindering cell migration induced
by TGF-β. Together, these results suggest that while 2APB hinders cell migration,
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it is essential for modulation of Snai1 expression. ORAI3 is thus a critical ion
channel that is needed for Snai1 expression, and knockdown of Orai3 can induce
both loss of cell migration and Snai1 expression in response to TGF-β.
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Discussion
Blockade of SOCE has been demonstrated to influence cell biological
processes, including the cell migratory phenotype associated with EMT, making
calcium channels an attractive target for chemotherapy. Here, we sought to
understand how 2APB could specifically amplify the TGF-β induced Snai1
expression levels. To do this, we utilized RNA-sequencing to obtain a global view
of genes that were differentially regulated with TGF-β in the presence or absence
of 2APB. Our analyses revealed substantial overlap between TGF-β and TGFβ+2APB datasets, suggesting that 2APB maintained the TGF-β dependent
regulation of genes to a large extent (Fig. 2.4). However, TGF-β dependent
changes in expression of a subset of genes that facilitate cell-extracellular matrix
adhesion such as integrins, were reversed by addition of 2APB (Fig. 2.5.A). This
explained how blocking SOCE could affect the migration phenotype seen with
EMT. However, EMT-related genes including Snai1 were upregulated upon TGFβ induction and maintained or increased their relative expression even with the
addition of 2APB. Expression of Snai1 target genes including Krt19, Ocln, Dsp,
etc. was also maintained even with 2APB treatment (Fig. 2.5.C). These
observations are consistent with previously published data that Snai1 upregulation
and the migratory phenotype seen with TGF-β addition can be physically
uncoupled [43].
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Pathway analysis of the RNA-seq data revealed that the AKT network was
differentially regulated between TGF-β and TGF-β+2APB (Fig. 2.6). Cytosolic AKT
signaling has been shown previously to trigger a signaling cascade ultimately
affecting the transactivation potential of NF-κB subunit p65 in the nucleus through
a region located upstream of the Snai1 promoter [35, 36]. AKT and p65 were
therefore potential candidates for the observed increase in Snai1 transcription. We
tested this idea in two ways. First, treatment with inhibitors targeting either AKT1/2
(Akti-1/2) or that prevented p65 binding to DNA (ACHP) both resulted in loss of
TGF-β dependent Snai1 transcription (Figs. 7A and B). Snai1 transcription was
also abolished in response to both TGF-β and TGF-β+2APB. We also noted
increased phosphorylation of AKTSer473 in response to TGF-β and TGF-β+2APB
relative to control treated cells, suggesting activation of AKT signaling even with
2APB addition. Secondly, we showed direct association of p65 and RNA
Polymerase II at the Snai1 gene promoter (Fig. 7 E-G) with TGF-β treatment. We
further demonstrated an increase in both RNA Polymerase and p65 with addition
of 2APB and TGF-β, which is consistent with the increased levels of Snai1
transcript relative to TGF-β alone. The increased phosphorylation status of AKT in
response to both TGF-β and TGF-β+2APB has consequences for both cell growth
and metastasis [30-33]. Further, both AKT [34,35] and its downstream target NFκB [36,37] have been previously linked to an increase in drug resistance. Activation
of both AKT and NF-κB would result in increased Snai1 expression, which in turn
has been shown by several groups to confer drug resistance to cancer cells [14,
48-50]. Our RNA-seq data support this idea, as several known drug resistance
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genes (e.g. Abcg1, Ercc1, Igfbp4, and Cyp1b1) were upregulated in the 2APB
dataset, but not with TGF-β alone. Additional studies are needed to determine
whether calcium blockers that are proposed for use in clinical treatments might
contribute to acquisition of drug resistance.
Secondly, we asked which calcium channel proteins were involved
specifically in TGF-β induced Snai1 transcription. 2APB was previously shown to
block calcium entry through ORAI1 and ORAI2 channels [46]. We demonstrated
that 2APB treatment increased calcium influx through the ORAI3 channel as
suggested previously [45, 47], which was lost when ORAI3 was knocked down
(Fig. 2.11). The stromal interaction partners of ORAI channels, namely STIM1 and
STIM2, were previously shown to facilitate TGF-β induced EMT, although it was
suggested that STIM2 appears to participate in non-SOCE mechanisms [51].
Knockdown of these four channel proteins showed that loss of ORAI3 and STIM1,
but not ORAI1 or STIM2, also reduced TGF-β dependent Snai1 transcription
(Fig. 2.8). While we do not observe a complete loss of SNAI1 protein expression
upon ORAI3 knockdown, this is to be expected due to incomplete knockdown of
Orai3 (Fig. 2.8.B), or possible compensation through ORAI1/2. Interestingly, both
2APB (which activates ORAI3) and siOrai3 treated cells showed reduced TGF-β
induced migration. We predict that first, in the presence of 2APB, some of the
genes induced by TGF-β that contribute to cell migration are reversibly regulated
through as yet unknown means, which reverts them to the non-migratory
phenotype, even in the presence of active ORAI3 and SNAI1 proteins.
Alternatively, changes at the level of proteins in response to 2APB+TGF-β
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(whether through stability, post-translational modifications, etc.) might play a role
in the reversal of phenotype, but this remains untested. When Orai3 is
downregulated in the presence of TGF-β, loss of Snai1 expression might prevent
EMT gene expression programs from fully activating. These results further
highlight the separation of cell migration from gene expression programs during
EMT and underscore the need to target both pathways.
On the other hand, ORAI1, which is inhibited by 2APB [46], does not appear
to be as critical for Snai1 expression as ORAI3. In support of this idea, knockdown
of ORAI1, although partial as observed by western blots (Figs. 2.8.A and E and
Fig. 2.9) did not result in any loss of TGF-β dependent Snai1 transcription
(Figs. 2.8.A and E). Taken together, our data suggest that calcium influx through
ORAI3 and STIM1, and downstream signaling, is required for TGF-β dependent
Snai1 activation. No significant difference in wound closure was noted when
comparing Orai3 knockdown to 2APB treatment during TGF-β induced EMT
suggesting that blocking multiple channels through 2APB or simply knocking down
Orai3 have similar effects in preventing cell migration during EMT. Crucially,
contrary to 2APB+ TGF-β treatment, knockdown of Orai3 when combined with
TGF-β induction of EMT decreased Snai1 expression while also reducing the
migratory phenotype. This reinforces the importance of the ORAI3 and the ERα
protein STIM1 in upregulation of Snai1 gene expression. We can therefore predict
a model whereby 2APB blocks calcium entry through ORAI1 and ORAI2, but
allows calcium “leakage” [47] into the endoplasmic reticulum through ORAI3 in
partnership with STIM1 (Fig. 2.12.D). In parallel, the calcium entry activates AKT
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[37] signaling, potentially through PI3K [52]. AKT in turn transactivates NF-κB
subunit p65, which binds to the Snai1 promoter, recruit RNA Polymerase and
increases activation in response to TGF-β (Fig. 2.12.D).
The expression of ORAI proteins, and hence their functional role, appears
to be highly dependent on the breast cancer subtype. For instance, Orai1 appears
to be upregulated in the poor prognosis basal breast cancer molecular subtype
[53], and silencing of ORAI1 reduces the proliferation of breast cancer cell lines in
vitro [53, 54] and in vivo [54], the invasiveness of MDA-MB-231 breast cancer cells
in vitro, and metastasis in vivo [20]. The basal subtype breast cancers are also
more likely to have higher mRNA levels of the canonical ORAI channel activator
STIM1, and lower levels of its related isoform STIM2 [53]. However, SOCE in less
aggressive, estrogen receptor positive luminal subtype of breast cancer cells
occurs mainly through ORAI3 [24], and upon loss of estrogen receptor alpha,
metastatic cells appear to switch to SOCE through the ORAI1 channel, [23, 24].
Finally, the importance of ORAI3 in conferring chemoresistance has been
underscored by a recent study that linked ORAI3 overexpression and
chemoresistance in human breast cancer data sets [55], and further demonstrated
that ORAI3 overexpression conferred chemoresistance properties to cells. In
summary, understanding individual roles of ORAI channel proteins in cancer
proliferation, metastasis and chemoresistance has implications in development of
targeted therapies to treat cancer. Future studies will address how these calcium
channel proteins function during breast tumor progression and affect drug
resistance and EMT. Additionally, the role of transiently expressed SNAI1, and the
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temporal expression of the other EMT transcription factors during EMT, their
interplay with calcium channels, and especially their effect on the multistep process
of metastasis formation is of continuing interest to our laboratories and is the
subject of ongoing research.
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CHAPTER 3
PROJECT 2: REQUIREMENT OF CTCF FOR TGF-Β, BUT NOT EGF,
INDUCTION OF SNAI1 EXPRESSION IN NMuMG CELLS.
Abstract
The epithelial to mesenchymal transition (EMT), which is induced by
cytokines like transforming growth factor beta (TGF-β), can result in dramatic
alterations in chromatin structure and gene expression. It was reported in
Drosophila that the multifunctional and highly conserved chromatin organizer
CCCTC binding factor CTCF participates in the recruitment of SMAD proteins in
response to TGF-β signaling. To further explore the role of CTCF in TGF-β
mediated EMT, we used two different stimuli TGF-β and EGF to induce EMT in
NMuMG cells and determined that CTCF depletion resulted in loss of Snai1
expression in TGF-β but not EGF stimulated cells. We also noticed a higher
enrichment of CTCF at the Snai1 gene upon induction with TGF-β but not with
EGF, relative to the control, which corresponded to the TGF-β dependent
expression of Snai1 mRNA. Further, knockdown of CTCF with siRNA in NMuMG
cells that were treated with TGF-β led to a decrease in Snai1 expression as well
as reduced wound healing capacity compared to EGF. Finally, use of a Smadspecific inhibitor blocked TGF-β but not EGF-dependent Snai1 induction,
suggesting that CTCF might be working through Smad proteins. Together, our data
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suggest a role for CTCF in TGF- β mediated Snai1 expression during the process
of EMT.
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Introduction
Despite improvements in therapy, cancer mortality remains high, imposing
a huge health and economic burden on the population. One of the major
contributors to cancer mortality, due to acquisition of drug resistance and
metastasis, is the process of epithelial to mesenchymal transition (EMT), in which
adherent epithelial cells assume a migratory, mesenchymal cell phenotype [1].
EMT is induced by different intracellular signaling pathways like epidermal growth
factor (EGF) and transforming growth factor beta (TGF-β) leading to transcription
of EMT specific genes [2], [3]. When these transitions occur in cancer, a hybrid
phenotype is reached after the carcinoma undergoes a subtle EMT. The
conversion to full mesenchymal form (complete EMT) facilitating metastatic spread
depends on various stimuli and not all stimuli lead to a complete EMT [4]. Among
these, transforming growth factor-β (TGFβ) family signaling has a predominant role
in transforming epithelial cells to a more aggressive mesenchymal form by
upregulating the transcription factor SNAIL. TGF-β transmits a signal through the
SMAD transactivator family of proteins, which upregulate transcription factors like
SNAIL, a master regulatory protein, leading to complete EMT [2], [5]–[7]. Signaling
pathways are key druggable targets, hence identification of mechanisms behind
activation of these pathways can help in designing targeted therapies for patients.
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Eukaryotic genomes are tightly organized in order to maintain proper
transcriptional regulation in a cell type-specific and developmental fashion [8].
Chromatin is arranged into dynamic higher-order structures, which can localize to
distinct subnuclear compartments that affect genome configuration and
consequently transcription [9–12].Regulatory regions are marked by specific
chromatin features and are brought together through long range interactions to
influence transcription. Long-range interactions can also separate domains to
establish independent transcription regulation in each individual domain [13–15].
It has been reported that induction of EMT can result in dramatic alterations in both
chromatin structure and global changes in gene expression but how this occurs is
not fully understood[16]. This is important because dysregulation of chromatin
interactions is known to lead to errors in transcription [17]. However, the underlying
cause for what triggers these chromatin structure changes during the process of
EMT remain unknown.
The CTCF protein has been identified as playing a crucial role in regulating
chromatin structure and spatial organization [18]. CTCF is a highly conserved
ubiquitously expressed nuclear protein [19], [20], and is essential for cell viability
[21–23]. The CTCF protein has eleven-zinc finger (ZF) domains surrounded by Nand C-terminal regions, which do not contain any conspicuous motif, except for an
AT-hook motif [24]. CTCF has been identified in independent studies as a
transcriptional repressor [25], [26] and as well as transcriptional activator [27], [28].
The protein has since been implicated in many other cellular processes, including
the regulation of genomic imprinting to maintain mono-allelic gene expression.
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Additionally, CTCF is often located at transitions of distinct chromatin states, where
it appears to act as a boundary element that prevents spreading of distinct
chromatin signatures across the genome [29], [30]. It also organizes chromatin by
binding to the borders of topological domains and mediating long-range
interactions within subdomains [14], [31–34].
CTCF mediates its function via protein-DNA, protein-protein, and proteinRNA interactions [24], [35]. CTCF binds to DNA via its ZF domain, and genomewide studies reveal that it can bind approximately 50,000 sites in human and
mouse genomes [24], [36], [37]. It has been reported that CTCF participates in the
recruitment of Smad proteins to their DNA binding sites in Drosophila cells in
response to TGF- β and BMP signaling [38]. Although the connection between
TGF-β and CTCF is not well-known, it is nonetheless of importance. Earlier, the
interactions between CTCF, TGF-β, and Smads have been of interest for studies
regarding Alzheimer’s disease (AD) where it has been shown that TGF-β induced
transcription of the beta-amyloid precursor protein gene involves interaction
between the CTCF-complex and Smads [39], [40]. A study has also demonstrated
that Smad3 a downstream effector molecule of the TGF- β signaling pathway
interacts with CTCF via the Mad homology 1 domain of Smad3 on the H19
imprinting control region of chromatin [38]. The same study also reported that
Smad2 and Smad4 fail to interact with CTCF, suggesting specificity in which Smad
protein interacts with CTCF. Although all these studies point to a link between
CTCF and the TGF-β signaling pathway, little is known regarding the role of CTCF
in regulating gene expression during TGF-β mediated EMT. In this study, we noted

117

that the binding sites of the protein CTCF are enriched at the promoter of the Snai1
gene in humans as well as mouse. We observed an enrichment of CTCF around
the TSS as well as upstream of the SNAIL gene in human breast cancer cell lines
MCF-7 and MDA-MB 231. Our data also suggested that CTCF is enriched at the
mouse Snai1 gene TSS as well as upstream in non-cancerous NMuMG cells with
TGF-β, but not EGF treated or vehicle treated cells. Depletion of CTCF using
siRNA showed resulted in decreased Snail expression upon induction with TGF-β
but was unaffected by EGF induction. Finally, we show that inhibiting Smad3
binding to the DNA affects CTCF enrichment at the Snai1 gene in NMuMG cells
upon induction with TGF-β but not with EGF. Taken together, these studies
highlight the fact that CTCF might play a role in TGF-β mediated Snai1 expression,
but not EGF, possibly due to the involvement of Smad3 in recruitment of CTCF.
As multiple E/M states exist, we predict that CTCF is required for a complete EMT.
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Materials and Methods
Cell Culture
NMuMG cells were obtained from American Type Culture Collection
(ATCC) and were cultured at 37°C under 5% CO2 in DMEM/F-12 media (Thermo
Fisher) containing 10% fetal bovine serum (FBS). Cells were serum-starved for 4h
prior to treatment with TGF-β (5ng/ml final; Sigma-Aldrich# H8541) and EGF
(10ng/ml final; Sigma-Aldrich # E9644).
Treatments and Transfection
Cells were treated with TGF-β (5ng/ml final; Sigma-Aldrich) for 2 h and with
EGF (10ng/ml final; Sigma-Aldrich) for 3h prior to RNA isolation. Cells were treated
with SIS3 (15uM final; Tocris, CAS Number: 521984-48-5) or DMSO for a period
of 2h prior to TGF-β treatment or EGF treatment.Transfections of cells with
siControl (Ambion) or siCTCF (Dharmacon, cat # L-044693-01) were performed
using Lipofectamine 3000 as per the manufacturer’s protocol. for two rounds of
transfection (40 pmol reverse for 48 h, 40 pmol forward for 48 h) using a final
concentration of 80 pico moles of siRNA. The cells were treated with TGF-B or
EGF after 96h of transfection for 2h and 3h respectively prior to RNA isolation.
RNA Isolation
RNA was isolated from cells using the RNeasy kit (Qiagen) according to the
manufacturer’s instructions. Genomic DNA was removed by on-column DNA
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digestion with RNase-Free DNase Set (Qiagen). RNA quality and concentration
were assessed using a spectrophotometer (NanoDrop), and by electrophoresis on
a 2% agarose gel.
qRT-PCR
Total RNA was extracted from cells using RNeasy kit (Qiagen) and checked
for integrity using agarose gel electrophoresis. One microgram of RNA was used
to synthesize cDNA using random hexamer priming and SSRT-III reverse
transcriptase (Life Technologies), followed by qPCR using Quantitect (Qiagen)
primers, as shown in Table 3.1, for Snai1 (QT00240940) . Data were normalized
against Gapdh (QT01658692) and Rrn18S (QT02448075) gene transcripts
(Quantitect, Qiagen). Data were derived from at least three independent biological
replicates and are represented as mean ± SEM values. Data were analyzed using
the delta-delta Ct method as described previously. Statistical analyses were
performed using the GraphPad Prism software, version 7.0.

Table 3.1. List of RT primers used
Qiagen Quantitect Primer Assays
Mm_Snai1_1_SG

QT00240940

Mm_Rn18s_3_SG

QT02448075

Mm_Gapdh_3_SG

QT01658692
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Protein Isolation and Immunoblotting
Proteins were extracted by lysing cell pellets in urea lysis buffer (8M urea,
1%SDS in Tris-HCl pH 6.5) containing CompleteTm protease inhibitors (Roche) and
phosphatase inhibitors (Sigma- Aldrich), and subsequent heating to 95°C for 5 min.
Protein concentration was estimated using the Qubit (Thermo Scientific) protein
assay kit, following the manufacturer’s instructions. Western blotting was
performed as previously described, using the following monoclonal or polyclonal
antibodies: anti-CTCF(Active-Motif, # 61311 rabbit pAb), anti-phospho-SMAD3
(Cell Signaling #9520S rabbit mAb) , anti-total-SMAD3 (Abcam,# 28379 rabbit
mAb ) with a dilution of 1:1000 in 5% non-fat dried milk in 0.1% TBS-T, and antibeta actin (Millipore) with a dilution of 1:10,000 in 5% non-fat dried milk in 0.1%
TBS-T. Secondary antibodies anti-rabbit IgG, peroxidase-linked species-specific
whole antibody (from donkey)-45-001-276(GE Healthcare) and anti-mouse IgG,
peroxidase-linked-species-specific whole antibody (from sheep; 45-001-275; GE
Healthcare) were diluted 1:10,000 in 5% non-fat dried milk in 0.1% TBST and blots
were developed using the Li-COR Odyssey instrument (Li-COR Biosciences)
using Luminata Forte Western HRP substrate (WBLUF0500). Western blots
presented are representative of at least 3-4 biological replicates, and were
quantified using Licor software, and signal normalized to GAPDH or ACTB as
denoted for each figure. Statistical analyses were performed with GraphPad Prism
software.
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Immunofluorescence
Cells were seeded on glass coverslips in six-well tissue culture dishes and
grown to ~50-60% confluence. They were fixed with 4% formaldehyde and 0.1%
Triton X-100 (to permeabilize cells) in PBS for 15 min in the cell culture incubator
under CO2. The media was then removed, and cells were washed with PBS and
blocked for 30 minutes with 3% BSA in PBS. Cells were incubated with primary
antibody for 1 h, washed with PBS, incubated with the secondary antibody (Alexa
Fluor 488 or 568) for 1 h, washed with PBS, and mounted on glass slides with
Vectashield mounting medium containing 4’,6-diamidino-2-phenylindole (DAPI).
The cover slips were sealed with clear nailpolish and examined and photographed
using an Olympus IX71 microscope. Data are representative of at least three
biological replicates.
Library Construction and RNA-Sequencing
The total RNA isolated as described above was used for 50 bp single-end
RNA-Sequencing at the University of Minnesota Genomics Center (UMGC) on the
Illumina HiSeq 2000. RNA quality was assessed with the Agilent Bioanalyzer, and
samples with high RNA integrity number (RIN >8) were used for library
construction following the manufacturer’s (Illumina) instructions. In summary,
1 microgram of total RNA was oligo-dT purified using oligo-dT coated magnetic
beads, chemically fragmented and then reverse transcribed into cDNA. The cDNA
was fragmented, blunt-ended, and ligated to indexed (barcoded) adaptors and
amplified using 15 cycles of PCR. Final library size distribution was validated using
capillary electrophoresis and quantified using fluorimetry (PicoGreen) and via Q-
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PCR. Indexed libraries were normalized, pooled and then size selected to 320bp
+/- 5% using Caliper’s XT instrument. TruSeq libraries were hybridized to a single
end flow cell and individual fragments clonally amplified by bridge amplification on
the Illumina cBot. Once clustering was complete, the flow cell was loaded on the
HiSeq 2000 and sequenced using Illumina’s SBS chemistry. Two biological
replicates for each treatment were sequenced, resulting in an average of 50 million
reads per sample. Base call (.bcl) files for each cycle of sequencing were
generated by Illumina Real Time Analysis (RTA) software. The base call files and
run folders were then exported to servers maintained at the Minnesota
Supercomputing Institute. Primary analysis and de-multiplexing were performed
using Illumina’s CASAVA software 1.8.2. The result of the CASAVA workflow is
de-multiplexed FASTQ files that were subject to subsequent analyses as
described below.
RNA-seq Data Analyses
Preliminary quality control analysis of fastq files was performed with FastQC
v0.11.2. Reads were aligned to mouse genome (mm10), using TopHat v2.0.13
[41]. Read counts were summarized at the gene level using the featureCounts
function in the Rsubread v1.16.1 package [42]. Differential expression analysis
was performed using the R/ Bioconductor package DESeq2 v1.6.3. Genes were
considered differentially expressed if they had an FDR of 0.05 or less and a mean
count of 20 or more[43]. Hierarchical clustering of Pearson correlation values was
performed using the aheatmap function in the R package NMF v0.20.6 [44]. Venn
diagrams were drawn with the R package VennDiagram v1.6.17 [45]. Network
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mapping and functional analyses were generated using QIAGEN’s Ingenuity
Pathway Analysis (IPA®, QIAGEN) [46]. To investigate the expression changes
causing the induction of the mesenchymal phenotype seen in the TGF- β treated
cells compared to the EGF treated cells we looked at differentially expressed
genes with both the treatment. First, we calculated the ratio of the expression log2
fold change values (as calculated by DESeq2) of the TGF-β to vehicle treated cells
and the EGF to vehicle treated cells. Network mapping and functional analyses
were generated using QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN
Redwood City, www.qiagen.com/ingenuity).
Chromatin Immunoprecipitation (ChIP)
ChIP was performed as previously described [47] with the following
exceptions. In brief, cells were crosslinked with 1% formaldehyde for 5 minutes at
37°C, quenched with 2M glycine and washed with PBS, and then sonicated in the
Covaris S220 sonicator (peak power =120, duty factor=3, cycles/burst= 200) to
generate 300-600bp DNA fragments. Immunoprecipitation was performed using
the CTCF antibody (Active Motif, #61311, rabbit pAb) and IgG was used as a
control. Precipitated DNAs were detected by PCR using specific primers as shown
in Table 3.2. Quantitation was performed on immunoprecipitated DNA using the
CFX384 real-time PCR machine (Bio-Rad) with SYBR-green, and the percent
input for each sample was calculated based on a standard curve using 10%, 1%,
0.1% and 0.01% of input DNA.
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Table 3.2. List of primers used for ChIP
SNAI1_4Kb_ChIP_F
SNAI1_4Kb_ChIP_R
SNAI1_Prom_ChIP_F
SNAI1_Prom_ChIP_R
SNAI1_P2_ChIP_F
SNAI1_P2_ChIP_R
Snai1_ChIP_P1_F
Snai1_ChIP_P1_R
Snai1_ChIP_prom_F
Snai1_ChIP_prom_R
Snai1_ChIP_P2_F
Snai1_ChIP_P2_R
Snai1_ChIP_P3_F
Snai1_ChIP_P3_R

ttcgtgagcacactaggtattc
gacatctgcggcccaggt
ccggagtacttaaagggagtt
agcagtagcgcagaagaacc
actcagattgggtgacctgg
gggctgctggaaggtaaact
tgtttattctgtctgtctctctct
agccagaaagtgcgatgatatg
tacctaggtcgctctggccaacat
cgtcctgcagctcgctatagt
ttcaccttccagcagccct
gacagcgaggtcagctcta
gacctgtggaaaggccttct
aatggagaacaaccaacatctact

Migration Assays
Confluent cells in a 6-well plate were serum starved for 4h prior to treatment,
and TGF-β (for 8h) or EGF (for 8h) were added to the wells prior to wounding using
a sterile 200ul tip. Three representative fields were marked and imaged
immediately at time of (0h) and a time period after (8h) wounding as described
[47]. Cell migration across the wound was analyzed using ImageJ with MRI Wound
healing plugin. The tool measures the area of the wound, i.e. the area that does
not contain cells, in each image. A ratio of the area of the wound at the start of
wounding and at the end of wound closure is estimated as the percent of cell
migration. Data are the average of at least 4 independent experiments, and
statistical analyses were performed using GraphPad Prism 7 software.
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Results
Putative CTCF Binding Sites are Present at the Snai1 Promoter in Both
Human and Mouse Genome
Previous studies have already demonstrated what happens during the
process of EMT after the EMT transcription factors get activated or transcribed.
However, how these EMT transcription factors are regulated at the transcriptional
level is not well studied. To better understand the regulation of the EMT
transcription factors we tried to determine the presence overrepresented
transcription factor binding sites (TFBS) at these genes.
So, we used a bioinformatics approach with the help of the genomatix suite
software which is a TFBS analysis tool to determine the putative TFBS at these
genes. We used the DNA sequence of 10 EMT transcription factors 1000bp
upstream and downstream of the transcription start site (TSS) as shown in
Fig 3.1.A and used it as an input for the genomatix suite software. The output of
the software was in the form of a table as shown in Fig 3.1.B. From the table we
determined that the binding sites of CTCF are enriched at the Snai1 promoter
region in humans as well as in mouse.
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B

Figure 3.1. Bioinformatic analysis showed the presence of putative
CTCF binding sites at the promoter region of 10 EMT transcription
factors.DNA sequence of 10 EMT transcription factors 1000bp before and
after the TSS was used as an input for the Transcription Factor Binding Site
(TFBS) analysis tool from Genomatix Suite (A). The software generated a
table (B) showing list of TFBS at the Snai1 gene in mouse with CTCF having
a Z-score value of 36.87 indicating towards its increased probability of being
associated with the Snail gene promoter.

CTCF Associates with the SNAI1 Promoter in Cancer Cell Lines
To determine whether CTCF associates with the SNAI1 promoter we
performed chromatin immunoprecipitation (ChIP) using a CTCF antibody in
MCF-7 and MDA-MB-231 cells breast cancer cell lines, and A375 malignant
melanoma cell line.
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The immunoprecipitated DNA was amplified using primers designed across
the SNAI1 promoter, gene body, and in a region ~4kb upstream from the SNAI1
transcription start site (Fig. 3.2.A). We found enrichment of CTCF at the SNAI1
gene promoter (Fig. 3.2.C) or at the 4kb upstream region (Figs. 3.2.B and D).

A

B

C

D

Figure 3.2. CTCF associates with SNAI1 gene in cancer cell lines. (A)
Schematic representation of the primer sets used in chromatin IP covering ~4
Kb of the SNAI1 promoter region. Locations of primer sets are indicated below
the gene, as are the distances between the primer pairs in bp. Chromatin
immunoprecipitation (ChIP) was performed using antibody against CTCF in
(B) MCF-7 cells, (C) MDA-MB 231 cells and (D) A375 cells. Real-time PCR
amplification of ChIP DNA across the SNAI1 locus reveals a peak of CTCF
over the 4kb upstream region as well as the promoter region encompassed by
primer set ‘P1’ and ‘Prom.’ in the 3 cancer cell lines. All data are
representative of two independent biological replicates.
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TGF-β Induces a More Robust EMT Compared to EGF Induced EMT
As we observed the association of CTCF with the SNAI1 gene in steady
state cancer cell lines, we wanted to determine whether CTCF could associate
with the Snai1 gene during induction of EMT. EMT can be induced by different
signaling pathways like TGF-β, EGF, hypoxia, etc. We used two cytokines TGF-β
and EGF to induce EMT in non-cancerous epithelial murine mammary gland cell
line (NMuMG). NMuMG cells are a well-characterized model of EMT that responds
to both TGF-β and EGF, leading to the upregulation Snai1 and other EMT
transcription factors within a few hours. We treated NMuMG cells with TGF-β and
EGF over a time course of several hours (Figs. 3.3.A and B). We determined that
Snai1 expression is the highest in these cells at 2h and 3h respectively following
TGF- β and EGF treatment (Figs. 3.3.A and B). We found that that addition of TGFβ upregulated Snail1 expression ~20-fold relative to vehicle treated cells at 2 hours
(Fig. 3.3.A), and upon treatment with EGF there was ~ 4-fold increase in Snail1
transcription (Fig 3.3.B), suggesting differences in the effectiveness of these two
signaling pathways in regulation of Snai1 transcription and hence EMT.
To better understand the differences between TGF-β and EGF induced
EMT, we performed an immunofluorescence (IF) experiment to observe changes
in expression of the cell adhesion marker protein E-cadherin (CDH1), which is lost
as EMT progresses. NMuMG cells were treated with TGF-β or EGF for 48 hours,
fixed and stained with an antibody to CDH1 (red). We observed almost complete
loss of CDH1 expression with TGF- β treatment (Fig. 3.4.C) compared to the
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B

Figure 3.3. TGF-β and EGF lead to upregulation of Snai1 transcription.
NMuMG cells were serum-starved for 4h, and then treated with TGF-β for
2,8,12,48 hours (A), and EGF for 3,8,24,48 hours (B). RNA was isolated from
NMuMG cells and cDNA prepared using reverse transcription. Expression of Snai1
gene was examined by real-time PCR of the cDNA using primers against Snai1
and normalized to Gapdh rRNA. Data were derived from at least three
independent biological replicates and are represented as mean ± SEM values. The
* indicates p-value of ≤ 0.05, and *** indicates p-value ≤ 0.001 as measured by a
paired t-test.

A

B

C

Figure 3.4. Immunofluorescence shows complete loss of CDH1 with TGF-β
treatment and partial loss of CDH1 with EGF relative to vehicle treated cells.
NMuMG cells were serum-starved for 4 hours and then treated with 0.1% BSA (A)
or EGF(B) or TGF- β (C) for 48 hours. IF was done using CDH1 as the primary
antibody and fluorescent secondary antibody.

130

vehicle treated cells (Fig. 3.4.A), whereas only partial loss of CDH1 expression
was seen with EGF treatment (Fig. 3.4.B).
Having established that TGF- β treated cells had a higher expression of
Snai1 and greater loss of CDH1 compared to EGF treated cells, we wanted to see
its effect on cell migration as a result of EMT. To this end, we tested cell migration
ability using a wound healing assay in cells induced with TGF-β and EGF. As
expected, cells treated with TGF-β healed the wound faster than untreated controls
(Fig. 3.5.A and B). We did not see a significant difference in wound closure relative
to vehicle treated cells when we compared EGF induced cells, indicating that TGFβ treatment has a greater effect on cell migration compared to EGF treatment.
To obtain a genome-wide view of the gene expression signature induced by
TGF-β and EGF, we performed RNA-sequencing on NMuMG cells that were
treated with 0.1% BSA in PBS (vehicle control), TGF-β or EGF for 2 hours and
3 hours respectively. Differential expression analysis revealed that there were
905 genes significantly altered in TGF-β treatment relative to control (Fig. 3.6.A).
Of the 905 genes differentially expressed with TGF- β 637 genes were upregulated
and 267 genes were downregulated (Fig. 3.6.A). 339 genes were significantly
differentially expressed with EGF treatment, of which 161 genes were upregulated
and 178 genes were downregulated (Fig. 3.6.A).
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Figure 3.5. NMuMG cells have increased cell migration in response to
TGF- β compared to EGF. Confluent NMuMG cells in a 6-well plate were
serum starved for 4h prior to treatment, and TGF-β or EGF (for 8h) were
added to the wells prior to wounding using a sterile 200ul tip. Three
representative fields were marked and imaged immediately at time of (0h)
and a time period after (8h) wounding as described in materials and
methods(A). The images were captured using an Olympus IX71 microscope
camera. (B) All data are representative of at least 3 biological replicates.
Statistical analyses were performed with Graphpad Prism software.
*= p-value ≤ 0.05, **= p-value ≤ 0.01.
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Figure 3.6. Differential gene expression changes following TGF-β
and EGF treatment. RNA isolated from NMuMG cells treated with 0.1%
BSA, TGF-β or EGF was sequenced, and gene expression changes
calculated. List of number of differentially expressed genes with three
different treatments. Venn diagram depicting the number of unique and
overlapping genes with the two different treatments.The differentially
expressed genes with the two different treatment conditions were analyzed
using IPA. The top five scoring hits in these categories using IPA are
shown, together with significance scores (p-values) and the number of
genes included in each class.
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Comparison of TGF-β to the EGF treated groups revealed 637differentially
expressed genes with TGF-β and 161 with EGF, with only 33 genes that were
common to both datasets. This left 604 genes that were unique to the TGF-β
dataset and 128 genes that were unique to the EGF dataset (Fig. 3.6.B). Similarly,
of the differentially downregulated genes (267 with TGF-β and 178 with EGF), only
19 genes overlapped both datasets (Fig. 3.6.C). We generated network maps and
functional analyses of these genes using QIAGEN’s Ingenuity Pathway Analysis
software. The top 5 significantly altered pathways with the TGF-β comparison and
EGF comparison generated the same top 3 significantly altered pathways, namely
cell movement, cell growth and proliferation, and cell death and survival, although
with different numbers of molecules in each category (Fig. 3.6.D).
Comparison of differences in gene functions and diseases between TGF-β
and EGF treatments using IPA revealed significant differences between these two
signaling pathways (Fig. 3.7). Overall, TGF-β appears to have a more pronounced
effect on cellular movement, cell migration, cell proliferation and differentiation,
which are hallmarks of EMT, thereby leading to a more complete EMT as
compared to EGF treatment.
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Figure 3.7. IPA analysis of DE
genes.
RNA isolated from NMuMG cells
treated with 0.1% BSA in PBS,
TGF-β or EGF was sequenced,
and gene expression changes
calculated. The gene lists were
analyzed using IPA to determine
the differences in gene functions
and diseases for the two different
treatments.

CTCF Associates with the Snai1 Promoter During TGF-β Induced EMT but
not EGF Induced EMT
Next, we wanted to understand how CTCF associates with the Snai1
promoter upon induction of EMT with TGF- β compared to EGF. After the induction
of EMT in NMuMG cells, we performed chromatin immunoprecipitation (ChIP) of
CTCF using primers designed across the Snai1 promoter and gene body
(Fig. 3.8.A). The primers were designed based on the list of putative CTCF binding
sites at the Snai1 gene (Fig. 3.8.B). The Gapdh gene promoter primers were used
as a negative control. We found that relative to vehicle-treated cells, there is
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increased association of CTCF at the promoter region of Snai1 at 2h after addition
of TGF-β (Fig. 3.9.A), and this association of CTCF at the Snai1 gene corresponds
to the increase in mRNA expression of the Snai1 gene with TGF-β treatment
(Fig. 3.9.A). However, we did not observe an increased association of CTCF at the
promoter region of Snai1 with EGF induction relative to the vehicle treated cells
(Fig. 3.9.B), suggesting that TGF-β pathway is required for CTCF recruitment to
Snai1.There was no change in CTCF association at the Gapdh promoter region
with TGF-β or EGF treatment relative to the vehicle treated cells (Fig 3.9.C and
3.9.B). Together, these data suggest that CTCF associates with the Snai1 gene
promoter during TGF- β induced EMT, but not with EGF, thereby suggesting that
association of CTCF with the Snai1 gene might be required for a more complete
EMT.

A

B

Fig 3.8. Schematic of the mouse ChIP primers and mouse CTCF binding
sites. (A) Schematic representation of the primer sets used in chromatin IP
covering the Snai1 promoter region. Locations of primer sets are indicated below
the gene, as are the distances between the primer pairs in bp. (B)The putative
CTCF binding sites are depicted as vertical black lines over the gene.
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A

B

C

D

Figure 3.9. CTCF association at the Snai1 promoter increases following
TGF-β induced EMT but not EGF induced EMT. Chromatin immunoprecipitation
(ChIP) was performed using antibodies against CTCF. Real-time PCR
amplification of ChIP DNA across the Snai1 locus reveals a peak of CTCF over the
upstream and promoter region encompassed by primer set ‘P1’ and ‘Prom.’ in
vehicle treated cells (black bars). (A) This peak increases with treatment (blue
bars). (B) No increase in CTCF binding is apparent in EGF treated cells. No peak
was observed at the Gapdh promoter region either with TGF-β treatment (C) or
EGF treatment (D). All data are representative of three independent biological
replicates.
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Depletion of CTCF Leads to Downregulation of TGF-β Mediated Snai1
Expression but not EGF Induced Snai1 Expression
While our ChIP data suggests that CTCF is recruited at the Snai1 gene in
a TGF-β dependent manner in NMuMG cells, and that this association of CTCF at
the Snai1 gene corresponds to the increased mRNA expression of the Snai1 gene,
whether CTCF binding regulates Snai1 gene transcription is not known. To
address the question whether CTCF binding regulates SNAIL expression we
depleted CTCF using siRNA (Fig 3.10.A). A significant decrease in Snai1
expression was observed when siCtcf was used in combination with TGF-β
treatment as shown in (Fig 3.10.B). No such decrease in Snai1 expression was
observed when siCtcf was used in combination with EGF as shown in (Fig 3.10.C).
This decrease in Snai1 expression with TGF-β induction and not with EGF
confirms that CTCF regulates TGF-β, but not EGF, mediated Snai1 gene
transcription.
Having established that CTCF regulates TGF-β mediated Snai1 expression,
we asked if CTCF was also needed for cell migration that occurs as a result of
TGF-β induced EMT. To this end, we tested wound healing by a scratch assay in
cells induced with TGF-β (Fig. 3.11.A and B). We noted that cells treated with TGFβ with the scrambled siRNA healed the wound faster than cells treated with TGFβ combined with siCtcf (Fig. 3.11.A and B). Taken together, these data suggest
that CTCF plays a role either directly or indirectly in TGF-β mediated EMT by
regulating Snai1 expression in NMuMG cells.
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A

B

C

Figure 3.10. Depletion of CTCF leads to downregulation of TGF-β
mediated Snai1 transcription. (A) NMuMG cells were transfected with
CTCF siRNA for 96h using a final concentration of 80 picomoles of siRNA.
Western blot was performed against CTCF to test efficiency of knockdown
and normalized using ACTB. After transfection the cells were treated with
TGF-β for 2h (B) or EGF for 3h prior to RNA and protein isolation. RNA was
converted to cDNA and RT-PCR performed to analyze both the gene
knockdown efficiency for each gene, and Snai1 transcript levels. All data are
representative of at least 3 biological replicates. Statistical analyses were
performed with Graphpad Prism software. **= p-value ≤ 0.01; ***= p-value ≤
0.001.
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A

B

Figure 3.11. CTCF depletion decreases TGF-β induced cell
migration. (A) Confluent NMuMG cells in a 6-well plate were transfected
with CTCF siRNA for 96 hours prior to treatment, and TGF-β were added
to the wells prior to wounding using a sterile 200ul tip. Three
representative fields were marked and imaged immediately at time of
(0h) and a time period after (8h) wounding as described in materials and
methods. The images were captured using an Olympus IX71 microscope
camera. (B) All data are representative of at least 3 biological replicates.
Statistical analyses were performed with Graphpad Prism software. **=
p-value ≤ 0.01.
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CTCF-Dependent Snai1 Expression During TGF-β Mediated EMT and Not
EGF Mediated EMT is Linked to SMAD3
TGF-β mediated EMT involves the phosphorylation of the downstream
effector molecule SMAD3 for gene transcription. EMT master regulatory proteins
SNAI1 and SNAI2 are among the key targets of SMAD proteins [48]. CTCF has
been reported to form a complex with SMAD3 and following addition of TGF-β,
CTCF was shown to recruit SMAD proteins to their target genes in Drosophila [38].
SMAD3 acts a transcriptional activator exclusive to the TGF-β pathway. Therefore,
we hypothesized that the differential localization of CTCF and its effect on Snai1
transcription during TGF-β (but not EGF) mediated EMT could be associated with
the binding of SMAD3 to the Snai1 gene. To test our hypothesis, we treated the
cells with SMAD3 inhibitor SIS3, which selectively inhibits TGF-β signaling by
suppressing Smad3 phosphorylation without affecting the MAPK/p38, ERK, or PI3kinase signaling pathways prior to TGF-β and EGF treatment. We observed that
addition of SIS3 blocked TGF- β mediated transcription of Snai1 but not EGF
mediated transcription of Snai1 (Fig. 3.12.A, B) thereby confirming that SMAD3
acts as a transcriptional transactivator only during TGF-β mediated EMT.
Next, we wanted to evaluate how inhibition of SMAD3 phosphorylation
affects the association of CTCF at the Snai1 gene with TGF-β and EGF induction.
To test this, we inhibited SMAD3 phosphorylation with SIS3 and then treated the
cells with TGF-β or EGF before performing a ChIP for CTCF using primers
designed across the Snai1 promoter and gene body as before (Fig. 3.8.A). As
expected, SMAD3 inhibition did not have any effect on CTCF localization at the
Snai1 gene with EGF treatment (Fig. 3.13.B). We also noted that TGFβ-mediated
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A

B

Figure 3.12. Blocking SMAD3 phosphorylation inhibits TGF-β mediated
Snai1 transcription. NMuMG cells were serum starved for 4hours and then
treated with 15uM of SIS3 for 2 hours prior to treatment with TGF-β (A) or EGF
(B) Data are representative of 3 independent biological replicates and statistical
analyses performed using GraphPad Prism. *= p-value ≤ 0.05.
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B

A

Figure 3.13. Inhibition of SMAD3 phosphorylation affects TGF-β
induced association of CTCF at the Snai1 gene. NMuMG cells were
serum-starved for 4h prior to pre-treatment with SIS3 for 2 hours followed by
TGF-β or EGF treatment. Chromatin immunoprecipitation (ChIP) was
performed using antibodies against CTCF. Real-time PCR amplification of
ChIP DNA across the Snai1 locus reveals a peak of CTCF over the
upstream and promoter region encompassed by primer set ‘P1’ and ‘Prom.’
in vehicle treated cells (black bars). (A) This peak increases with TGF-β
treatment (light grey bars) but decreases on pre-treatment with SIS3 (dark
grey bars). (B) No increase or decrease in CTCF binding is apparent in EGF
treated cells. All data are representative of three independent biological
replicates.

enrichment of CTCF at the Snai1 gene was decreased, but not completely blocked
by SIS3 (Fig. 3.13.A) suggesting that SMAD3 might play a role in the differential
localization of CTCF at the Snai1 gene and subsequent regulation of its expression
via the TGF- β mediated pathway.
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Discussion
The process of EMT, in which epithelial cells undergo molecular and
structural changes can result in the acquisition of a mesenchymal phenotype and
drug resistance that permits cell migration. This switch in cell differentiation and
behavior is mediated by key transcription factors like SNAIL, which also plays a
role in acquisition of drug resistance. This cell state transition during EMT is
initiated and controlled by signaling pathways that respond to extracellular cues.
TGF-B and EGF are both known to upregulate SNAIL expression, but little is
known about how SNAIL is regulated at the level of transcription. Thus,
understanding the molecular events that regulate the conversion of epithelial cells
to a more aggressive mesenchymal phenotype via upregulation of SNAIL would
elucidate the upstream signaling events regulating the biological process of EMT
leading to metastasis. As these signaling pathways are often druggable, they can
represent important targets for novel therapeutics.
In order to answer the question how SNAIL is regulated at the transcriptional
level, we determined through bioinformatics that the binding sites of the protein
CTCF are enriched at the promoter of the Snai1 gene in humans as well as mouse.
In eukaryotic genomes, maintenance of distinct chromatin domains is critical for
transcriptional control and CTCF has been identified as playing a crucial role in the
global organization of this chromatin architecture. This protein has been implicated
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in tumor suppression and appears to be involved in several aspects of gene
regulation including activation, repression, imprinting of genetic information, and
insulator function. Our data also showed that CTCF is enriched at the SNAI1
promoter region in cancer cell lines. Next, we checked whether CTCF associates
with the Snai1 promoter during induction of EMT in non-cancerous murine
mammary gland epithelial cells using two different EMT inducing stimuli TGF-β
and EGF. TGF-β is known to induce a more aggressive form of EMT and we
observed that CTCF is present at Snai1 gene promoter as well as upstream in
TGF-β treated non-cancerous NMuMG cells unlike the vehicle treated or EGF
treated cells. In the current study, we addressed this paradox of differential CTCF
binding at the Snai1 gene by asking two questions: first, how different is the EMT
induced by these two different signaling pathways. Secondly, we asked how and
why the differential localization of CTCF affects Snai1 expression with these
different stimuli.
To address the first question, we treated NMuMG cells with TGF-β and EGF
and examined SNAI1 and CDH1 expression as well functional assays like wound
healing. We also used RNA sequencing followed by pathway analysis of
differentially expressed genes to better understand the differences between these
two signaling pathways. We observed that TGF-β induces a more complete EMT
relative to EGF.
Next, we asked the question if and how this differential localization of CTCF
at the Snai1 gene affects transcription. We determined that knockdown of CTCF
with siRNA reduced the expression of TGF-β mediated induction of Snai1 but did
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not affect the EGF-mediated induction. This suggests that CTCF regulates TGF-β
mediated Snai1 expression either directly or indirectly. As CTCF is known to recruit
SMAD3 [49] , which is the downstream effector molecule in the TGF-β signaling
pathway [50]–[53], we asked whether blocking SMAD3 phosphorylation would
affect CTCF localization at the Snai1 gene and we noted that there was a slight
decrease in the CTCF enrichment at the Snai1 gene upon blocking of SMAD3
phosphorylation suggesting that CTCF and SMAD3 might co-operate with each
other to regulate TGF-β mediated Snai1 transcription. Additional studies are
needed to determine whether depletion of CTCF affects SMAD3 binding thereby
resulting in a decrease in Snai1 transcription, thus reinforcing the idea that CTCF
and SMAD3 co-operatively regulate TGF-β mediated Snai1 transcription.
Decades of research have elucidated the major drivers and genetic
mechanisms responsible for tumorigenesis in a one-dimensional fashion.
However, the mechanisms by which these alterations contribute to cancer
progression are not well known. Only recently, the three-dimensional context of
the genome has been identified as a major player in the development and
progression of cancer. Therefore, additional studies are required to understand a
potential mechanism in which disruption of chromatin reorganization through
differential localization of CTCF in response to two different signaling pathways
can play a role in the conversion of epithelial cells to a complete mesenchymal
form facilitating metastatic spread.
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CHAPTER 4

PROJECT 3: TGF-ß INDUCTION OF EMT PRIMES CHROMATIN TO
ESTABLISH HERITABLE TRANSCRIPTIONAL MEMORY

Abstract
Cells respond and adapt to environmental stimuli by stably retaining
epigenetic marks of prior transcriptional activation, altering cellular responses to
the same stimulus when encountered in the future. This phenomenon wherein the
rate or strength of gene expression is enhanced by previous exposure to that
stimulus is termed transcriptional memory, and has been previously documented
in yeast, plants, and even some mammalian cells. However, these studies
primarily involved short-term responses of less than a week to a few days, and
longer-term responses to stimuli have not been well studied. We therefore
developed in vitro cell culture models using mouse mammary gland cells to study
short and long-term transcriptional memory responses to transforming growth
factor beta (TGF-β). Here we show that TGF-β stimulation establishes
transcriptional memory, leading to elevated transcriptional response upon restimulation. In our model of long-term memory, the memory response was
inherited through 27 cell divisions and led to increased migratory capacity upon restimulation with TGF- β.
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The memory response was determined to be selective, as only a fourth of
all initial TGFβ responsive genes demonstrate this elevated response to restimulation. Further, TGF-β induced memory at these genes does not appear to
be due to increased cell proliferation, increased TGF- β signaling, or presence of
pre-bound Smad3 transcription factor at the memory genes but the higher
enrichment of SMAD3 and POL II upon restimulation with TGF-β at the memory
genes might contribute to the memory response. Using a modified CUT&RUN
protocol, we observed that all TGF-β responsive genes were marked by increased
histone H3K4 monomethylation and H3K27 acetylation relative to the naïve cells.
These marks persist several generations after removal of the initial response,
unlike H3K4Me3 and other histone marks we tested, which are not retained once
the initial burst of transcription is lost upon removal of TGF-β. We show that this
increased response is potentially due to a higher baseline of the repressive mark
H3K27me3 at a subset of TGF-β responsive genes, which coincides with the
acquisition of H3K4Me1 and H3K27Ac marks and loss of H3K27Me3 mark at those
genes.
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Introduction
The Epithelial to Mesenchymal Transition (EMT) is a change in cell state
from an attached, epithelial morphology to a migratory, mesenchymal phenotype.
This transition is driven by transcription factors in response to environmental cues
such as hypoxia, cytokines like TGF-β, etc., resulting in epigenetic and
transcriptional changes. Ultimately, these changes alter cellular mobility, the ability
to degrade extracellular matrix components and apico-basal polarity [1]. EMT is a
critical feature of early gastrulation and embryo development but can be hijacked
in pathological states as well. In general, responses to stimuli leading to EMT
involve mobilizing transcription machinery across the genome, resulting in global
gene activation and repression. Previous work suggests that transcriptional
responses to stimuli are quantitatively or qualitatively altered by prior exposures
through epigenetically heritable mechanisms, enabling previously expressed
genes to be primed for reactivation, a phenomenon called ‘transcriptional memory’
[2–7]. The emerging picture is that transcriptional memory arises from a
combination of different mechanisms, including histone modification, alteration of
nucleosome position and conformation, and specific targeting of multisubunit
complexes to regulate genes. These mechanisms allow cells to mount a more
rapid or robust transcriptional response to an environmental challenge that they
have previously experienced [2–7]. Several questions about cellular responses to
environmental stimuli remain unanswered, including what the mechanisms are,
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how are they propagated, whether these mechanisms are the same in response
to diverse stimuli and in different cell types, and importantly, can they be reversed
to drive de-differentiation.
The phenomenon of transcriptional memory is particularly pertinent in EMT,
which is increasingly thought of as a multi-step process rather than a binary
conversion of epithelial to mesenchymal state [8], and it is now depicted as a
succession of epigenetic states, with each state moving closer to the mesenchymal
form [8]. We suggest that developmental EMT or differentiation proceeds via
gradual phenotypic transitions, and transcriptional memory of prior responses to
stimuli are fundamentally relevant phenomena in these contexts. Therefore,
determining how transcriptional memory is established and maintained will shed
light on mechanisms of cell state transitions and differentiation. To this end, we
developed and characterized an epithelial model of long-term transcriptional
memory that can mount rapid responses to an EMT-inducing stimulus even ~27
generations/ cell divisions after the initial stimulus, relative to naïve cells. We
observe that this “memory” is not due to Pol II pausing and there are no changes
in divergent transcription. Here, we show that a transient transcriptional activation
event in NMuMG cells with TGF-β leads to reprogramming of histone marks, which
are stably inherited. Specifically, we demonstrate that the TGFβ responsive genes
are marked by acquisition of H3K4me1 and H3K27ac marks and loss of
H3K27me3 mark at those genes. Additionally, the increased memory response
appears to be associated with greater loss of the repressive chromatin mark
H3K27me3. Additional work is needed to understand how these marks affect
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establishment and maintenance of transcriptional memory responses. This study
highlights a tissue culture model to study how transcriptional states are propagated
long-term across several generations, especially in attached, epithelial cells.
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Materials and Methods
Cell Culture
NMuMG cells were obtained from American Type Culture Collection
(ATCC). Cells were cultured at 37°C in 5% CO2 in DMEM/F-12 media containing
10% FBS.
Treatments
NMuMG cells were started at P3 (with passage 1 being the vial obtained
from ATCC) in 3 different flasks at the same time. One flask was treated with
vehicle for 48 hours (VT) and passaged every ~3 days for ~30days, a total of 9
passages following treatment, prior to RNA and protein isolation as well as ChIP
and sequencing experiments. The second flask was treated with TGF-β (5ng/ml
final; Sigma-Aldrich) for 48h (1xT), and then left untreated for 9 passages prior to
RNA and protein isolation, ChIP and sequencing experiments. The third flask was
treated with TGF-β (5ng/ml final; Sigma-Aldrich) for 48h, with a 24h rest period
after trypsinization and passaging, for 10 consecutive passages (10xT) prior to
further experiments. For the RNA-Seq and PRO-Seq experiments the VT and 1xT
cells were serum starved for 4h, then treated with TGF-β (5ng/ml final; SigmaAldrich) for 30 mins and 2h prior to RNA isolation and run on experiments.
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RNA Isolation and cDNA Conversion
RNA was isolated from cells using the RNeasy kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. Briefly, after aspiration of media, cells
were directly lysed by addition of QIAzol lysis reagent, detached using cell lifters,
homogenized and transferred to an RNase-DNase free Eppendorf tube. Cells were
treated with chloroform for 2-3 minutes and centrifuged at 12,000 x g for 15 minutes
at 4°C. The upper aqueous phase was mixed with 70% ethanol and spun through
a Qiagen column. Genomic DNA was removed by on-column DNA digestion with
RNase-Free DNase Set (catalog # 79254, Qiagen). RNA concentration and quality
were assessed using a spectrophotometer (NanoDrop), and by electrophoresis on
a 2% agarose gel respectively. One microgram of RNA was used to synthesize
cDNA using random hexamer priming and SSRT-III reverse transcriptase (Life
Technologies), followed by qPCR using Quantitect (Qiagen) primer assays or
primers designed and ordered from IDT (Table 4.1). Data were normalized against
Rrn18S gene transcripts (Quantitect, Qiagen). Data were derived from at least
three independent biological replicates and are represented as mean ± SEM
values. Data were analyzed using the delta-delta Ct method as described
previously. Statistical analyses were performed using the GraphPad Prism
software, version 7.0.
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Table 4.1. Primers used for RNA RT PCR
IDT RT PRIMERS
gggcttcagatcttcattgg

Mm_Nfatc2_RT_F

tggtggctctcatgttgttc

Mm_Nfatc2_RT_R

atcgccgagtgcaagacgcg

Mm_Pdgfb_RT_F
Mm_Pdgfb_RT_R
Qiagen Quantitect Primer Assays
Mm_Snai1_1_SG
Mm_Mta3_1_SG
Mm_Cdh1_1_SG
Mm_Rn18s_3_SG
Mm_Gapdh_3_SG

aagcaccattggccgtccga
QT00240940
QT00097223
QT00121163
QT02448075
QT01658692

Western Blotting
Proteins were extracted by lysing cell pellets in urea lysis buffer (8M urea,
1%SDS in Tris-HCl pH 6.5) containing CompleteTm protease (Roche) and
phosphatase (Sigma- Aldrich) inhibitors, and subsequent heating to 95°C for 5 min.
Protein concentration was estimated using the Qubit (Thermo Scientific) protein
assay kit, following the manufacturer’s instructions. Western blotting was
performed as previously described [9], using the following antibodies: anti-SNAI1
(Cell signaling, mouse mAb #3895), anti-pSMAD3 (Cell Signaling, rabbit mAb
#9520S), anti-SMAD3 (Cell Signaling rabbit mAb #9513S) with a dilution of 1:1000
in 5% non-fat dried milk (5% BSA for the antibodies specific to phosphorylated
proteins) in 0.1% TBS-T. Anti-GAPDH (Millipore, rabbit pAb # ABS16), antiH3K4Me1 (Abcam, rabbit pAb # 8895), anti-H3K4Me3 (Millipore, rabbit pAb # 07473), anti-H3K27Ac ( Active-Motif, rabbit pAb # 39133), anti-H3K27Me3 (Cell
Signaling, rabbit mAb # 9733) was used with a dilution of 1:5,000 in 5% non-fat
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dried milk in 0.1% TBS-T. Secondary antibodies anti-rabbit IgG, peroxidase-linked
species-specific whole antibody (from donkey)-45-001-276(GE Healthcare) and
anti-mouse IgG, peroxidase-linked-species-specific whole antibody (from sheep;
45-001-275; GE Healthcare) were diluted 1:10,000 in 5% non-fat dried milk in 0.1%
TBST and blots were developed using the Li-COR Odyssey instrument (Li-COR
Biosciences) using Luminata Forte Western HRP substrate (WBLUF0500).
Western blots were quantified using Licor software and normalized to GAPDH.
Immunofluorescence
Cells were seeded on glass coverslips in six-well tissue culture dishes and
grown to ~50-60% confluence. They were fixed with 4% formaldehyde and 0.1%
Triton X-100 (to permeabilize cells) in PBS for 15 min in the cell culture incubator
under CO2. The media was then removed, and cells were washed with PBS and
blocked for 30 minutes with 5% BSA in PBS. Cells were incubated with primary
antibody anti-SNAI1 (Cell Signaling, mouse ) or anti-CDH1 (Cell Signaling, rabbit)
for 1 h, washed with PBS, incubated with the secondary antibody (Alexa Fluor 488
or 568) for 1 h, washed with PBS, and mounted on glass slides with Vectashield
mounting medium containing 4’,6-diamidino-2-phenylindole (DAPI). The cover
slips on the slides were sealed with nailpolish, allowed to set and and imaged using
an Olympus IX71 microscope. Data are representative of at least three biological
replicates.
Migration Assays
Confluent cells in a 6-well plate were serum starved for 4h prior to treatment,
and TGF-b (for 8h) were added to the wells prior to wounding using a sterile 200ul
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tip. Three representative fields were marked and imaged immediately at time of
(0h) and a time period after (8h) wounding as described [10]. Cell migration across
the wound was analyzed using ImageJ with MRI Wound healing plugin. The tool
measures the area of the wound, i.e. the area that does not contain cells, in each
image. A ratio of the area of the wound at the start of wounding and at the end of
wound closure is estimated as the percent of cell migration. Data are the average
of at least 4 independent experiments, and statistical analyses were performed
using GraphPad Prism 7 software.
Chromatin Immunoprecipitation (ChIP)
ChIP was performed as previously described [11] with the following
exceptions. In brief, cells were crosslinked with 1% formaldehyde for 5 minutes at
37°C, quenched with 2M glycine and washed with PBS, and then sonicated in the
Covaris S220 sonicator (fill level=8, peak power =120, duty factor=3, cycles/burst=
200) to generate 300-600bp DNA fragments. Immunoprecipitation was performed
using the antibodies indicated, and IgG was used as a control. Precipitated DNAs
were detected by PCR using specific primers (see Table 4.2). Quantitation was
performed on immunoprecipitated DNA using the CFX384 real-time PCR machine
(Bio-Rad) with SYBR-green, and the percent input for each sample was calculated
based on a standard curve using 10%, 1%, 0.1% and 0.01% of input DNA.
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TABLE 4.2. ChIP Primers used in study
Nfatc2_ChIP_P1_F
Nfatc2_ChIP_P1_R
Nfatc2_ChIP_prom_F
Nfatc2_ChIP_prom_R
Nfatc2_ChIP_P2_F
Nfatc2_ChIP_P2_R
Snai1_ChIP_P1_F
Snai1_ChIP_P1_R
Snai1_ChIP_prom_F
Snai1_ChIP_prom_R
Snai1_ChIP_P2_F
Snai1_ChIP_P2_R
Snai1_ChIP_P3_F
Snai1_ChIP_P3_R
Pim1_ChIP_P2_F
Pim1_ChIP_P2_R
Pim1_ChIP_Prom_F
Pim1_ChIP_Prom_R
Gapdh_ChIP_Prom_F
Gapdh_ChIP_Prom_R

agggctccacccacctaga
tgggcagtgctccctgataa
ctcaccgtgcgccacaga
tccagctcgtcttggggact
ccccccttctctttccagaa
aagggggttgcatggcttga
tgtttattctgtctgtctctctct
agccagaaagtgcgatgatatg
tacctaggtcgctctggccaacat
cgtcctgcagctcgctatagt
ttcaccttccagcagccct
gacagcgaggtcagctcta
gacctgtggaaaggccttct
aatggagaacaaccaacatctact
acaccctggaggtggggat
caggggctccttctctttgc
atcgctaccacggcaggt
attgggggtgtctgaggga
aatgagagaggcccagctac
aagaagatgcggccgtctct

Statistical Analysis
All statistical analyses for RT-PCR, ChIP and migration assays were
performed using GraphPad Prism 7 (GraphPad Software). Data were expressed
as mean ± standard error of the mean (S.E.M). The statistical correlation of data
between groups was analyzed by a two-tailed Student’s t-test, where P<0.05 was
considered significant.
Karyotyping
Cell lines were shipped to Karyologic, Inc. (Research Triangle Park, NC)
and G-banding staining followed by Wright’s stain (GTW) using standard
procedures was performed. Cytogenetic analysis was performed on twenty
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G-banded metaphase spreads from mouse cell line NMuMG, an untreated control.
In 17 of the 20 spreads, the karyotype consistently displayed a count of 39, XX
with monosomy of Chromosome 4, monosomy of Chromosome 14, and trisomy of
Chromosome 19, with no other apparent aberrations. Similar results were seen in
1xT cells.
Cell-Proliferation Assay
Cell proliferation was assessed using Flow-Cytometry. VT and 1xT cells
were stained with a cell proliferation dye BV-450 (Thermo-Fisher, Cat. # 65-0842,)
according to the manufacturer’s protocol to compare their proliferation status. At
0h, 48h and 72h post-culture the cells were counter-stained with viability dye Ghost
Dye Red 710 (Tonbo Biosciences, Cat. # 13-0871,) and cell counts acquired using
BD Symphony Flow Cytometer.
Data was analyzed with FCS Express 6.06.0022 [De NovoSoftware;
(https://www.denovosoftware.com/site/manual/proliferationstatistics.htm)],
and the frequency of precursors was calculated according to the automatic
proliferation fit statistics, as described in the manufacturer’s instructions.
Imaging Cytometry
The expression of N-Cadherin and E-Cadherin were measured using FlowCytometry. The VT and 1xT cells were stained with appropriate antibodies.
Antibodies and permeabilization kits were obtained from BioLegend, eBioscience,
and

Tonbo

Biotechnology

Corporation.

Unstained,

single

stained,

and

fluorescence-minus-one (FMO) controls were used to set gating parameters,
determine specificity, and set up compensation panels for acquisition to avoid
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spectral overlaps. At least 50,000 cells were acquired in the live gate for further
analysis. Expression of the surface markers N-Cadherin and E-cadherin was
evaluated by staining with the following panel: BV510-Live/Dead fixable viability
dye for live/dead cell staining, Alexa Fluor 647-conjugated anti-mouse/human
CD324 (clone DECMA1) and PE-conjugated anti-human CD325 (clone 8C11)
antibodies were used to stain the cells following the manufacturer’s instructions
(BioLegend). Briefly, after live/dead cell staining, the cells were washed twice with
fluorescence-activated cell sorter (FACS) buffer (PBS with 2% FBS) and
nonspecific binding sites were blocked by incubation with Fc block solution (dilution
ratio, 1:300) for 10 min on ice in the dark. After blocking, the cells were washed
twice with FACS buffer and incubated with the respective antibodies against
surface markers overnight at 4°C. After incubation cells were washed twice
with FACS buffer and finally resuspended in FACS buffer containing 5 mM EDTA.
Cells were acquired using BD Symphony Flow Cytometer. Data was analysed
with

FCS

Express

6.06.0022

[De

NovoSoftware;

(https://www.denovosoftware.com/site/manual/proliferationstatistics.htm)],
and data were analyzed using FloJo software (FloJO, Treestar, Ashland, OR).
Library Construction and RNA-Sequencing
The quality of total RNA isolated as described above and the quality was
assessed by Bioanalyzer 2100 and and samples with high RNA integrity number
(>8) were used for library construction with the NEBNext Ultra II RNA-seq library
kit nondirectional (E7775S) with the PolyA mRNA Magnetic Isolation Module
(E7490S) according to the manufacturer’s protocol for PE150 RNA-Sequencing at
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Novogene on the Illumina. Two biological replicates for each treatment were
sequenced, resulting in an average of 50 million reads per sample. Base call (.bcl)
files for each cycle of sequencing were generated by Illumina Real Time Analysis
(RTA) software. The base call files and run folders were then exported to servers
maintained at the Minnesota Supercomputing Institute. Primary analysis and demultiplexing were performed using Illumina’s CASAVA software 1.8.2. The result
of the CASAVA workflow is de-multiplexed FASTQ files that were subject to
subsequent analyses as described below.
RNA-Seq Data Analyses
Preliminary QC of the RNA-Seq reads was done using FastQC v0.11.2 [12].
Adapters were trimmed using Trimmomatic v0.33 [13].Transcript expression was
quantified against the mm10 genome using Salmon v.0.12.0 [14]. Transcript
abundances were imported into R and summarized using tximport v1.10.1 [15].
Differential expression done using DESeq2 v1.22.2 [16] with the FDR controlled at
0.05. Clustering of significant genes was performed using log2(cpm) values.
Network mapping and functional analyses were generated through the use of
QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City,
www.qiagen.com/ingenuity).
ATAC-Seq Library Preparation and Data Analysis
ATAC-seq was performed as previously published [17]. Briefly, 25,000 cells
were used and tagmented with 2.5ul of Tn5 transposase and the sequence library
was prepared as previously described [18] Reads were mapped to mm10 genome
using Hisat2 [19] with the same parameter used in [18]. Only non-duplicate reads
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were used for the subsequent analysis. The offset parameters suggested in the
publication[18] were applied to each mapped read.
PRO-Seq Cell Fractionation
Cells were grown in a 15cm dish and harvested at a confluency of 80%.
Cells were washed with 10ml cold PBS, scraped in PBS and centrifuged at 4C at
1000xg for a minute. The supernatant was discarded. Cells were resuspended in
lysis buffer (10mMTris-Cl pH7.5, 2mM MgCl2, 3mM CaCl2, 0.5% IGEPAL (SigmaAldrich), 10% glycerol, 2 Units/ml SUPERase-In (Invitrogen), Protease Inhibitor
Cocktail (Sigma)) and gently pipetted up and down 20 times using a p1000 tip with
the end cut off to reduce shearing and incubated on ice for 7 minutes. The nuclei
were centrifuged and pelleted for 7mins at 4°C at 1000 – 2000xg. and the
supernatant was discarded. The nuclei were resuspended in 100ul of Freezing
buffer (50mM Tris-Cl pH 8.3, 40% glycerol, 5mM MgCl2, 0.1mM EDTA) for storage
-80°C. This protocol was adapted from the work as previously described [20].
PRO-Seq Library Preparation and Data Analysis
VT and 1xT cells were treated with TGF-β for 30 mins and 120 mins as
previously described. Nuclei were prepared by the above cell-fractionation protocol
from two 15 cm dishes. The nuclei were treated with biotin-11-NTPs (Perkin
Elmer). All four biotinylated NTPs were used in each run-on reaction. Run-on
reactions and library preparations was done exactly according to [21]. Libraries
were validated on the Bioanalyzer 2100 and quantified by the Biorad QX200
Droplet Digital PCR (ddPCR) system prior to sequencing.
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Preliminary QC of the RNA-Seq reads was done using FastQC v0.11.2 [22].
Sequencing adapters were removed using Trimmomatic v0.33 [13]. All alignments
were done using hisat2 v 2.1.0. [19]. First, reads aligning to the hg19 genome , the
heterologous spike-in, or ribosomal reads were removed. The remaining reads
were aligned to the mm10 genome, keeping only reads with fewer than 2
mismatches. For differential expression, reads aligning to gene bodies (defined
as +200bp from TSS to end of gene) were counted using featureCounts v1.6.4
[23]. Differential expression analysis was performed using using DESeq2 v1.22.2
[16].
CUT&RUN Library Preparation and Data Analysis
Thanks to the kind gift of the pA-MNase fusion protein from Dr. Steve
Henikoff (Fred Hutchinson Cancer Center, WA), we have further optimized
CUT&RUN (Cleavage under targets and release using nuclease) in our laboratory,
such that we can complete the procedure in 3.5h, in a multiplex format using 24well dishes. Using this “On-plate” CUT&RUN procedure, cells were seeded at
50,000 cells per well in 24-well dishes overnight. The next day (before cells
double), cells were washed thrice with wash buffer [20mM HEPES pH 7.5, 150mM
NaCl, 0.5 mM Spermidine, and protease inhibitors] each time swirling the dish and
aspirating supernatant, while ensuring cells did not dislodge. Next, cells were
incubated with appropriate primary antibody in antibody buffer [8 μL 0.5 M EDTA
in 2 ml Dig-wash buffer] for 15 minutes at RT, then washed thrice with Dig Wash
buffer [wash buffer containing 0.02% Digitonin] as before. Protein A-MNase [pAMNase, kind gift of Henikoff Lab, Batch#5, at 364ug/mL diluted 1:1000] was added
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and bound to the primary antibody for 15 minutes at RT and washed thrice with
Dig Wash Buffer to remove unbound pA-MNase. Targeted cleavage of DNA was
performed by addition of calcium [Dig wash buffer+ 2mM final CaCl2] on ice for 30
minutes. The reaction as stopped by addition of STOP buffer [340 μl 5M NaCl, 200
μL 0.5M EDTA, 100 μL 0.2M EGTA, 20 μL 5% Digitonin, 10 μL RNaseOUT, 16.6
μL of 15 mg/ml glycogen and 2 pg/ml heterologous spike-in DNA (1uL of a 10ng/ml
stock per 5ml) in 4.2 ml dH2O]. Cleaved fragments of DNA were released into
supernatant by incubation at 37C for 12 minutes, and supernatant was pipetted
into an eppendorf tube. The supernatant was treated with 0.1% final SDS and 125
ug/ml final Proteinase K to digest proteins, and samples were mixed and incubated
for 10 min at 70C. The DNA was isolated by phenol-chloroform-isoamylalcohol
extraction using standard procedures and made into libraries using the NEB-Ultra
II kit. Libraries were sequenced at Novogene with 150bp paired-end reads. Reads
were aligned and peaks were defined as previously published [24].
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Results
TGF-β Stimulation Generates Heritable Transcriptional Memory
in NMuMG Cells
While short-term transcriptional memory (STTM) responses have been
studied in detail [3–5], [25–30], mechanistic studies of long-term transcriptional
memory (LTTM) in mammalian cells are currently limited. To date, there are few
to no available tissue culture models to study how transcriptional states are
propagated long-term across several generations, especially in attached, epithelial
cells. To this end, we developed and characterized an epithelial model of LTTM
that can mount rapid responses to TGFβ for upto ~27 generations/ cell divisions
after the initial stimulus. To develop this model, non-cancerous murine mammary
gland epithelial cells (NMuMGs) were treated with TGF-β for 48 hours, washed,
and then passaged for 9 passages. These cells were called pre-treated or 1xT
cells. The control or naïve cells (VT) were treated with vehicle (PBS) for
10 passages (Fig. 4.1.A). The cells were started at P3 and frozen down at P13
after 10 passages. We developed three independent biological replicates for this
model. To test whether pre-treatment with TGFβ resulted in a memory response,
the VT cells were treated with TGF-β for the first time for 30 mins and 120 mins,
while the 1xT cells were re-treated with TGF-β for 30 mins and 120 mins
(Fig.4.1.A). RNA isolation and cDNA were prepared, and RT-PCR analysis
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Figure 4.1. NMuMG cells retain memory of prior TGF-β treatment.
(A) Experimental scheme: NMuMG cells were treated with vehicle or TGF-β for
48 hours, washed and passaged for 9 passages. Naïve and pre-treated cells
were treated with TGF-β for 30 mins and 2 hours after 10 passages. (B) RNA
was isolated from the treated VT and 1xT cells after restimulation and cDNA
prepared using reverse transcription. Expression of Snai1, Nfatc2, Pdgfb and
Mta3 genes were examined by real-time PCR of the cDNA using primers
against the respective genes and normalized to 18s rRNA. Data were derived
from at least three independent biological replicates and are represented as
mean ± SEM values. The ** indicates p-value ≤ 0.01 as measured by a paired ttest. (C) Naïve and pre-treated cells were labelled with BV-450 and the staining
was detected by flow-cytometry. Equal number of one cell division was detected
in both VT and 1xT cells in a 72h experiment. (D) Confluent VT and 1xT cells in
a 6-well plate were serum starved for 4h prior to treatment, and TGF-β (for 8h)
were added to the wells prior to wounding using a sterile 200ul tip. Three
representative fields were marked and imaged immediately at time of (0h) and a
time period after (8h) wounding as described in materials and methods. All data
are representative of at least 3 biological replicates. Statistical analyses were
performed with Graphpad Prism software. *= p-value ≤ 0.05.

174

showed that some TGF-β responsive genes like Snai1 and Nfatc2 were indeed
induced to a greater extent in the 1xT cells relative to naïve (VT) cells upon retreatment with TGF-β, while other TGF-β responsive genes like Pdgfb and Mta3
did not exhibit a memory response (Fig.4.1.B). This result suggested that only a
fraction of TGF-β responsive genes are “memorized”, i.e. display a more robust
response to subsequent TGF-β exposure even after 27 generations of cell
divisions.
To rule out the possibility that the elevated response is not due to
differences in cell division rates between the two cell lines, we compared the
proliferation status of the VT and 1xT cells. To do this, the cells were stained with
BV-450 a cell proliferation dye as described in the methods. Flow-cytometry
analysis of the stained cells over a time period of 0, 48 and 72 hours showed that
both naïveand pre-treated cells divided equally and underwent at least one cell
division at 48 hours, indicating, that they had a similar rate of cell division and that
TGF-β induced memory was transmitted across cell divisions (Fig. 4.1.C).
To further investigate the functional significance of memory we tested ability
of the cell lines to migrate and heal a wound using a scratch assay as previously
described [9] . While untreated VT and 1xT cells showed no significant difference
in the ability of cells to heal the wound, we observed that upon TGFβ treatment,
the 1xT cells healed the wound faster than the VT cells (Fig. 4.1.D), suggesting
that TGF-β induced memory contributes to faster wound healing. Thus, TGF-β
stimulation generates transcriptional memory in non-cancerous murine mammary
gland epithelial cells, and the pre-treated cells remember the first exposure to the
175

TGF-β stimulus even after 27 generations that confers some TGF-β responsive
genes greater transcription upon re-stimulation.
Pre-treated (1xT) Cells are Phenotypically Indistinguishable from Naïve
Cells
To further assess the memory response in the 1xT treated cells, we wanted
to understand the phenotypic or molecular differences between the naïve cells and
pre-treated cells. Before doing any further experiments, we wanted to know if there
were any gross genetic anomalies in these cells as they were in culture for a long
time. To answer that question, we performed karyotyping for the VT and 1xT cells,
which ruled out gross genetic anomalies in these two cell lines (Fig. 4.2.A). Next,
we did an immunofluorescence experiment to check for the expression of SNAI1
and CDH1 protein in these cells and observed no significant difference in these
two cell lines (Fig. 4.2.B). We also measured the mRNA levels, which again
confirmed that there was no significant difference in the expression of Snai1 and
Cdh1 between the VT and 1xT cells (Fig. 4.2.C). Next, we performed a functional
wound healing assay to determine any differences between these two cell lines
where we tested wound healing by a scratch assay in VT and 1xT cells without
any treatment. We observed that unlike the TGF-β re-treated cells there was no
significant difference in the rate of wound healing in the VT and 1xT cells
(Fig. 4.2.D).
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Figure 4.2. Pre-treated cells are phenotypically indistinguishable from
naïve cells (A) Karyotyping of the VT and 1xT cells do not show any gross
genetic anomalies or differences between the two cell lines. (B)
Immunofluorescence was done on VT and 1xT cells using antibodies against
SNAI1 and CDH1. (C) RNA was isolated from the treated VT and 1xT cells
before restimulation and cDNA prepared using reverse transcription.
Expression of Snai1, Cdh1 were examined by real-time PCR of the cDNA
using primers against Snai1 and Cdh1 and normalized to Gapdh. Data were
derived from at least three independent biological replicates and are
represented as mean ± SEM values. (D) Confluent VT and 1xT cells in a 6well plate were wounded using a sterile 200ul tip. Three representative fields
were marked and imaged immediately at time of (0h) and a time period after
(8h) wounding as described in materials and methods. All data are
representative of at least 3 biological replicates. Statistical analyses were
performed with Graphpad Prism software.
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To obtain a genome-wide view of the gene expression signature differences
we performed RNA-Sequencing on the VT and 1xT cells. Differential gene
expression analysis revealed that there were only 120 genes that were
differentially expressed in the 1xT cells compared to the VT cells (Fig. 4.3.B). Snail
and some other EMT related markers are part of this list. A whole transcriptome
heatmap of the VT and 1xT cells also did not show any significant difference in
gene expression between the two cell lines (Fig.4.3.A).

A

B

Figure 4.3. Pre-treated cells are indistinguishable from the naïve cells at
the transcriptomic level. (A) RNA isolated from VT and 1xT cells was
sequenced. List of all genes expressed were used to make the heatmap, using
the aheatmap function in the NMF v0.20.6 package in R. The values in the
heatmap are z-scores and all colors are relative to the average expression for
each gene across all samples. (B) RNA isolated from VT and 1xT cells was
sequenced and gene expression changes calculated using Deseq2 with an FDR
of 0.05 and the number of differentially expressed genes are listed in the table.
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Next, we performed flow cytometric analysis using antibodies to N-Cadherin
(mesenchymal marker) and E-cadherin (epithelial marker) in these cell lines, to
determine if 1xT cells are further along the EMT pathway relative to VT cells. As
previously reported NMuMG cells are comprised of mostly E+N+ cells, but also
have a smaller number of E-N+ cells. We observed that there was a slight increase
in the E-N+ population in the 1xT cells over the VT cells (Fig. 4.4.A, B).
To rule out the possibility that this slight increase in the E-N+ population
could be responsible for the increased transcriptional memory response in the pretreated cells, we sorted and removed the E-N+ population from the VT and 1xT
cells. The rest of the cells (primarily E+N+) were reseeded after sorting and treated
with TGF-β for 30 mins and 120 mins to determine if they would still show a
memory response after removal of the E-N+ population. PCR analysis showed that
even after removal of the E-N+ population, the pre-treated cells had a more robust
response to TGF-β restimulation compared to the naïve cells (Fig. 4.4.B),
suggesting that the memory response of the 1xT cells was intact, and carried by
the majority E+N+ population.
Next, we speculated whether the memory response could be ascribed to
increased TGF-β signaling. As TGF-β works through activation of SMAD3 through
phosphorylation to elicit its biological activity, we assessed whether levels of
phospho-SMAD3 are different in the two cell lines. Using an antibody to phosphoSmad3, we observed by immunoblotting that the expression of phospho-SMAD3
was virtually identical in the naïve and pre-treated cells upon treatment with
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Figure 4.4. 1xT pre-treated cells are phenotypically indistinguishable from
VT naïve cells. (A) VT and 1xT cells were stained with N-Cadherin (PE) and ECadherin (APC) fluorescent antibodies and a flow cytometry analysis was done.
(B) The percentage of different population of cells were plotted using Graphpad.
The E-N+ populations (black bars) were sorted and removed from the total
population. (C) The rest of the population (E+N+, light gray bars; and E+N-, dark
gray bars) of VT and 1xT cells were seeded together into 6 well dishes. RNA
was isolated after restimulation with TGF-β for 30 mins and 120 mins, and cDNA
was prepared. Expression of Snai1, Nfatc2, Pdgfb and Mta3 genes were
examined by real-time PCR of the cDNA using primers against the respective
genes and normalized to 18s rRNA as in Fig.1.
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TGF-β (Fig. 4.5.A), ruling out the possibility that memory response is simply an
increase in phosphor-Smad3 levels in 1xT cells. It is possible that while pSMAD3
levels were unaffected, there could be increased binding of pSMAD3 protein at
SMAD target gene promoters, which could account for the increased response to
TGFβ. To test this possibility, we performed chromatin immunoprecipitation (ChIP)
of SMAD3 using primers designed across the promoter of the memory gene Snai1
in the VT and 1xT cells. We found that relative to the naïve cells, there was no prebound SMAD3 at the promoter of the 1xT cells, but we observed an increased
association of SMAD3 as well as Pol II at the promoter region of the memory genes
in the pre-treated cells at 2h after addition of TGF-β (Fig. 4.5.B). This result
suggested that TGF-β induced memory formation is not a result of substantial
changes in TGF-β signaling or presence of pre-bound transcription factors at the
genes, but higher recruitment of transcription factors at the genes, but higher
recruitment of transcription factors and Pol II might contribute to the mechanism
of memory formation.
Memory Response is Selective and Leads to Increased Activation of
Certain Genes Upon TGF-β Re-stimulation
To generate a comprehensive list of TGF-β responsive genes that gain
memory after TGF-β treatment, transcriptome sequencing (RNA-Seq) was
performed for naïve and pre-treated cells that were re-stimulated with TGF-β for
30 mins and 2 hours. About 1986 TGF-β responsive genes were differentially
expressed in the 1xT cells compared to the VT cells at 30 mins and120 mins taken
together. Of these 1986 genes, 491 show memory response, which we define as
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Figure 4.5. Memory formation is not a result of changes in TGF-β signaling
or presence of pre-bound transcription factors at the genes. (A) Naïve and
pre-treated cells were stimulated with TGF-β for indicated times in minutes, and
expression of pSMAD3 detected by immunoblot analysis of whole cell extracts
using corresponding antibodies. GAPDH and total SMAD3 was used as loading
control. (B) Naïve and pretreated cells were stimulated with TGF-β for 120 mins
and Chromatin immunoprecipitation (ChIP) was performed using antibodies
against SMAD3 and POL II. Real-time PCR amplification of ChIP DNA across
the Snai1 locus reveals SMAD3 binding across the Snai1 gene in cells treated
with TGF-β and Pol II enrichment at the promoter of the Snai1 gene in the VT
and 1xT cells treated with TGF-β. No discernable SMAD3 and Pol II signal is
noted in the VT and 1xT cells without TGF-β stimulation. Upon addition of TGFβ we observed a higher enrichment of Pol II and SMAD3 in the 1xT treated cells
over the VT cells.

genes with a higher expression in the pre-treated cells over the naïve cells, and
with a difference in log2 fold change of 1 or higher in the 1xT cells over the VT
cells (Fig. 4.6.A and B, red dots, and Fig. 4.7.A). 494 genes were classified as nonmemory genes, as there was no difference in the expression levels of these genes
between the VT and 1xT cells upon TGF-β re-stimulation (Fig. 4.6.A and B, green
dots, and Fig. 4.7.A). Of the 1986 genes, approximately 1001 genes were
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classified as refractory genes as although they were induced in both the naïve and
pre-treated cells, their level of induction in the pre-treated cells was lower than the
naïve cells (Fig. 4.6.A and B, blue dots, and Fig. 4.7.A). The memory genes were
subjected to further analysis and a heatmap was generated based on hierarchical
clustering as shown in (Fig 4.7.B).

A

B

C

Figure 4.6. Memory response is selective- RNA-Seq analysis. RNA isolated
from VT and 1xT cells stimulated with TGF-β for 30 mins and 120 mins was
sequenced and gene expression changes calculated using Deseq2 with an FDR
of 0.05. (A) Scatter-plot showing the different categories of differentially
expressed TGF-β responsive genes. The log 2-fold change of the VT cells were
plotted on the x axis and the 1xT cells were plotted on the y axis. Genes with a
difference in log 2-fold change of 0.1 or higher in the 1xT cells shown in orange
were classified as memory genes. Genes with log 2-fold change difference value
close to zero in the 1xT cells were classified as non-memory genes and are
shown in green. Genes with a log 2-fold change difference value of less than 0 in
the 1xT cells were classified as refractory genes shown in blue. The nonresponsive genes are shown in grey. (B) The total TGF-β responsive genes were
sub-divided into 3 groups and the number of genes in each group is represented
in the form of a pie-chart. (C) Genes that were differentially expressed with TGF-β
addition, were analyzed using IPA. The top five scoring hits in these categories
using IPA are shown, together with significance scores (p-values) and the number
of genes included in each class for the 3 different categories of TGF-β responsive
genes.
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Figure 4.7. Increased activation and repression of genes in pre-treated cells
upon TGFβ re-stimulation. (A) The difference in log 2-fold change between the VT
and 1xT cells from the RNA-Seq data after re-stimulation was plotted in the form of
violin plots with the help of the ggplot function in R showing that the memory genes
have log 2-fold change differences greater than 0.1, the non-memory genes have log
2-fold change differences closer to 0 and the refractory genes have negative fold
change differences. (B) Hierarchical clustering analysis of the memory genes were
done in the naïve and pre-treated cells before and after stimulation using log
(TPM+1) and this was used to generate the heatmap using the aheatmap function in
the NMF package in R. The values in the heatmap are z-scores- where a value of 1
means that the expression for a gene in a sample is 1 standard deviation above the
average expression for that gene and all colors are relative to the average
expression for each gene across all samples.

IPA analysis (Fig. 4.6.C) showed that memory and non-memory genes
share overlapping and related categories like cellular development and gene
expression. In contrast, the categories highlighted in the refractory gene list was
unrelated to those in the memory category, suggestive of negative transcriptional
regulation, and indicating distinct functional traits for this group of TGF-β
responsive genes. Thus, TGF-β stimulation imparts transcriptional memory to
more than 450 TGF-β responsive genes. Further, this memory response varied in
different TGF-β responsive genes, revealing selectivity in memory formation.
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These data suggest that the second TGF-β stimulation does not produce carbon
copy of the first response, but it likely imposes reprogramming of gene expression
patterns.
Nascent-RNA Sequencing Reveals Early Temporal Changes During TGF-β
Induced Establishment of Transcriptional Memory Not Seen by RNA-Seq
RNA transcription in eukaryotic cells is actively regulated in multiple stages,
including RNA polymerase recruitment, transcription initiation, elongation, and
termination. The RNA polymerase pauses immediately downstream of a
transcription start site (TSS) and constitutes another critical step in transcriptional
regulation [20], [31–34]. Nascent RNA sequencing technologies, such as precision
nuclear run-on sequencing (PRO-Seq) [35], [36] enable the measurement of
transient RNA transcription at multiple stages on a genome-wide scale, for multiple
RNA species, including protein-coding genes. When used for comparison across
different conditions, these technologies provide a direct and sensitive
measurement of transcriptional changes at each stage, without interference from
splicing, capping, and post-transcriptional stabilization. Therefore, we performed
PRO-Seq to rule out the possibility that the TGF-β induced memory response is a
result of de novo transcription and not mRNA carryover. PRO-Seq was performed
using naïve and pre-treated cells treated with TGF-β for 30 mins and 2 hours. The
PRO-Seq technique maps the location of active RNA polymerase II, and the
density of polymerases at a locus directly reflects the level of nascent transcription
in the cells. From the nascent RNA sequencing data, we observed that out of 368
differentially expressed genes at 30 mins of TGF-β treatment, 134 genes showed
a memory response, 34 were classified as non-memory genes and the remaining
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200 genes were refractory (Fig. 4.8.A, B). At the 2h time point, out of 3627
differentially expressed genes 1038 were memory genes, 203 were non-memory
genes, and the remaining 2386 genes were refractory (Fig. 4.8.C, D).

A

B
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D

Figure 4.8. Nascent-RNA sequencing reveals early temporal changes (A)
PRO-Seq libraries made from VT and 1xT cells stimulated with TGF-β for 30
mins and 120 mins was sequenced and gene expression changes calculated
using Deseq2 with an FDR of 0.05. (A), (C) Scatter-plot showing the different
categories of differentially expressed TGF-β responsive genes at 30 mins and
120 mins respectively. The log 2-fold change of the VT cells were plotted on the
x axis and the 1xT cells were plotted on the y axis. Genes with a difference in
log 2-fold change of 0.1 or higher in the 1xT cells shown in orange were
classified as memory genes. Genes with log 2-fold change difference value
close to zero in the 1xT cells were classified as non-memory genes and are
shown in green. Genes with a log 2-fold change difference value of less than 0
in the 1xT cells were classified as refractory genes shown in blue. The nonresponsive genes are shown in grey. (B), (D) The total TGF-β responsive genes
were sub-divided into 3 groups and the number of genes in each group is
represented in the form of a pie-chart.
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Next, we wanted to compare the RNA-Seq and the PRO-Seq datasets to
generate a comprehensive list of memory events, and to determine whether TGFβ induced memory response is a result of de novo transcription, and not just mRNA
carry over. We observed that there was very little overlap when directly comparing
the 30-minute RNA-Seq to PRO-Seq timepoints, or the 120-minute time points for
RNA-Seq and PRO-Seq. Further, over 95% of the memory genes from the 30minute PRO-Seq data set fell under the category of non-responsive genes in the
RNA-Seq 30 mins data-set (Fig. 4.9.A). Interestingly, there was a degree of
overlap between the memory genes of the PRO-Seq data-set at 30 mins with the
RNA-Seq memory genes at 120 mins (Fig. 4.9.D). It was interesting to note that
Snai1, which is classified as a memory gene in the RNA-Seq data-sets for both
30- and 120-minute time points, is classified as a refractory gene in both PRO-Seq
data sets. This suggests that PRO-Seq takes into consideration early
transcriptional events and exhibits changes that occur early in the TGFβ memory
response, whereas RNA-Seq appears to inform on steady changes during
transcription.
It has been reported earlier that Pol II is recruited at higher levels in
macrophages upon re-stimulation with Interferon [5]. Thus, we also wanted to
know whether TGF-β induced memory is attributed to higher enrichment of Pol II
at the TGF-β responsive memory genes in the pre-treated cells compared to the
naïve cells upon retreatment with TGF-β. To answer this question, we used the
PRO-Seq data to determine the promoter density of Pol II at the different
categories of genes like memory, non-memory, refractory and non-responsive
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Figure 4.9. PRO-Seq data reveal early temporal changes in memory genes
not seen by RNA-Seq. (A) Comparison between the list of PRO-Seq memory
genes at 30 mins and 120 mins with the RNA-Seq TGF-β responsive gene
categories at 30 mins. (B) Comparison between the list of PRO-Seq memory
genes at 30 mins and 120 mins with the RNA-Seq TGF-β responsive gene
categories at 120 mins. (C) Comparison between the list of RNA-Seq memory
genes at 30 mins and 120 mins with the PRO-Seq TGF-β responsive gene
categories at 30 mins. (D) Comparison between the list of RNA-Seq memory
genes at 30 mins and 120 mins with the PRO-Seq TGF-β responsive gene
categories at 120 mins.

categories of genes like memory, non-memory, refractory and non-responsive
genes in both the VT and 1xT cells. We counted the number of reads that fell within
the promoter region (defined as +/- 100 bp from the TSS) and divided these by
total number of mapped reads for each sample, to perform normalization. These
values were used to plot the promoter density of Pol II using ggplot from R. We did
not observe any significant difference in Pol II promoter enrichment at the memory
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genes over the non-memory or refractory genes between the naïve and the pretreated cells (Fig. 4.10), suggesting that in this system Pol II is not recruited to the
memory genes at higher levels upon re-stimulation. We did not observe any
significant difference in Pol II promoter enrichment at the memory genes over the
non-memory or refractory genes between the naïve and the pre-treated cells (Fig.
10), suggesting that in this system Pol II is not paused near the transcription start
sites (TSSs) of various genes [37], [38]. Some genes with paused Pol II such as
heat-shock genes and LPS responsive genes are induced rapidly after stimulation
[39], [40]. Therefore, we asked whether TGF-β induced memory can be attributed
to a change in the Pol II status from the non-paused to paused state. To answer
this question, we calculated the pausing index of the different gene categories for
the VT and 1xT cells from the PRO-Seq data, where we counted the number of
reads at the promoter region (as 100 bp upstream and downstream of the TSS),
and the gene body region (200 bp downstream from the TSS to the end of the
gene).
To get the Pol II pausing index the number of reads at the promoter region
were divided by the number of reads at the gene body. Genes need to have at
least 10 reads at the gene body for calculating the pausing index, and therefore
genes that had reads less than 10 across the gene body were discarded for the
analysis. We observed that there was no significant difference in the pausing index
at the different gene categories between the VT and 1xT cells (Fig. 4.11),
suggesting that paused Pol II does not play a role in TGF-β induced transcriptional
memory.
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Figure 4.10. PRO-Seq data reveals no change in the Pol II enrichment at
the promoter of the VT and 1xT cells. PRO-Seq libraries made from VT and
1xT cells stimulated with TGF-β for 30 mins and 120 mins was sequenced. The
number of reads that fell within the promoter region which is defined by +/- 100
bp from the TSS was counted an divided by total number of mapped reads for
each sample to do the normalization and then those values were used to plot
the promoter density using ggplot from R (A),(B) Plot showing the enrichment
of Pol II at the promoter region of the different categories of TGF-β responsive
genes for the VT and 1xT cells prior to and after stimulation with TGF-β.
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Figure 4.11. PRO-Seq data reveals no change in the Pol II pausing index
at the promoter of the VT and 1xT cells. PRO-Seq libraries made from VT
and 1xT cells stimulated with TGF-β for 30 mins and 120 mins was sequenced.
The number of reads that fell within the promoter region which is defined by +/100 bp from the TSS and the gene body region which is defined as 200 bp
downstream from the TSS to the end of the gene was counted. The number of
reads at the promoter and gene body region were divided to get the pausing
index Plot showing the enrichment of Pol II at the promoter region of the
different categories of TGF-β responsive genes for the VT and 1xT cells prior to
and after stimulation with TGF-β.
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All TGF-β Responsive Genes are Marked by H3K4me1 and H3K27Ac Mark
in the Pre-treated Cells
Given that Pol II and other transcription factors do not remain on memory
genes and contribute to memory formation, we hypothesized that the TGF-β
induced memory information might be stored somewhere else, presumably in the
chromatin milieu, based on past studies in yeast and macrophages that
demonstrated deposition of histone marks like H2AZ, Histone H3.3 and
H3K36me3 as associated with transcriptional memory [3], [5], [25]–[28], [41]–[45].
To identify the chromatin marks that might contribute to TGF-β induced memory,
we investigated the distribution of histone variant H2A.Z, histone marks of
activation such as H3K4me3 and H3K9ac, and active enhancer marks including
H3K4me1 and H3K27Ac.
To this end, we performed chromatin immunoprecipitation (ChIP) of these
histone marks using primers designed for a few memory genes like the Snai1,
Nfatc2, Pim1 across the promoter. Gapdh promoter primers were used as negative
control. Of all the histone marks we tested, we found that relative to the naïve cells,
there is increased association of H3K4me1 and H3K27ac at the promoter regions
of the memory genes in the pre-treated cells (Fig.4.12).
Next, we wanted to investigate the genome-wide distribution of these marks
at the different categories of TGF-β responsive genes that we obtained from our
RNA-Seq data. We therefore performed a modified version of the CUT&RUN
technique from Steve Henikoff’s lab that we call “On-plate CUT&RUN”
(Fig.4.13.A), to determine the genome wide distribution of these marks in the VT
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Figure 4.12. H3K4me1 and H3K27Ac marks are enriched at the
memory genes. Chromatin immunoprecipitation (ChIP) was performed
with the naïve and pre-treated cells using antibodies against H3K4me1,
H3K27Ac and H3K4me3. Real-time PCR amplification of ChIP DNA
across the Snai1, Nfatc2, Pim1, Gapdh promoter reveals H3K4me1 and
H3K27Ac enrichment in the 1xT cells over the VT cells at the Snai1
gene(A) Nfatc2 gene(B) Pim1 gene(C) but not at Gapdh (D). No
differences were observed in H3K4me3 enrichment at these genes
between the VT and 1xT cells.

and 1xT cells without re-stimulation. Surprisingly, we observed that all the TGF-β
responsive genes that had seen the stimulus before were marked by the two
activation marks H3K4me1 and H3K27Ac in the 1xT cells, and these marks were
absent from these promoters in the VT cells. In contrast, there was no difference
in the enrichment of the activation mark H3K4me3 between the VT and 1xT cells
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at the TGF-β responsive genes (Figs.4.12 and 4.13). This observation suggested
that the histone marks H3K4me1 and H3K27ac mark all TGF-β responsive genes
that have seen the stimulus once before, regardless of their current transcriptional
state.

Figure 4.13. H3K4me1 and H3K27Ac mark all TGF-β responsive genes in
the pretreated cells. (A) Overview of the modified “On-plate CUT&RUN”
technique. (B) IGV images of H3K4Me1, H3K27Ac, and H3K4me3 peaks over
memory gene (Nfatc2), non-memory gene (Pdgfb), refractory gene (Zeb2) in
naïve and pre-treated cells. (C) Metagene plots showing all TGF-β responsive
genes that have the seen the stimulus once before are marked by H3K4me1
and H3K27Ac marks in the 1xT cells but not in the VT or naïve cells.
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Figure 4.14. All TGF-β responsive genes have a significant enrichment of
H3K4me1 and H3K27Ac mark at the promoter as well as gene body in the
1xT cells. (A) Average signal around the promoter region defined as 1000bp
upstream and downstream of the TSS for each gene was counted and
normalized to counts per million. The values derived from the normalized signal
were used to derive the box plot. Wilcoxon’s test was used to calculate the
significance. (B) Average signal 5000 bp upstream and downstream of the full
gene was counted and normalized to counts per million. The values derived
from the normalized signal were used to derive the box plot. Wilcoxon’s test
was used to calculate the significance.

As we observed an enrichment in H3K4me1 and H3K27ac mark at the TGFβ responsive genes in the pre-treated cells we wanted to ensure that this
enrichment was not due to prior TGF-β treatment leading to an overall increase in
the protein levels of these enhancer marks. To answer that question, we performed
western blots of these proteins in the VT and 1xT cells, and observed no change
in the overall protein levels of these marks between the two cell lines (Fig.4.15),
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Figure 4.15. Protein levels of the histone marks do not change between
the naïve and the pre-treated cells. (A) Expression of H3K4me1, H3K27Ac
and H3K4me3 was detected by immunoblot analysis of whole cell lysates
using corresponding antibodies. Pan H3 was used as a loading control. (B)
Data were derived from at least three independent biological replicates and
are represented as mean ± SEM values.

suggesting that the enrichment of these marks at the TGF-β responsive genes in
the pre-treated cells is not due to an increase in protein levels, but rather due to
increased recruitment.
After observing the presence of H3K4me1 and H3K27ac mark at all TGF-β
responsive genes in the pre-treated cells, we wanted to investigate the order of
acquisition of these histone marks at the genes. To this end, we performed
chromatin immunoprecipitation (ChIP) of these histone marks, using primers
designed across the Snai1 promoter, gene body, and in a region ~11kb upstream
from the Snai1 transcription start site in NMuMG cells. We found that relative to
untreated cells (Fig. 4.16.A, left panel, blue bars), there is increased association
of H3K27ac mark at the promoter region of Snai1 as early as 2h (Fig. 4.16.A, left
196

panel, purple bars) after addition of TGF-β, and this mark is retained at the
promoter region for 48 hours (Fig. 4.16.A, left panel, pink bars) and after the
stimulus has been washed away (Fig. 4.16.A, left panel, green bars). On the other
hand, H3K4me1 is not discernable at the promoter at 2h, but is seen 48 hours after
addition of TGF-β and was retained even after the stimulus was washed away
(Fig. 4.16.A, middle panel). As expected, the activation mark H3K4me3 showed
the highest enrichment at 2h after TGF-β addition, when the gene is most active
(Fig. 4.16.A, right panel), and is not retained at the gene after the stimulus is
washed away.
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Figure 4.16. Order of acquisition of the histone marks at the TGF-β
responsive genes. (A) Chromatin immunoprecipitation (ChIP) was performed
with NMuMG cells treated with TGF-β for 2h, 48h and grown for another 48
hours after removal of stimulus at 48 hours(B) using antibodies against
H3K4me1, H3K27Ac and H3K4me3. Real-time PCR amplification of ChIP
DNA was done across the Snai1 promoter(C).
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This suggests that H3K4me3 is more of an activation mark that indicates
gene activity, but H3K4me1 and H3K27ac appear to mark genes in response to
TGFβ stimulus even after removal of the stimulus, and regardless of transcriptional
activity.
Memory Genes Display a Higher Level of H3K27me3 Prior to Stimulation
with TGF-β and Lose H3K27me3 Following TGFβ Stimulus
In our analysis, we observed that the genes in the VT cells generally
displayed lower levels of the active enhancer marks H3K4me1 and H3K27Ac
especially at the promoters (Fig. 4.14). We asked if lack of active histone marks
indicated a higher level of repression, and thus analyzed the levels of the
repressive mark H3K27me3 on the memory versus non-memory and refractory
genes in the VT and 1xT cells using CUT&RUN. Our analysis revealed that prior
to TGFβ stimulation, memory genes displayed higher levels of H3K27me3 at the
promoter region of these genes (Fig. 4.17). As H3K27me3 is frequently associated
with PRC2-mediated repression of gene transcription, loss of H3K27me3
suggested that memory genes exist in a repressed chromatin state relative to other
responsive genes that do not acquire memory. We also examined the overall
protein levels of H3K27me3 in the two cell lines using western blotting and did not
observe any changes in the overall protein expression (Fig.4.18), suggesting that
the changes are due to localization at individual loci.
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Figure 4.17. Memory genes exist in a more repressed chromatin
state prior to stimulation. (A) Average profiles of H3K27me3 levels at
the promoter region of the TGF-β responsive genes were plotted as
metagene plots showing all TGF-β responsive genes. The memory
genes appeared to have a higher baseline of H3K27me3 in the VT over
the 1xT compared to the non-memory and refractory genes. (B) IGV
genome browser snapshots showing distribution of H3K27me3 in the VT
and 1xT cells at the memory gene Snai1, non-memory gene Pdgfb, and
refractory gene Zeb2.
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Figure 4.18. Protein levels of H3K27me3 do not change between the
naïve and the pre-treated cells. (A) Expression of H3K27me3 was detected
by immunoblot analysis of whole cell lysates using corresponding antibodies.
Pan H3 was used as a loading control. (B) Data were derived from at least
three independent biological replicates and are represented as mean ± SEM
values.

Previous studies have reported that loss of H3K27me3 contributes to
transcriptional memory and facilitates active Pol II elongation. Therefore, we asked
if the memory gene promoters were depleted of H3K27me3 after the stimulation,
and this loss was sustained through cell passages, thereby enabling increased
activation upon re-stimulation. When we looked across the memory genes and the
other genes, we observed a significant loss of H3K27me3 at gene promoters of
both memory and non-memory genes (Fig. 4.19). We reasoned that the removal
of H3K27me3 from the promoter region of the memory genes could be biologically
significant, as memory genes have higher base line levels of H3K27me3 than
those of the non-memory genes (Fig. 4.17) in the VT cells. To substantiate the
importance of H3K27 demethylation on memory establishment and retention,
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Figure 4.19. Memory genes have increased H3K27me3 at promoters prior
to stimulation. Average signal around the promoter region defined as 1000bp
upstream and downstream of the TSS for each gene was counted and
normalized to counts per million. The values derived from the normalized signal
were used to derive the box plot. The Kolmogorov-Smirnov test was used to
calculate the significance.

further studies are required using small molecule inhibitors that impair the
enzymatic activity of the H3K27me3 demethylases.
Chromatin Accessibility at the Promoter Does Not Contribute to Formation
of Transcriptional Memory
As we observed a more repressed chromatin signature for the memory
genes due to higher baseline levels of H3K27me3 in the VT cells before
stimulation, we investigated whether chromatin accessibility played a role in
formation of transcriptional memory. To this end, we performed ATAC-seq an
assay using transposase to assess genome wide chromatin accessibility. We
wanted to measure the chromatin accessibility at the TGF-β responsive genes in
the VT and 1xT cells and observed that there was no significant difference in
chromatin accessibility in the gene categories between the naïve and pre-treated
cells (Fig. 4.20), suggesting that chromatin accessibility does not contribute to
memory.
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A
Figure 4.20. Chromatin
accessibility does not
affect memory formation.
(A) IGV genome browser
snapshots showing example
of open chromatin structure in
both the VT and 1xT cells at
Nfatc2 (memory gene) Pdgfb
(non-memory gene) Zeb2
(refractory gene) Gapdh
(constitutively active gene
and closed chromatin
structure at Esr1 (nonresponsive) gene.
(B) Metagene plots showing
all TGF-β responsive genes
in both the 1xT cells as well
as the VT or naïve cells
exhibit an open chromatin
structure.

B
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Discussion
Epigenetic changes are defined as changes that are sustained during cell
divisions and are therefore transmitted to the progeny. This transmission of
parental information to the progeny helps the progeny to better respond to
environmental cues. Here, we show that TGF-β stimulation generated
transcriptional memory on a subset of genes in epithelial cells conferring them with
higher levels of induction upon re-stimulation. This memory survives multiple
rounds of cell divisions. Many of the identified memory genes play important roles
in cellular development and gene expression. This memory led to faster wound
healing, even though not all TGF-β responsive genes acquired memory. The
memory was largely attributed to the acquisition of H3K4me1, H3K27Ac and loss
of the H3K27me3 marks.
Genome wide analysis revealed three types of TGF-β responsive genes:
memory, non-memory and refractory highlighting that only a subset of genes
acquire memory. Memory and non-memory genes shared a couple of common
molecular functions based on IPA analysis. Paused Pol II has been shown to be
associated with memory in some genes in yeast and IFNγ treated HeLa cells but
in our system Pol II binding status did not vary across the different gene categories
suggesting that multiple mechanisms are likely to contribute to transcriptional
memory. The phosphorylation status of SMAD3 did not change in the naïve and
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pre-treated cells after TGF-β stimulation suggesting that TGF-β signaling is not
likely to be a major mechanism of memory formation.
There was no pre-bound Pol II or SMAD3 at the memory genes in either the
VT or 1xT cells. Pol II and SMAD3 were recruited to the memory genes only after
TGF-β stimulation in both naïve and pre-treated cells but there was a higher
enrichment of both SMAD3 as well as Pol II at the promoter of the memory genes
in the 1xT cells after TGF-β stimulation thus suggesting that not Pol II pausing and
pre-bound transcription factor but higher recruitment of SMAD3 and Pol II at the
memory genes after restimulation in the 1xT might contribute to the memory
response.
Memory formation has been associated with long-lived retention of
H3K4me1/2/3 at gene promoters or enhancers in previous models of
transcriptional memory. However, in our system retained H3K4me1 and H3K27Ac
were observed at all the TGF-β responsive genes after the pre-stimulation in the
1xT cells suggesting that these marks mark prior TGF-β responsive genes.
However, we did observe a significant difference in the enrichment of these marks
at the TGF-β responsive genes between the VT and 1xT cells where the vehicle
treated TGF-β responsive genes had low levels of these two marks to begin with
and stimulation with TGF-β acquisition and retention of these marks at those
genes. This led us tointerrogate the levels of the repressive H3K27me3 mark
before and after the prestimulation in the VT and 1xT cells which led us to
understand that the memorygene promoters have a higher baseline of H3K27me3
compared to the non- memory genes in the VT cells prior to stimulation and had a
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sustained loss of the H3K27me3 mark but that did not affect the chromatin
accessibility as shown by our ATAC-seq data. Together these findings support the
hypothesis thatchromatin-priming events result in transcriptional memory, where
the memory genes are epigenetically primed during the first stimulation for greater
induction upon restimulation due to increased recruitment of Pol II and transcription
factors which act as the downstream effector molecules during the process of
transcription. These observations also offer an insight into signal induced longterm epigenetic memory in epithelial cells.
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CHAPTER 5
DISCUSSION
Transdifferentiation of epithelial cells into motile mesenchymal cells, a
process known as Epithelial to Mesenchymal Transition (EMT), is integral to
normal processes of development and wound healing, but also contributes to
pathological conditions like fibrosis and cancer metastasis. Stimuli from the
environment such as growth factors like TGFβ, hypoxia, and signals from the
cellular microenvironment promote EMT by transcriptionally and epigenetically
regulating the expression of the epithelial and mesenchymal genes. This switch in
cell differentiation and behavior is mediated by key transcription factors (TFs) like
SNAI1 (SNAIL) and SNAI2 (SLUG). There is an abundance of literature
characterizing EMT related TFs (EMT-TFs) in orchestrating EMT, but not much
has been studied about how these transcription factors are regulated, and how the
upstream molecular events lead to the EMT-TFs contributing to EMT.
In this dissertation, I have tried to address three major events that occur
during TGF-β induced EMT. My first project focuses on how environmental stimuli
influence EMT, through upregulation of SNAIL. In my second project, I addressed
the question of how the EMT transcription factor SNAIL is upregulated in response
to these stimuli. Finally, in the third project, I attempted to elucidate the
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mechanisms that allows cells to “remember” and “record” prior exposures to
environmental stimuli through epigenetic mechanisms.
First, I explored how calcium signaling regulated EMT. Calcium is a
ubiquitous second messenger that influences several biological processes in the
cell, and deregulation of calcium signaling can affect all the “hallmarks of cancer”
proposed by Hanahan and Weinberg [1] , but the molecular identities of the
calcium channels and their role(s) in cancer is not yet established. In fact, through
deregulation of calcium signaling, tumor cells can gain a growth advantage, as well
support their metastatic capacity. When the internal calcium stores in the
endoplasmic reticulum are depleted, there is an increased calcium influx in cells
through store operated calcium entry (SOCE) mechanisms [2], [3] . Studies have
now linked either the calcium channel (ORAI channels) or the endoplasmic
reticulum calcium level sensors (STIMs) to breast cancer, which make them
attractive targets for anticancer therapy. While it was previously observed that
blocking calcium signaling could increase SNAIL expression in response to TGFβ, the mechanism for how this worked was unclear.
My research suggested that calcium channels differentially regulate SNAILdependent transcription and cell migration in cancer, and each of these steps could
be targeted to ensure complete blockade of cancer progression. To determine
which calcium channels were involved in SNAIL upregulation during TGF-β
induced EMT, we blocked store-operated calcium entry (SOCE) with 2aminoethoxydiphenylborane (2APB). Addition of 2APB reduced cell migration but,
paradoxically, increased the level of TGF-β dependent SNAIL gene activation. We
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determined that this increased SNAIL transcription involved signaling through the
AKT pathway and subsequent binding of NF-κB (p65) at the SNAIL promoter in
response to TGF-β. We also demonstrated that the calcium channel protein ORAI3
and the stromal interaction molecule 1 (STIM1) are required for TGF-β dependent
SNAIL transcription.
These results suggest that calcium channels differentially regulate cell
migration and SNAIL transcription, indicating that each of these steps could be
targeted to ensure complete blockade of cancer progression. ORAI3 has been
reported to play a role in conferring chemoresistance to breast cancer cells
recently [4] and it would be interesting to understand how the individual calcium
channel proteins function during cancer progression and play a role in
chemoresistance during EMT. As EMT is a multi-step process and involves
multiple gene expression programs that advocate tumor progression, invasion and
metastasis it would be interesting to further understand how these different calcium
channels and the other EMT-TFs interplay a role in EMT.
How SNAIL is specifically activated in response to TGF-β signaling through
promoter activation remains unclear till date. In my second project I tried to
understand how SNAIL is regulated during EMT progression. We used a
bioinformatics approach to determine which protein binding sites were present at
the SNAIL gene and determined that the CCCTC-binding factor (CTCF) is
potentially associated with the SNAIL gene. Although CTCF is a well-studied TF
that is very important for maintenance of chromatin 3D structure, its role in EMT is
understudied. My experiments suggested that CTCF might play a role either
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directly or indirectly in the activation of SNAI1 gene in TGF-β mediated EMT.
Interestingly, this function of CTCF in activation of SNAIL transcription appears to
be dependent on the EMT stimulus, as we determined that TGFβ, but not EGF,
resulted in increased recruitment of CTCF to the SNAIL promoter. This highly
specific recruitment of CTCF appears to function through the Smad proteins, which
are intergral to TGFβ but not EGF signaling, suggesting that not all EMT events
are created equal. As vast reorganization of chromatin has been determined to
occur during EMT[5], it would be interesting to study how CTCF reorganizes the
chromatin structure in response to different EMT inducing stimuli like TGF-β and
EGF during the process of EMT. These studies will enable us to understand the
interplay between chromatin and gene expression dynamics when cells undergo
the process of EMT, which will be of broad interest to the chromatin/ epigenetics
and cancer fields.
In recent years, there has been a shift in focus towards the epigenetic
control of EMT, as gene regulation by EMT-TFs and epigenetic modifications are
tightly inter-linked, and because TFs are dependent on the chromatin milieu to be
able to access and bind DNA leading to gene expression. Recent studies have
suggested that some genes can “remember” stimuli if they are encountered again,
resulting in more rapid and/or elevated response to the stimulus, and that
epigenetic mechanisms are involved in this “memory” [6–13]. Establishment of
transcriptional memory and its faithful propagation over generations is critical for
cells to remember and maintain their lineage, allowing for proper development of
organisms. This is also important to allow cells to respond better to environmental
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stressors. My research asked the question of whether EMT can be “remembered”
and asked how cells remember previous exposures to EMT stimuli, pass on this
memory to future generations, enabling them to mount a more robust response
when they encounter the same stimulus again.
Most transcription memory experiments till date have been performed with
yeast, plants or suspension cells like macrophages, and there was no model
available to study memory in epithelial cells. Therefore, we first had to create our
own model of long-term transcriptional memory using a cell line that easily
undergoes EMT. The NMuMG cells were treated with TGFβ for a short time, and
then the stimulus was removed, and cells passaged for several generations. Then
we asked whether the cells showed an elevated response (i.e.’memory’) to reapplication of TGFβ compared to naïve cells, and showed that indeed, a memory
of EMT could be established, both at the molecular (RNA and protein) level, and
functionally (migration ability). We attempted to probe the mechanism behind this
memory.
We determined that with TGF-β stimulation, genome wide changes occur in
acquisition of the histone marks H3K4me1 and H3K27Ac mark at the TGF-β
responsive genes that has seen the stimulus 27 generations ago. These TGF-β
responsive genes were classified as memory, non-memory and refractory genes
based on their responses to a second exposure of TGF-β. The “memory” genes
have a more robust response to restimulation even after 27 generations. We
observed that these memory genes exhibit a more repressed chromatin structure
compared to the non-memory and refractory genes as they have a higher baseline
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of the repressive mark H3K27me3 to begin with that gets demethylated after the
first exposure to TGF-β and the genes are maintained in this demethylated state
for 27 generations leading to higher recruitment of Pol II and SMAD3 upon
restimulation with TGF-β in the pre-treated cells which might contribute to the
memory formation.
Thus, our research describes both epigenetic and transcriptomic changes
that aim to address how memory is propagated in response to an EMT stimulus.
In the future it would be interesting to study whether we can actually erase the
acquired memory from being transmitted to future generations through the use of
inhibitors as it will be of huge potential benefit in reversing pathological disease
states. For instance, a metastatic cell could have its memory of being a migratory
cell erased, and potentially revert to being stationary.
In summary, my three projects aim to provide a better understanding of how
cells respond to signals from their environment, and remember and mount a
transcriptional response to these signals. These studies will make an impact not
only on the molecular mechanisms involved in the process of EMT, chromatin
dynamics and memory, but might also provide some insight into development of
future therapeutic targets in cancer.
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APPENDIX A
ABBREVIATIONS
2APB
5hmC
5mC
AD
ATAC-seq
ATCC
BMP
CAR
CDH1
CGIs
ChIP
ChIP-seq
COX-2
CSC
CtBP
CTCF
CTCs
CUT&RUN
DMSO
DNA
DNMTs
ECM
EGF
EMT
ER-α

2-aminoethoxydiphenyl borate
5- hydroxymethylcytosine
5-methyl cytosine
Alzheimer’s disease
Assay for transposase accessible chromatin sequencing
American type culture collection
Bone Morphogenetic Protein
Coxsackievirus-adenovirus receptor
E-cadherin
CpG islands
Chromatin immunoprecipitation
Chromatin immunoprecipitation sequencing
Cyclooxygenase 2
Cancer stem cell
C-terminal binding protein
CCCTC binding factor
Circulating tumor cells
Cleavage under targets and release using nuclease
Dimethylsulfoxide
Deoxy Ribonucleic Acid
DNA methyl transferases
Extra cellular matrix
Epidermal growth factor
Epithelial to Mesenchymal Transition
Estrogen receptor alpha
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EZH2
FACS
FBS
FGF
FN1
FOXC2
FZD8
GDF
GPC3
GRB2
GSK3β
HATs
HDAC1/2
HGF
HIF-1α
HMGA2
HP1
ID1
IFNγ
IKKα
JAG1
JNK
KLF4
LEF1
LOCKs
LOX
LSD1
LTTM
MAPK
MBD
MET
min
MMP2
MMP9
mRNA

Enhancer of zeste homolog 2
Fluorescence activated cell sorter
Fetal bovine serum
Fibroblast growth Factor
Fibronectin
Fork-head box protein C 2
Frizzled class receptor 8
Growth differentiation factor
Glypcian 3
Growth Factor Receptor Bound Protein2
Glycogen Synthase Kinase 3 Beta
Histone acetyl transferases
Histone Deacetylase 1/2
Hepatocyte growth factor
Hypoxia-inducible factor 1α
High Mobility group A 2
Heterochromatin protein 1
Inhibitor of DNA Binding 1, HLH protein
Interferon gamma
Inhibitor of nuclear factor kappa-B kinase subunit alpha
Jagged 1
Jun N-terminal kinase
Kruppel like factor 4
Lymphoid enhancer factor 1
Large organized chromatin K9-modifications
Lysyl oxidas
Lysine-Specific demethylase 1
Long term transcriptional memory
Mitogen-Activated Protein Kinase
Methyl CpG binding domain
Mesenchymal to Epithelial Transition
minutes
Matrix metallopeptidase 2
Matrix metallopeptidase 9
messenger RNA
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MTA3
MUC1
NF-κB
NMuMGs
NuRD
OCLN
ORAI
PBS
PCR
PDGF
PI3K
Pol II
PRC2
PRMT5
PRO-seq
PTMs
RKIP
RNA
RT
RTK
RT-PCR
SKF
SNAI1
SNAI2
SOCE

Metastasis Associated 1 Family Member 3
Mucin 1
Nuclear Factor Kappa Beta
NAMRU murine mammary gland cells
Nucleosome Remodeling Decaetylase
Occludin
Orai Calcium Release-Activated Calcium Modulator
Phosphate buffered saline
Polymerase Chain Reaction
Platelet derived growth factor
Phosphoinositide 3-kinase
RNA Polymerase II
Polycomb Repressive Complex 2
Protein Arginine Methyl Transferase 5
Precision nuclear run-on sequencing
Post translational modifications
Raf kinase inhibitor protein
Ribonucleic Acid
Reverse Transcription
Receptor tyrosine kinase
Reverse Transcription- Polymerase Chain Reaction
SKF96365 hydrochloride
Snail
Slug
Store-operated calcium entry

SPARC
STIM
STTM
Suv39H1
TAD
TAK1
TCF4
TES
TET1
TF
TFBS

Secreted Protein Acidic and Cysteine Rich
Stromal Interaction Molecule
Short term transcriptional memory
Suppressor of variegation 3-9 homolog 1
Topologically associated domain
Transforming growth factor beta-activated kinase 1
Transcription factor 4
Transcription End Site
Ten-eleven translocation methylcytosine dioxygenase 1
Transcription Factor
Transcription factor binding site
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TGF-β
TNF-α
TRAF6
TRP
TSS
WNT
ZEB1
ZEB2
ZF

Transforming growth factor-β
Tumor Necrosis Factor alpha
TNF Receptor Associated Factor 6
Transient receptor potential
Transcription Start Site
Wingless-related integration site
Zinc finger E-box binding homeobox 1
Zinc finger E-box binding homeobox 2
Zinc finger
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